Feeds:
Posts
Comments

Archive for the ‘Coagulation Therapy and Internal Bleeding’ Category

Common blood-thinning heart drug ‘increases the risk of Alzheimer’s’

Reporter: Aviva Lev-Ari, PhD, RN

 

Scientists in Utah found patients diagnosed with atrial fibrillation and prescribed the blood thinner, Warfarin are more likely to develop dementia, Alzheimer’s disease and vascular dementia.

Sourced through Scoop.it from: www.dailymail.co.uk

See on Scoop.itCardiovascular Disease: PHARMACO-THERAPY

Read Full Post »

Warfarin and Dabigatran, Similarities and Differences

Author and Curator: Danut Dragoi, PhD

 

What anticoagulants do?

An anticoagulant helps your body control how fast your blood clots; therefore, it prevents clots from forming inside your arteries, veins or heart during certain medical conditions.

If you have a blood clot, an anticoagulant may prevent the clot from getting larger. It also may prevent a piece of the clot from breaking off and traveling to your lungs, brain or heart. The anticoagulant medication does not dissolve the blood clot. With time, however, this clot may dissolve on its own.

Blood tests you will need

The blood tests for clotting time are called prothrombin time (Protime, PT) and international normalized ratio (INR). These tests help determine if your medication is working. The tests are performed at a laboratory, usually once a week to once a month, as directed by your doctor. Your doctor will help you decide which laboratory you will go to for these tests.

The test results help the doctor decide the dose of warfarin (Coumadin) that you should take to keep a balance between clotting and bleeding.

Important things to keep in mind regarding blood tests include:

  • Have your INR checked when scheduled.
  • Go to the same laboratory each time. (There can be a difference in results between laboratories).
  • If you are planning a trip, talk with your doctor about using another laboratory while traveling.
Dosage

The dose of medication usually ranges from 1 mg to 10 mg once daily. The doctor will prescribe one strength and change the dose as needed (your dose may be adjusted with each INR).

The tablet is scored and breaks in half easily. For example: if your doctor prescribes a 5 mg tablet and then changes the dose to 2.5 mg (2½ mg), which is half the strength, you should break one of the 5 mg tablets in half and take the half-tablet. If you have any questions about your dose, talk with your doctor or pharmacist.

What warfarin (Coumadin) tablets look like

Warfarin is made by several different drug manufacturers and is available in many different shapes. Each color represents a different strength, measured in milligrams (mg). Each tablet has the strength imprinted on one side, and is scored so you can break it in half easily to adjust your dose as your doctor instructed.

https://my.clevelandclinic.org/health/drugs_devices_supplements/hic_Understanding_Coumadin

Today, on the basis of 4 clinical trials involving over 9,000 patients, PRADAXA is approved to treat blood clots in the veins of your legs(deep vein thrombosis, or DVT) or lungs (pulmonary embolism, or PE)in patients who have been treated with blood thinner injections, and to reduce the risk of them occurring again.

In these trials, PRADAXA was compared to warfarin or to placebo (sugar pills) for the treatment of DVT and PE patients.

https://www.pradaxa.com/pradaxa-vs-warfarin?gclid=CMaRq7al9ssCFUxZhgodZuoC5w

Warfarin (NB-which goes by the brand name Coumadin, see link in here) reduces the risk of stroke in patients with atrial fibrillation (NB- atrial fibrillation (also called AFib or AF) is a quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications. Some people refer to AF as a quivering heart, see link here) but increases the risk of hemorrhage and is difficult to use.

Dabigatran is a new oral direct thrombin inhibitor (NB-direct thrombin inhibitors are a class of medication that act as anticoagulants by directly inhibiting the enzyme thrombin). Some are in clinical use, while others are undergoing clinical development), see link in here.

Some international large clinical trials, see link in here,  show results for patients with atrial fibrillation, dabigatran given at a dose of 110 mg was associated with rates of stroke and systemic embolism that were similar to those associated with warfarin, as well as lower rates of major hemorrhage. Dabigatran administered at a dose of 150 mg, as compared with warfarin, was associated with lower rates of stroke and systemic embolism but similar rates of major hemorrhage.

Picture below shows a deep vein thrombosis which is a blood clot that forms inside a vein, usually deep within the leg. About half a million Americans every year get one, and up to 100,000 die because of it. The danger is that part of the clot can break off and travel through your bloodstream. It could get stuck in your lungs and block blood flow, causing organ damage or death, see link in here.

Blod Clot

Image SOURCE: http://www.webmd.com/heart-disease/guide/warfarin-other-blood-thinners

The behaviour of blood thinning drugs is dependent on their physico-chemical properties and since a significant proportion of drugs contain ionisable centers a knowledge of their pKa (NB-pKa was introduced as an index to express the acidity of weak acids, where pKa is defined as follows. For example, the Ka constant for acetic acid (CH3C00H) is 0.0000158 (= 10-4.8), but the pKa constant is 4.8, which is a simpler expression. In addition, the smaller the pKa value, the stronger the acid, see link in here ) is essential, see link in here. The pKa is defined as the negative log of the dissociation constant, see link in here:

pka=-log10(Ka)              (1)

where the dissociation constant is defined thus:

Ka=[A][H+]/[AH]

Most drugs have pKa in the range 0-12, and whilst it is possible to calculate pKa it is desirable to experimentally measure the value for representative examples. There are a number of instruments that are capable of measuring pKa utilising Sirius T3 instrument, see link in here .

Table 1 below shows the pka values for warfarin, see link in here  and dabigatran, see link in here.

Table 1

==========================

Anticoagulant           pka          

warfarin                     4.99

dabigatran                 4.24        11.51*

==========================

* dabigatran possess both acidic and basic functionality.

Both groups are at ionized at blood pH and exist as zwitterionic

structures, see link in here.

Adding physico-chemical features of anticoagulants utilized in “dissolving” blood clots is important for better understanding the de-blocking process within the veins utilizing anticoagulants.

SOURCE

http://theochem.chem.rug.nl/publications/PDF/ft683.pdf

http://www.rsc.org/chemical-sciences-repository/articles/article/dr000000003197?doi=10.1039/c5ra04680g

http://pubs.rsc.org/en/content/articlelanding/2015/ra/c5ra11623f#!divAbstract

http://www.cambridgemedchemconsulting.com/resources/physiochem/pka.html

http://www.webmd.com/heart-disease/guide/warfarin-other-blood-thinners

https://www.google.com/#q=define+atrial+fibrillation

https://www.researchgate.net/profile/Lars_Wallentin/publication/26777612_Dabigatran_versus_Warfarin_in_Patients_with_Atrial_Fibrillation/links/02bfe50c8c2fa639c0000000.pdf

http://www.webmd.com/heart-disease/guide/warfarin-other-blood-thinners

 

Other related articles published in this Open Access Online Scientific Journal, include the following:

Coagulation N=69

http://pharmaceuticalintelligence.com/?s=Coagulation

Peripheral Arterial Disease N=43

http://pharmaceuticalintelligence.com/?s=Peripheral

Antiarrhythmic drugs

http://pharmaceuticalintelligence.com/?s=Antiarrhythmic+drugs

A-Fib

http://pharmaceuticalintelligence.com/?s=a-fib

Electrophysiology N = 80

http://pharmaceuticalintelligence.com/?s=Electrophysiology

 

Read Full Post »

Neutrophil Serine Proteases in Disease and Therapeutic Considerations

Larry H. Bernstein, MD, FCAP, Curator

LPBI

 

SERPINB1 Regulates the activity of the neutrophil proteases elastase, cathepsin G, proteinase-3, chymase,
chymotrypsin, and kallikrein-3. Belongs to the serpin family. Ov-serpin subfamily. Note: This description may
include information from UniProtKB.
Chromosomal Location of Human Ortholog: 6p25
Cellular Component: extracellular space; membrane; cytoplasm
Molecular Function: serine-type endopeptidase inhibitor activity
Reference #:  P30740 (UniProtKB)
Alt. Names/Synonyms: anti-elastase; EI; ELANH2; ILEU; LEI; Leukocyte elastase inhibitor; M/NEI; MNEI; Monocyte/neutrophil elastase inhibitor; Peptidase inhibitor 2; PI-2; PI2; protease inhibitor 2 (anti-elastase), monocyte/neutrophil derived; serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 1; Serpin B1; serpin peptidase inhibitor, clade B (ovalbumin), member 1; SERPINB1
Gene Symbols: SERPINB1
Molecular weight: 42,742 Da
 

SERPIN PEPTIDASE INHIBITOR, CLADE B (OVALBUMIN), MEMBER 1; SERPINB1

Alternative titles; symbols
PROTEASE INHIBITOR 2, MONOCYTE/NEUTROPHIL DERIVED; ELANH2
ELASTASE INHIBITOR, MONOCYTE/NEUTROPHIL; EI
HGNC Approved Gene Symbol: SERPINB1
Cloning and Expression
Monocyte/neutrophil elastase inhibitor (EI) is a protein of approximately 42,000 Mr with serpin-like functional properties.
Remold-O’Donnell et al. (1992) cloned EI cDNA and identified 3 EI mRNA species of 1.5, 1.9, and 2.6 kb in monocyte-like cells
and no hybridizing mRNA in lymphoblastoid cells lacking detectable EI enzymatic activity. The cDNA open reading frame encoded
a 379-amino acid protein. Its sequence established EI as a member of the serpin superfamily. Sequence alignment indicated that
the reactive center P1 residue is cys-344, consistent with abrogation of elastase inhibitory activity by iodoacetamide and making
EI a naturally occurring cys-serpin.
 

 

Mapping

In the course of studying 4 closely linked genes encoding members of the ovalbumin family of serine proteinase inhibitors
(Ov-serpins) located on 18q21.3, Schneider et al. (1995) investigated the mapping of elastase inhibitor. They prepared PCR
primer sets of the gene, and by using the NIGMS monochromosomal somatic cell hybrid panel, showed that the EI gene maps
to chromosome 6.

By amplifying DNA of a somatic cell hybrid panel, Evans et al. (1995) unambiguously localized ELANH2 to chromosome 6.
With the use of a panel of radiation and somatic cell hybrids specific for chromosome 6, they refined the localization to
the short arm telomeric of D6S89, F13A (134570), and D6S202 at 6pter-p24.

http://www.phosphosite.org/getImageAction.do?id=27292293

 

 

REFERENCES
Evans, E., Cooley, J., Remold-O’Donnell, E. Characterization and chromosomal localization of ELANH2, the gene encoding human
monocyte/neutrophil elastase inhibitor. Genomics 28: 235-240, 1995. [PubMed: 8530031related citations] [Full Text]
Remold-O’Donnell, E., Chin, J., Alberts, M. Sequence and molecular characterization of human monocyte/neutrophil elastase inhibitor.
Proc. Nat. Acad. Sci. 89: 5635-5639, 1992. [PubMed: 1376927related citations][Full Text]
Schneider, S. S., Schick, C., Fish, K. E., Miller, E., Pena, J. C., Treter, S. D., Hui, S. M., Silverman, G. A. A serine proteinase inhibitor locus at
18q21.3 contains a tandem duplication of the human squamous cell carcinoma antigen gene. Proc. Nat. Acad. Sci. 92: 3147-3151, 1995.
[PubMed: 7724531,related citations] [Full Text]

 

Leukocyte elastase inhibitor (serpin B1) (IPR015557)

Short name: Serpin_B1

Family relationships

  • Serpin family (IPR000215)
    • Leukocyte elastase inhibitor (serpin B1) (IPR015557)

Description

Leukocyte elastase inhibitor is also known as serpin B1. Serpins (SERine Proteinase INhibitors) belong to MEROPS inhibitor family I4 (clan ID)
[PMID: 14705960].

Serpin B1 regulates the activity of neutrophil serine proteases such as elastase, cathepsin G and proteinase-3 and may play a regulatory role to
limit inflammatory damage due to proteases of cellular origin [PMID: 11747453]. It also functions as a potent intracellular inhibitor of granzyme
H [PMID: 23269243]. In mouse, four different homologues of human serpin B1 have been described [PMID: 12189154].

 

The neutrophil serine protease inhibitor SerpinB1 protects against inflammatory lung injury and morbidity in influenza virus infection

Dapeng Gong1,2, Charaf Benarafa1,2, Kevan L Hartshorn3 and Eileen Remold-O’Donnell1,2
J Immunol April 2009; 182(Meeting Abstract Supplement) 43.10
http://www.jimmunol.org/cgi/content/meeting_abstract/182/1_MeetingAbstracts/43.10

SerpinB1 is an efficient inhibitor of neutrophil serine proteases. SerpinB1-/- mice fail to clear bacterial lung infection with increased inflammation and neutrophil death. Here, we investigated the role of serpinB1 in influenza virus infection, where infiltrating neutrophils and monocytes facilitate virus clearance but can also cause tissue injury. Influenza virus (H3N2 A/Phil/82) infection caused greater and more protracted body weight loss in serpinB1-/- vs. WT mice (20% vs. 15%; nadir on day 4 vs. day 3). Increased morbidity was not associated with defective virus clearance. Cytokines (IFN, TNF, IL-17, IFN, G-CSF) and chemokines (MIP-1, KC, MIP-2) were increased in serpinB1-/- mice vs. WT on days 2-7 post-infection but not on day 1. In WT mice, histology indicated large infiltration of neutrophils peaking on day 1 and maximal airway injury on day 2 that resolved on day 3 coincident with the influx of monocytes/macrophages. In serpinB1-/- mice, neutrophils also peaked on day 1; epithelial injury was severe and sustained with accumulation of dead cells on day 2 and 3. Immunophenotyping of lung digests on day 2 and 3 showed delayed recruitment of monocytes, macrophages and DC in serpinB1-/- mice, but increase of activated CD4 (day 2-3) and CD8 (day 3) T cells. Our findings demonstrate that serpinB1 protects against morbidity and inflammatory lung injury associated with influenza infection.

 

The neutrophil serine protease inhibitor serpinb1 preserves lung defense functions in Pseudomonas aeruginosainfection

Charaf Benarafa 1 , 2 Gregory P. Priebe 3 , 4 , and Eileen Remold-O’Donnell 1 , 2
JEM July 30, 2007; 204(8): 1901-1909   http://dx.doi.org:/10.1084/jem.20070494

Neutrophil serine proteases (NSPs; elastase, cathepsin G, and proteinase-3) directly kill invading microbes. However, excess NSPs in the lungs play a central role in the pathology of inflammatory pulmonary disease. We show that serpinb1, an efficient inhibitor of the three NSPs, preserves cell and molecular components responsible for host defense against Pseudomonas aeruginosa. On infection, wild-type (WT) and serpinb1-deficient mice mount similar early responses, including robust production of cytokines and chemokines, recruitment of neutrophils, and initial containment of bacteria. However, serpinb1−/− mice have considerably increased mortality relative to WT mice in association with late-onset failed bacterial clearance. We found that serpinb1-deficient neutrophils recruited to the lungs have an intrinsic defect in survival accompanied by release of neutrophil protease activity, sustained inflammatory cytokine production, and proteolysis of the collectin surfactant protein–D (SP-D). Coadministration of recombinant SERPINB1 with the P. aeruginosa inoculum normalized bacterial clearance inserpinb1−/− mice. Thus, regulation of pulmonary innate immunity by serpinb1 is nonredundant and is required to protect two key components, the neutrophil and SP-D, from NSP damage during the host response to infection.

 

Neutrophils are the first and most abundant phagocytes mobilized to clear pathogenic bacteria during acute lung infection. Prominent among their antimicrobial weapons, neutrophils carry high concentrations of a unique set of serine proteases in their granules, including neu trophil elastase (NE), cathepsin G (CG), and proteinase-3. These neutrophil serine proteases (NSPs) are required to kill phagocytosed bacteria and fungi (12). Indeed, neutrophils lacking NE fail to kill phagocytosed pathogens, and mice deficient for NE and/or CG have increased mortality after infection with pulmonary pathogens (34). However, NSPs in the lung airspace can have a detrimental effect in severe inflammatory lung disease through degradation of host defense and matrix proteins (57). Thus, understanding of the mechanisms that regulate NSP actions during lung infections associated with neutrophilia will help identify strategies to balance host defense and prevent infection-induced tissue injury.

 

SERPINB1, also known as monocyte NE inhibitor (8), is an ancestral serpin super-family protein and one of the most efficient inhibitors of NE, CG, and proteinase-3 (910). SERPINB1 is broadly expressed and is at particularly high levels in the cytoplasm of neutrophils (1112). SERPINB1 has been found complexed to neutro phil proteases in lung fluids of cystic fibrosis patients and in a baboon model of bronchopulmonary dysplasia (1314). Although these studies suggest a role for SERPINB1 in regulating NSP activity, it is unclear whether these complexes reflect an important physiological role for SERPINB1 in the lung air space.

RESULTS

To define the physiological importance of SERPINB1 in shaping the outcome of bacterial lung infection, we generated mice deficient for serpinb1 (serpinb1−/−) by targeted mutagenesis in embryonic stem (ES) cells (Fig. 1, A–C). Crossings of heterozygous mice produced WT (+/+), heterozygous (+/−), and KO (−/−) mice for serpinb1 at expected Mendelian ratios (25% +/+, 51% +/−, and 24% −/−; n = 225; Fig. 1 D), indicating no embryonic lethality. Bone marrow neutrophils of serpinb1−/− mice lacked expression of the protein, whereas heterozygous serpinb1+/− mice had reduced levels compared with WT mice (Fig. 1 E). Importantly, levels of the cognate neutrophil proteases NE and CG, measured as antigenic units, were not altered by deletion of serpinb1 (Fig. 1 F). When maintained in a specific pathogen-free environment, serpinb1−/− mice did not differ from WT littermates in growth, litter size, or life span (followed up to 12 mo), and no gross or histopathological defects were observed at necropsy in 8-wk-old mice.

6–8-wk-old animals were intranasally inoculated with the nonmucoid Pseudomonas aeruginosa strain PAO1. Using two infection doses (3 × 106 and 7 × 106 CFU/mouse),serpinb1−/− mice had a significantly lower survival probability and a shorter median survival time compared with WT mice (Fig. 2 A). Further groups of infected mice were used to evaluate bacterial clearance. At 6 h after infection, the bacteria were similarly restricted in mice of the two genotypes, suggesting that the serpinb1−/− mice have a normal initial response to infection. At 24 h, the median bacterial count in the lungs of serpinb1−/− mice was five logs higher than that of the WT mice (P < 0.001), and the infection had spread systemically in serpinb1−/− mice but not in WT mice, as shown by high median CFU counts in the spleen (Fig. 2 B). Histological examination at 24 h after infection revealed abundant neutrophil infiltration in the lungs of both WT and serpinb1−/− mice, and consistent with the bacteriological findings, numerous foci of bacterial colonies and large areas of alveolar exudates were found in serpinb1−/− mice only (Fig. 2 C). When challenged with the mucoid P. aeruginosa clinical strain PA M57-15 isolated from a cystic fibrosis patient, WT mice cleared >99.9% of the inoculum within 24 h, whereas serpinb1-deficient mice failed to clear the infection (Fig. 2 D). Thus, the NSP inhibitor serpinb1 is essential for maximal protection against pneumonia induced by mucoid and nonmucoid strains of P. aeruginosa.

Figure 2.

Serpinb1−/− mice fail to clear P. aeruginosalung infection. (A) Kaplan-Meier survival curves of WT (+/+) and serpinb1-deficient (−/−) mice intranasally inoculated with nonmucoid P. aeruginosa strain PAO1. Increased mortality of serpinb1−/− mice was statistically significant (P = 0.03 at 3 × 106CFU/mouse; P < 0.0001 at 7 × 106CFU/mouse). (B) CFUs per milligram of lung (left) and splenic (right) tissue determined 6 and 24 h after inoculation with 3 × 106 CFUP. aeruginosa PAO1 in WT (+/+, filled circles) and serpinb1−/− (−/−, open circles) mice. Each symbol represents a value for an individual mouse. Differences between median values (horizontal lines) were analyzed by the Mann-Whitney U test. Data below the limit of detection (dotted line) are plotted as 0.5 CFU × dilution factor. (C) Lung sections stained with hematoxylin and eosin show bacterial colonies (arrowheads) and alveolar exudate in lungs of serpinb1−/− mice 24 h after infection with P. aeruginosa PAO1. Bars, 50 μm. (D) Total CFUs in the lung and spleen 24 h after inoculation with 2 × 108 CFU of the mucoid P. aeruginosa strain PA M57-15 in WT (+/+, filled circles) and serpinb1−/− (−/−, open circles) mice. Differences between median values (horizontal lines) were analyzed by the Mann-Whitney U test.

To verify specificity of the gene deletion, we tested whether delivering rSERPINB1 would correct the defective phenotype. Indeed, intranasal instillation of rSERPINB1 to serpinb1−/− mice at the time of inoculation significantly improved clearance of P. aeruginosa PAO1 from the lungs assessed at 24 h and reduced bacteremia compared with infectedserpinb1−/− mice that received PBS instead of the recombinant protein (Fig. S1 A, available at http://www.jem.org/cgi/content/full/jem.20070494/DC1). We have previously demonstrated that rSERPINB1 has no effect on the growth of P. aeruginosa in vitro (15) and does not induce bacterial aggrega tion (16). Also, rSERPINB1 mixed with PAO1 had no effect on adherence of the bacteria to human bronchial epithelial and corneal epithelial cell lines (unpublished data). Therefore, the improved bacterial clearance in treated serpinb1−/− mice is not related to a direct antibacterial role for rSERPINB1 but rather to reducing injury induced by excess neutrophil proteases. In addition, previous in vivo studies in WT rats showed that rSERPINB1 can protect against elastase-induced lung injury (17) and accelerate bacterial clearance two- to threefold in the Pseudomonas agar bead model (15).

Evidence of excess NSP action was examined in the lungs of infected serpinb1−/− mice by measuring surfactant protein–D (SP-D). SP-D, a multimeric collagenous C-type lectin produced by alveolar epithelial cells, is highly relevant as a host defense molecule, because it functions as an opsonin in microbial clearance (18) and acts on alveolar macrophages to regulate pro- and antiinflammatory cytokine production (19). SP-D is also relevant as an NSP target because it is degraded in vitro by trace levels of each of the NSPs (1620). SP-D levels in lung homogenates of WT and serpinb1−/− mice were similar 6 h after P. aeruginosa infection. At 24 h, SP-D levels were reduced in the lungs ofserpinb1−/− mice compared with WT mice, as indicated by immunoblots. A lower molecular mass band indicative of proteolytic degradation is also apparent (Fig. 3 A). Densitometry analysis of the 43-kD SP-D band relative to β-actin indicated that the reduction of SP-D level was statistically significant (+/+, 45 ± 6 [n = 8]; −/−, 10 ± 2 [n = 8]; P < 0.0001 according to the Student’s t test). Furthermore, rSERPINB1 treatment ofP. aeruginosa–infected serpinb1−/− mice partly prevented the degradation of SP-D in lung homogenates compared with nontreated mice (Fig. S1 B). As a further test of the impact of serpinb1 deletion on NSP activity, isolated neutrophils of serpinb1−/− mice were treated with LPS and FMLP and tested for their ability to cleave recombinant rat SP-D (rrSP-D) in vitro. The extent of rrSP-D cleavage by serpinb1−/− neutrophils was fourfold greater than by WT neutrophils, as determined by densitometry. The cleavage was specific for NSPs because it was abrogated by rSERPINB1 and diisopropyl fluorophosphate (Fig. 3 B). Collectively, these findings indicate a direct role for serpinb1 in regulating NSP activity released by neutrophils and in preserving SP-D, an important-host defense molecule.

Efficient clearance of P. aeruginosa infection requires an early cytokine and chemokine response coordinated by both resident alveolar macrophages and lung parenchymal cells (2122). The IL-8 homologue keratinocyte-derived chemokine (KC) and the cytokines TNF-α, IL-1β, and G-CSF were measured in cell-free bronchoalveolar (BAL) samples. Although the tested cytokines were undetectable in sham-infected mice of both genotypes (unpublished data), comparable induc tion of these cytokines was observed in BAL of WT and serpinb1−/− mice at 6 h after infection, demonstrating that there is no early defect in cytokine production in serpinb1−/− mice. At 24 h, levels of TNF-α, KC, and IL-1β were sustained or increased in serpinb1−/− mice and significantly higher than cytokine levels in WT mice. G-CSF levels at 24 h were elevated to a similar extent in BAL of WT and KO mice (Fig. 3 C). However, G-CSF levels were significantly higher in the serum of serpinb1−/− mice (WT, 336 ± 80 ng/ml; KO, 601 ± 13 ng/ml; n = 6 of each genotype; P < 0.01). In addition, serpinb1−/− mice that were treated at the time of infection with rSERPINB1 had cytokine levels in 24-h lung homogenates that were indistinguishable from those of infected WT mice (Fig. S1 C). The increased cytokine production in the lungs of infected serpinb1−/− mice may be caused by failed bacterial clearance but also by excess NSPs, which directly induce cytokine and neutrophil chemokine production in pulmonary parenchymal cells and alveolar macrophages (2324).

Neutrophil recruitment to the lungs was next examined as a pivotal event of the response to P. aeruginosa infection (25). Lung homogenates were assayed for the neutrophil-specific enzyme myeloperoxidase (MPO) to quantify marginating, interstitial, and alveolar neutrophils. Neutrophils in BAL fluid were directly counted as a measure of neutrophil accumulation in the alveolar and airway lumen. MPO in lung homo genates was undetectable in uninfected mice and was comparably increased in mice of both genotypes at 6 h, suggesting normal early serpinb1−/− neutrophil margination and migration into the interstitium. However, by 24 h after infection, MPO levels in lung homogenates remained high in WT mice but were significantly decreased in serpinb1−/− mice (Fig. 4 A). Importantly, the content of MPO per cell was the same for isolated neutrophils of WT andserpinb1−/− mice (+/+, 369 ± 33 mU/106 cells; −/−, 396 ± 27 mU/106 cells). The numbers of neutrophils in BAL were negligible in uninfected mice and were similarly increased in WT and serpinb1−/− mice at 6 h after infection. Neutrophil counts in BAL further increased at 24 h, but the mean BAL neutrophil numbers were significantly lower in serpinb1−/− mice compared with WT mice (Fig. 4 B). The evidence from the 6-h quantitation of MPO in homogenates and neutrophils in BAL strongly suggests that neutrophil recruitment is not defective in infected serpinb1−/− mice. Moreover, the high levels of cytokines and neutrophil chemoattractant KC in serpinb1−/− mice at 24 h (Fig. 3 C) also suggest that, potentially, more neutrophils should be recruited. Therefore, to examine neutrophil recruitment in serpinb1−/− mice, we used a noninfectious model in which neutrophils are mobilized to migrate to the lung after intranasal delivery of P. aeruginosa LPS. MPO levels in lung homogenate and neutrophil numbers in BAL were not statistically different in WT and serpinb1−/− mice 24 h after LPS instillation (Fig. 4, C and D). Furthermore, the number of circulating blood neutrophils and recruited peritoneal neutrophils after injection of sterile irritants glycogen and thioglycollate did not differ in WT and serpinb1−/− mice (unpublished data). Alveolar macrophage numbers were similar in uninfected mice of both genotypes (∼5 × 105 cells/mouse) and did not substantially change upon infection. Collectively, these findings show that neutrophil recruitment to the lungs in response to P. aeruginosa infection is not defective in serpinb1−/− mice, and therefore, the recovery of lower numbers of serpinb1−/− neutrophils at 24 h after infection suggests their decreased survival.

To examine the putative increased death of serpinb1−/− neutrophils in the lungs after P. aeruginosa infection, lung sections were analyzed by immunohistochemistry. Caspase-3–positive leukocytes were more relevant in the alveolar space of serpinb1−/− mice compared with WT mice at 24 h after infection, suggesting increased neutrophil apoptosis (Fig. 5 A). The positive cells were counted in 50 high power fields (hpf’s), and mean numbers of caspase-3–stained cells were increased in the lungs of serpinb1/− mice (1.8 ± 0.2 cells/hpf) compared with WT mice (0.4 ± 0.1 cells/hpf; P < 0.0001). To characterize neutrophils in the alveoli and airways, neutrophils in BAL were identified in flow cytometry by forward scatter (FSC) and side scatter and were stained with annexin V (AnV) and propidium iodide (PI). At 24 h after infection, the proportion of late apoptotic/necrotic neutrophils (AnV+PI+) was increased at the expense of viable neutrophils (AnVPI) in the BAL of serpinb1−/− mice compared with WT mice (Fig. 5 B). Neutrophil fragments in BAL were also identified in flow cytometry by low FSC (FSClow) within the neutrophil population defined by the neutrophil marker Gr-1. The number of neutrophil fragments (FSClow, Gr-1+) relative to intact neutrophils was increased two- to threefold at 24 h after infection for serpinb1−/− compared with WT mice (Fig. 5 C). Moreover, free MPO in BAL supernatants was increased in serpinb1−/− mice compared with WT mice at 24 h after infection, indicating increased PMN lysis or degranulation (Fig. 5 D).

Finally, we questioned whether the enhanced death of serpinb1−/− pulmonary neutrophils was a primary effect of gene deletion or a secondary effect caused by, for example, bacteria or components of inflammation. To address this, neutrophils were collected using the noninfectious LPS recruitment model and were cultured in vitro to allow for spontaneous cell death. After 24 h, the percentages of apoptotic and necrotic neutrophils evaluated by microscopy were increased in serpinb1−/− neutrophils compared with WT neutrophils (Fig. 6, A–C). A similar increase in apoptotic cells was observed using AnV/PI staining and measurements of hypodiploid DNA (unpublished data). Moreover, live cell numbers from serpinb1−/− mice remaining in culture after 24 h were significantly decreased compared with WT mice (Fig. 6 D). The in vitro findings indicate that enhanced death of pulmonary neutrophils of infected serpinb1−/− mice is at least in part a cell-autonomous defect likely mediated by unchecked NSP actions.

 

In this paper, we have demonstrated that serpinb1, an intracellular serpin family member, regulates the innate immune response and protects the host during lung bacterial infection. Serpinb1 is among the most potent inhibitors of NSPs and is carried at high levels within neutrophils. Serpinb1-deficient mice fail to clear P. aeruginosa PAO1 lung infection and succumb from systemic bacterial spreading. The defective immune function in serpinb1−/− mice stems at least in part from an increased rate of neutrophil necrosis, reducing the number of phagocytes and leading to increased NSP activity in the lungs with proteolysis of SP-D. In addition, serpinb1-deficient mice also have impaired clearance of the mucoid clinical strain PA M57-15. Interestingly, mucoid strains of P. aeruginosa are cleared with a very high efficiency from the lungs of WT and cystic fibrosis transmembrane conductance regulator–deficient mice (26). The phenotype of serpinb1−/− mice reproduces major pathologic features of human pulmonary diseases characterized by excessive inflammation, massive neutrophil recruitment to the air space, and destruction of cellular and molecular protective mechanisms. Importantly, serpinb1 deficiency may be helpful as an alternative or additional model of the inflammatory lung pathology of cystic fibrosis.

The present study documents a key protective role for serpinb1 in regulating NSP actions in the lung. This role has previously been attributed to the NSP inhibitors α1-antitrypsin and secretory leukocyte protease inhibitor, which are found in the airway and alveolar lining fluid (2728). However, patients with α1-antitrypsin deficiency do not present with pulmonary infection secondary to innate immune defects despite increased NSP activity that leads to reduced lung elasticity and emphysema. Moreover, there is so far no evidence that deficiency in secretory leukocyte protease inhibitor results in failure to clear pulmonary infection. Because synthesis and storage of NSPs in granules is an event that exclusively takes place in bone marrow promyelocytes (29), the regulation of NSPs in the lung relies entirely on NSP inhibitors. Thus, the extent of the innate immune defect inserpinb1−/− mice and the normalization of bacterial clearance with topical rSERPINB1 treatment indicate that serpinb1 is required to regulate NSP activity in the airway fluids and that, during acute lung infection associated with high neutrophilic recruitment, there is insufficient compensation by other NSP inhibitors. The devastating effects of NSPs when released in the lungs by degranulating and necrotic neutrophils are well documented in human pulmonary diseases (5630). Therefore, our findings clearly establish a physiological and nonredundant role for serpinb1 in regulating NSPs during pulmonary infection.

NSPs also cleave molecules involved in apoptotic cell clearance, including the surfactant protein SP-D and the phosphatidylserine receptor on macrophages (3132), thereby tipping the balance further toward a detrimental outcome. The increased numbers of leukocytes with active caspase-3 in the alveolar space of P. aeruginosa–infectedserpinb1−/− mice suggest that the removal of apoptotic cells may be inadequate during infection. SP-D has been shown to stimulate phagocytosis of P. aeruginosa by alveolar macrophages in vitro (33), and SP-D–deficient mice were found to have defective early (6-h) clearance of P. aeruginosa from the lung (34). Although the destruction of SP-D alone may not entirely account for the defective phenotype of serpinb1−/− mice, loss of SP-D likely diminishes bacterial clearance and removal of apop totic neutrophils.

Given that NSPs also mediate bacterial killing, why would NSP excess lead to a failed bacterial clearance? In the NE KO mice, the decreased killing activity of neutrophils is a direct consequence of the loss of the bactericidal activity of NE. The absence of an early bacterial clearance defect at 6 h after infection in serpinb1−/− mice suggests that there is initially normal bacterial killing. The current understanding is that the compartmentalization of the NSPs is crucial to the outcome of their actions: on the one hand, NSPs are protective when killing microbes within phagosomes, and on the other hand, extracellular NSPs destroy innate immune defense molecules such as lung collectins, immunoglobulins, and complement receptors. We have shown that the regulation of NSP activity is essential and that cytoplasmic serpinb1 provides this crucial shield. Neutrophils undergoing cell death gradually transition from apoptosis, characterized by a nonpermeable plasma membrane, to necrosis and lysis, where cellular and granule contents, including NSPs, are released. The increased pace of serpinb1−/− neutrophil cell death strongly suggests that unopposed NSPs may precipitate neutrophil demise and, therefore, reduce the neutrophil numbers leading to a late-onset innate immune defect. High levels of G-CSF, a prosurvival cytokine for neutrophils, also indicate that increased cell death is likely independent or downstream of G-CSF.

In conclusion, serpinb1 deficiency unleashes unbridled proteolytic activity during inflammation and thereby disables two critical components of the host response to bacterial infection, the neutrophil and the collectin SP-D. The phenotype of the infectedserpinb1-deficient mouse, characterized by a normal early antibacterial response that degenerates over time, highlights the delicate balance of protease–antiprotease systems that protect the host against its own defenses as well as invading microbes during infection-induced inflammation.

 

 

Proteinase 3 and neutrophil elastase enhance inflammation in mice by inactivating antiinflammatory progranulin

K Kessenbrock,1 LFröhlich,2 M Sixt,3 …., A Belaaouaj,5 J Ring,6,7 M Ollert,6 R Fässler,3 and DE. Jenne1
J Clin Invest. 2008 Jul 1; 118(7): 2438–2447.   http://dx.doi.org:/10.1172/JCI34694

Neutrophil granulocytes form the body’s first line of antibacterial defense, but they also contribute to tissue injury and noninfectious, chronic inflammation. Proteinase 3 (PR3) and neutrophil elastase (NE) are 2 abundant neutrophil serine proteases implicated in antimicrobial defense with overlapping and potentially redundant substrate specificity. Here, we unraveled a cooperative role for PR3 and NE in neutrophil activation and noninfectious inflammation in vivo, which we believe to be novel. Mice lacking both PR3 and NE demonstrated strongly diminished immune complex–mediated (IC-mediated) neutrophil infiltration in vivo as well as reduced activation of isolated neutrophils by ICs in vitro. In contrast, in mice lacking just NE, neutrophil recruitment to ICs was only marginally impaired. The defects in mice lacking both PR3 and NE were directly linked to the accumulation of antiinflammatory progranulin (PGRN). Both PR3 and NE cleaved PGRN in vitro and during neutrophil activation and inflammation in vivo. Local administration of recombinant PGRN potently inhibited neutrophilic inflammation in vivo, demonstrating that PGRN represents a crucial inflammation-suppressing mediator. We conclude that PR3 and NE enhance neutrophil-dependent inflammation by eliminating the local antiinflammatory activity of PGRN. Our results support the use of serine protease inhibitors as antiinflammatory agents.

 

Neutrophils belong to the body’s first line of cellular defense and respond quickly to tissue injury and invading microorganisms (1). In a variety of human diseases, like autoimmune disorders, infections, or hypersensitivity reactions, the underlying pathogenic mechanism is the formation of antigen-antibody complexes, so-called immune complexes (ICs), which trigger an inflammatory response by inducing the infiltration of neutrophils (2). The subsequent stimulation of neutrophils by C3b-opsonized ICs results in the generation of ROS and the release of intracellularly stored proteases leading to tissue damage and inflammation (3). It is therefore important to identify the mechanisms that control the activation of infiltrating neutrophils.

Neutrophils abundantly express a unique set of neutrophil serine proteases (NSPs), namely cathepsin G (CG), proteinase 3 (PR3; encoded by Prtn3), and neutrophil elastase (NE; encoded by Ela2), which are stored in the cytoplasmic, azurophilic granules. PR3 and NE are closely related enzymes, with overlapping and potentially redundant substrate specificities different from those of CG. All 3 NSPs are implicated in antimicrobial defense by degrading engulfed microorganisms inside the phagolysosomes of neutrophils (48). Among many other functions ascribed to these enzymes, PR3 and NE were also suggested to play a fundamental role in granulocyte development in the bone marrow (911).

While the vast majority of the enzymes is stored intracellularly, minor quantities of PR3 and NE are externalized early during neutrophil activation and remain bound to the cell surface, where they are protected against protease inhibitors (1213). These membrane presented proteases were suggested to act as path clearers for neutrophil migration by degrading components of the extracellular matrix (14). This notion has been addressed in a number of studies, which yielded conflicting results (1517). Thus, the role of PR3 and NE in leukocyte extravasation and interstitial migration still remains controversial.

Emerging data suggest that externalized NSPs can contribute to inflammatory processes in a more complex way than by simple proteolytic tissue degradation (18). For instance, recent observations using mice double-deficient for CG and NE indicate that pericellular CG enhances IC-mediated neutrophil activation and inflammation by modulating integrin clustering on the neutrophil cell surface (1920). Because to our knowledge no Prtn3–/– mice have previously been generated, the role of this NSP in inflammatory processes has not been deciphered. Moreover, NE-dependent functions that can be compensated by PR3 in Ela2–/–animals are still elusive.

One mechanism by which NSPs could upregulate the inflammatory response has recently been proposed. The ubiquitously expressed progranulin (PGRN) is a growth factor implicated in tissue regeneration, tumorigenesis, and inflammation (2123). PGRN was previously shown to directly inhibit adhesion-dependent neutrophil activation by suppressing the production of ROS and the release of neutrophil proteases in vitro (23). This antiinflammatory activity was degraded by NE-mediated proteolysis of PGRN to granulin (GRN) peptides (23). In contrast, GRN peptides may enhance inflammation (23) and have been detected in neutrophil-rich peritoneal exudates (24). In short, recent studies proposed PGRN as a regulator of the innate immune response, but the factors that control PGRN function are still poorly defined and its relevance to inflammation needs to be elucidated in vivo.

In the present study, we generated double-deficient Prtn3–/–Ela2–/– mice to investigate the role of these highly similar serine proteases in noninfectious neutrophilic inflammation. We established that PR3 and NE are required for acute inflammation in response to subcutaneous IC formation. The proteases were found to be directly involved in early neutrophil activation events, because isolated Prtn3–/–Ela2–/– neutrophils were poorly activated by ICs in vitro. These defects in Prtn3–/–Ela2–/– mice were accompanied by accumulation of PGRN. We demonstrated that PGRN represents a potent inflammation-suppressing factor that is cleaved by both PR3 and NE. Our data delineate what we believe to be a previously unknown proinflammatory role for PR3 and NE, which is accomplished via the local inactivation of antiinflammatory PGRN.

 

Generation of Prtn3–/–Ela2–/– mice.

To analyze the role of PR3 and NE in neutrophilic inflammation, we generated a Prtn3–/–Ela2–/– mouse line by targeted gene disruption in embryonic stem cells (see Supplemental Figure 1; supplemental material available online with this article; doi: 10.1172/JCI34694DS1). Positive recombination of the Prtn3/Ela2locus was proven by Southern blotting of embryonic stem cell clones (Figure ​(Figure1A).1A). Prtn3–/–Ela2–/– mice showed no expression of mRNA for PR3 and NE in bone marrow cells, as assessed by RT-PCR (Figure ​(Figure1B).1B). The successful elimination of PR3 and NE was confirmed at the level of proteolytic activity in neutrophil lysates using a PR3/NE-specific chromogenic substrate (Supplemental Figure 3) as well as by casein zymography (Figure ​(Figure1C).1C). The substantially reduced casein degradation by heterozygous neutrophils indicates gene-dosage dependence of PR3/NE activities. Furthermore, PR3 and NE deficiency was proven by Western blotting using cell lysates from bone marrow–derived neutrophils, while other enzymes stored in azurophilic granula, such as CG and myeloperoxidase (MPO), were normally detected (Figure ​(Figure1D).1D). Crossing of heterozygous Prtn3+/–Ela2+/– mice resulted in regular offspring of WT, heterozygous, and homozygous genotype according to the Mendelian ratio. Despite the absence of 2 abundant serine proteases, and in contrast to expectations based on previous reports (911), we found unchanged neutrophil morphology (Figure ​(Figure1E)1E) and regular neutrophil populations in the peripheral blood of the mutant mice, the latter as assessed via flow cytometry to determine the differentiation markers CD11b and Gr-1 (Figure ​(Figure1F)1F) (2526). Moreover, Prtn3–/–Ela2–/– mice demonstrated normal percentages of the leukocyte subpopulations in the peripheral blood, as determined by the Diff-Quick staining protocol and by hemocytometric counting (Supplemental Figure 2, A and B). Hence, the proteases are not crucially involved in granulopoiesis, and ablating PR3 and NE in the germ line represents a valid approach to assess their biological significance in vivo.

 

Figure 1

Generation and characterization of Prtn3–/–Ela2–/– mice.

PR3 and NE are dispensable for neutrophil extravasation and interstitial migration.

To examine neutrophil infiltration into the perivascular tissue, we applied phorbol esters (croton oil) to the mouse ears. At 4 h after stimulation, we assessed the neutrophil distribution in relation to the extravascular basement membrane (EBM) by immunofluorescence microscopy of fixed whole-mount specimens (Figure ​(Figure2A).2A). We found that Prtn3–/–Ela2–/– neutrophils transmigrated into the interstitium without retention at the EBM (Figure ​(Figure2B),2B), resulting in quantitatively normal and widespread neutrophil influx compared with WT mice (Figure ​(Figure2C).2C). Moreover, we analyzed chemotactic migration of isolated neutrophils through a 3-dimensional collagen meshwork in vitro (Supplemental Video 1) and found unhampered chemotaxis toward a C5a gradient, based on the directionality (Figure ​(Figure2D)2D) and velocity (Figure ​(Figure2E)2E) of Prtn3–/–Ela2–/–neutrophils. These findings led us to conclude that PR3 and NE are not principally required for neutrophil extravasation or interstitial migration.

 

Figure 2

PR3 and NE are not principally required for neutrophil extravasation and interstitial migration.

Reduced inflammatory response to ICs in Prtn3–/–Ela2–/– mice.

The formation of ICs represents an important trigger of neutrophil-dependent inflammation in many human diseases (2). To determine the role of PR3 and NE in this context, we induced a classic model of subcutaneous IC-mediated inflammation, namely the reverse passive Arthus reaction (RPA) (27). At 4 h after RPA induction, we assessed the cellular inflammatory infiltrates by histology using H&E-stained skin sections (Figure ​(Figure3A).3A). Neutrophils, which were additionally identified by Gr-1 immunohistochemistry, made up the vast majority of all cellular infiltrates (Figure ​(Figure3A).3A). We found that neutrophil infiltration to the sites of IC formation was severely diminished in Prtn3–/–Ela2–/– mice. Indeed, histological quantification revealed significantly reduced neutrophil influx in Prtn3–/–Ela2–/– mice compared with WT mice, while Ela2–/– mice showed marginally reduced neutrophil counts (Figure ​(Figure3B).3B). These results indicate that PR3 and NE fulfill an important proinflammatory function during IC-mediated inflammation.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2430496/bin/JCI0834694.f3.jpg

Figure 3

Impaired inflammatory response to locally formed ICs inPrtn3–/–Ela2–/– mice.

(A) Representative photomicrographs of inflamed skin sections 4 h after IC formation. Neutrophils were identified morphologically (polymorphic nucleus) in H&E stainings and by Gr-1 staining (red). The cellular infiltrates were located to the adipose tissue next to the panniculus carnosus muscle (asterisks) and were primarily composed of neutrophil granulocytes. Scale bars: 200 μm. (B) Neutrophil infiltrates in lesions from Prtn3–/–Ela2–/– mice were significantly diminished compared with Ela2–/– mice and WT mice. Neutrophil influx in Ela2–/–mice was slightly, but not significantly, diminished compared with WT mice. Results are mean ± SEM infiltrated neutrophils per HPF. *P < 0.05.

PR3 and NE enhance neutrophil activation by ICs in vitro.

PR3 and NE enhance neutrophil activation by ICs in vitro.

Because PR3 and NE were required for the inflammatory response to IC (Figure ​(Figure3),3), but not to phorbol esters (Figure ​(Figure2),2), we considered the enzymes as enhancers of the neutrophil response to IC. We therefore assessed the oxidative burst using dihydrorhodamine as a readout for cellular activation of isolated, TNF-α–primed neutrophils in the presence of ICs in vitro. While both WT and Prtn3–/–Ela2–/– neutrophils showed a similar, approximately 20-min lag phase before the oxidative burst commenced, the ROS production over time was markedly reduced, by 30%–40%, in the absence of PR3 and NE (Figure ​(Figure4A).4A). In contrast, oxidative burst triggered by 25 nM PMA was not hindered in Prtn3–/–Ela2–/– neutrophils (Figure ​(Figure4B),4B), which indicated no general defect in producing ROS. We also performed a titration series ranging from 0.1 to 50 nM PMA and found no reduction in oxidative burst activity in Prtn3–/–Ela2–/– neutrophils at any PMA concentration used (Supplemental Figure 4). These data are consistent with our in vivo experiments showing that neutrophil influx to ICs was impaired (Figure ​(Figure3),3), whereas the inflammatory response to phorbol esters was normal (Figure ​(Figure2,2, A–C), in Prtn3–/–Ela2–/– mice. To compare neutrophil priming in WT and Prtn3–/–Ela2–/–neutrophils, we analyzed cell surface expression of CD11b after 30 min of incubation at various concentrations of TNF-α and found no difference (Supplemental Figure 5). Moreover, we observed normal neutrophil adhesion to IC-coated surfaces (Supplemental Figure 6A) and unaltered phagocytosis of opsonized, fluorescently labeled E. coli bacteria (Supplemental Figure 6, B and C) in the absence of both proteases. We therefore hypothesized that PR3 and NE enhance early events of adhesion-dependent neutrophil activation after TNF-α priming and binding of ICs. It is important to note that Ela2–/– neutrophils were previously shown to react normally in the same setup (20). Regarding the highly similar cleavage specificities of both proteases, we suggested that PR3 and NE complemented each other during the process of neutrophil activation and inflammation.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2430496/bin/JCI0834694.f4.jpg

Figure 4

Impaired oxidative burst and PGRN degradation by IC-activatedPrtn3–/–Ela2–/– neutrophils.

Oxidative burst as the readout for neutrophil activation by ICs was measured over time. (A) While no difference was observed during the initial 20-min lag phase of the oxidative burst, Prtn3–/–Ela2–/– neutrophils exhibited diminished ROS production over time compared with WT neutrophils. (B) Bypassing receptor-mediated activation using 25 nM PMA restored the diminished oxidative burst of Prtn3–/–Ela2–/–neutrophils. Results are presented as normalized fluorescence in AU (relative to maximum fluorescence produced by WT cells). Data (mean ± SD) are representative of 3 independent experiments each conducted in triplicate. (C) Isolated mouse neutrophils were activated by ICs in vitro and tested for PGRN degradation by IB. In the cellular fraction, the PGRN (~80 kDa) signal was markedly increased in Prtn3–/–Ela2–/–cells compared with WT and Ela2–/– neutrophils. Intact PGRN was present in the supernatant (SN) of IC-activated Prtn3–/–Ela2–/–neutrophils only, not of WT or Ela2–/– cells. (D and E) Exogenous administration of 100 nM PGRN significantly reduced ROS production of neutrophils activated by ICs (D), but not when activated by PMA (E). Data (mean ± SD) are representative of 3 independent experiments each conducted in triplicate.

Antiinflammatory PGRN is degraded by PR3 and NE during IC-mediated neutrophil activation.

PGRN inhibits neutrophil activation by ICs in vitro.

Both PR3 and NE process PGRN in vitro.

Figure 5

PR3 and NE are major PGRN processing enzymes of neutrophils.

PGRN inhibits IC-mediated inflammation in vivo.

Figure 6

PGRN is a potent inhibitor of IC-stimulated inflammation in vivo.

PR3 and NE cleave PGRN during inflammation in vivo.

Finally, we aimed to demonstrate defective PGRN degradation in Prtn3–/–Ela2–/– mice during neutrophilic inflammation in vivo. For practical reasons, we harvested infiltrated neutrophils from the inflamed peritoneum 4 h after casein injection and subjected the lysates of these cells to anti-PGRN Western blot. Intact, inhibitory PGRN was detected in Prtn3–/–Ela2–/– neutrophils, but not in WT cells (Figure ​(Figure6D).6D). These data prove that neutrophilic inflammation is accompanied by proteolytic removal of antiinflammatory PGRN and that the process of PGRN degradation is essentially impaired in vivo in the absence of PR3 and NE.

 

Chronic inflammatory and autoimmune diseases are often perpetuated by continuous neutrophil infiltration and activation. According to the current view, the role of NSPs in these diseases is mainly associated with proteolytic tissue degradation after their release from activated or dying neutrophils. However, recent observations suggest that NSPs such as CG may contribute to noninfectious diseases in a more complex manner, namely as specific regulators of inflammation (18). Here, we demonstrate that PR3 and NE cooperatively fulfilled an important proinflammatory role during neutrophilic inflammation. PR3 and NE directly enhanced neutrophil activation by degrading oxidative burst–suppressing PGRN. These findings support the use of specific serine protease inhibitors as antiinflammatory agents.

Much attention has been paid to the degradation of extracellular matrix components by NSPs. We therefore expected that ablation of both PR3 and NE would cause impaired neutrophil extravasation and interstitial migration. Surprisingly, we found that the proteases were principally dispensable for these processes:Prtn3–/–Ela2–/– neutrophils migrated normally through a dense, 3-dimensional collagen matrix in vitro and demonstrated regular extravasation in vivo when phorbol esters were applied (Figure ​(Figure2).2). This finding is in agreement with recent reports that neutrophils preferentially and readily cross the EBM through regions of low matrix density in the absence of NE (28).

Conversely, we observed that PR3 and NE were required for the inflammatory response to locally formed ICs (Figure ​(Figure3).3). Even isolated Prtn3–/–Ela2–/– neutrophils were challenged in performing oxidative burst after IC stimulation in vitro (Figure ​(Figure4A),4A), showing that the proteases directly enhanced the activation of neutrophils also in the absence of extracellular matrix. However, when receptor-mediated signal transduction was bypassed by means of PMA, neutrophils from Prtn3–/–Ela2–/– mice performed normal oxidative burst (Figure ​(Figure4B),4B), indicating that the function of the phagocyte oxidase (phox) complex was not altered in the absence of PR3 and NE. These findings substantiate what we believe to be a novel paradigm: that all 3 serine proteases of azurophilic granules (CG, PR3, and NE), after their release in response to IC encounter, potentiate a positive autocrine feedback on neutrophil activation.

In contrast to CG, the highly related proteases PR3 and NE cooperate in the effacement of antiinflammatory PGRN, leading to enhanced neutrophil activation. Previous studies already demonstrated that PGRN is a potent inhibitor of the adhesion-dependent oxidative burst of neutrophils in vitro, which can be degraded by NE (23). Here, we showed that PR3 and NE play an equally important role in the regulation of PGRN function. Ela2–/– neutrophils were sufficiently able to degrade PGRN. Only in the absence of both PR3 and NE was PGRN degradation substantially impaired, resulting in the accumulation of antiinflammatory PGRN during neutrophil activation in vitro (Figure ​(Figure4C)4C) and neutrophilic inflammation in vivo (Figure ​(Figure6D).6D). Moreover, we provided in vivo evidence for the crucial role of PGRN as an inflammation-suppressing mediator, because administration of recombinant PGRN potently inhibited the neutrophil influx to sites of IC formation (Figure ​(Figure6,6, A–C). Hence, the cooperative degradation of PGRN by PR3 and NE is a decisive step for the establishment of neutrophilic inflammation.

The molecular mechanism of PGRN function is not yet completely understood, but it seems to interfere with integrin (CD11b/CD18) outside-in signaling by blocking the function of pyk2 and thus dampens adhesion-related oxidative burst even when added after the initial lag phase of oxidase activation (23). PGRN is produced by neutrophils and stored in highly mobile secretory granules (29). It was recently shown that PGRN can bind to heparan-sulfated proteoglycans (30), which are abundant components of the EBM and various cell surfaces, including those of neutrophils. Also, PR3 and NE are known to interact with heparan sulfates on the outer membrane of neutrophils, where the enzymes appear to be protected against protease inhibitors (121331). These circumstantial observations support the notion that PGRN cleavage by PR3 and NE takes place at the pericellular microenvironment of the neutrophil cell surface.

Impaired outside-in signaling most likely reduced the oxidative burst in Prtn3–/–Ela2–/– neutrophils adhering to ICs. In support of this hypothesis, we excluded an altered response to TNF-α priming (Supplemental Figure 5) as well as reduced adhesion to immobilized ICs and defective endocytosis of serum-opsonized E. coli in Prtn3–/–Ela2–/– neutrophils (Supplemental Figure 6). MPO content and processing was also unchanged in Prtn3–/–Ela2–/– neutrophils (Figure ​(Figure1D);1D); hence, the previously discussed inhibitory effect of MPO on phox activity (3233) does not appear to be stronger in neutrophils lacking PR3 and NE. Because there was no difference in the lag phase of the oxidative burst, initial IC-triggered receptor activation was probably not affected by either PRGN or PR3/NE. Our concept is consistent with all these observations and takes into account that PGRN unfolds its suppressing effects in the second phase, when additional membrane receptors, endogenous PGRN, and some PR3/NE from highly mobile intracellular pools are translocated to the cell surface. The decline and cessation of ROS production suggested to us that outside-in signaling was not sustained and that active oxidase complexes were no longer replenished in the absence of PR3 and NE. Our present findings, however, do not allow us to exclude other potential mechanisms, such as accelerated disassembly of the active oxidase complex.

 

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2430496/bin/JCI0834694.f7.jpg

Proposed function of PR3 and NE in IC-mediated inflammation.

TNF-α–primed neutrophils extravasate from blood vessels, translocate PR3/NE to the cellular surface, and discharge PGRN to the pericellular environment (i). During transmigration of interstitial tissues (ii), neutrophil activation is initially suppressed by relatively high pericellular levels of antiinflammatory PGRN (green shading), which is also produced locally by keratinocytes and epithelial cells of the skin. Until IC depots are reached, neutrophil activation is inhibited by PGRN. Surface receptors (e.g., Mac-1) recognize ICs, which results in signal transduction (black dotted arrow) and activation of the phox. The molecular pathway of PGRN-mediated inhibition is not completely understood, but it may interfere with integrin signaling after IC encounter (green dotted line inside the cell). Adherence of neutrophils to ICs (iii) further increases pericellular PR3 and NE activity. PR3 and NE cooperatively degrade PGRN in the early stage of neutrophilic activation to facilitate optimal neutrophil activation (red shading), resulting in sustained integrin signaling (red arrow) and robust production of ROS by the phox system. Subsequently, neutrophils release ROS together with other proinflammatory mediators and chemotactic agents, thereby enhancing the recruitment of further neutrophils and establishing inflammation (iv). In the absence of PR3/NE, the switch from inflammation-suppressing (ii) to inflammation-enhancing (iii) conditions is substantially delayed, resulting in diminished inflammation in response to ICs (iv).

 

NSPs are strongly implicated as effector molecules in a large number of destructive diseases, such as emphysema or the autoimmune blistering skin disease bullous pemphigoid (143537). Normally, PR3/NE activity is tightly controlled by high plasma levels of α1-antitrypsin. This balance between proteases and protease inhibitors is disrupted in patients with genetic α1-antitrypsin deficiency, which represents a high risk factor for the development of emphysema and certain autoimmune disorders (38). The pathogenic effects of NSPs in these diseases have so far been associated with tissue destruction by the proteases after their release from dying neutrophils. Our findings showed that PR3 and NE were already involved in much earlier events of the inflammatory process, because the enzymes directly regulated cellular activation of infiltrating neutrophils by degrading inflammation-suppressing PGRN. This concept is further supported by previous studies showing increased inflammation in mice lacking serine protease inhibitors such as SERPINB1 or SLPI (3940). Blocking PR3/NE activity using specific inhibitors therefore represents a promising therapeutic strategy to treat chronic, noninfectious inflammation. Serine protease inhibitors as antiinflammatory agents can interfere with the disease process at 2 different stages, because they attenuate both early events of neutrophil activation and proteolytic tissue injury caused by released NSPs.

 

 

 

 

Editorial: Serine proteases, serpins, and neutropenia

David C. Dale

J Leuko Biol July 2011;  90(1): 3-4   http://dx.doi.org:/10.1189/jlb.1010592

Cyclic neutropenia and severe congenital neutropenia are autosomal-dominant diseases usually attributable to mutations in the gene for neutrophil elastase orELANE. Patients with these diseases are predisposed to recurrent and life-threatening infections [1]. Neutrophil elastase, the product of the ELANE gene, is a serine protease that is synthesized and packaged in the primary granules of neutrophils. These granules are formed at the promyelocytes stage of neutrophil development. Synthesis of mutant neutrophil elastase in promyelocytes triggers the unfolded protein response and a cascade of intracellular events, which culminates in death of neutrophil precursors through apoptosis [2]. This loss of cells causes the marrow abnormality often referred to as “maturation arrest” [34].

Neutrophil elastase is one of the serine proteases normally inhibited by serpinB1. In this issue of JLB, Benarafa and coauthors [5] present their intriguing studies of serpinB1 expression in human myeloid cells and their extensive investigations ofSERPINB1−/− mice. They observed that serpinB1 expression parallels protease expression. The peak of serpinB1 expression occurs in promyelocytes. Benarafa et al. [5] found that SERPINB1−/− mice have a deficiency of postmitotic neutrophils in the bone marrow. This change was accompanied by an increase in the plasma levels of G-CSF. The decreased supply of marrow neutrophils reduced the number of neutrophils that could be mobilized to an inflammatory site. Using colony-forming cell assays, they determined that the early myeloid progenitor pool was intact. Separate assays showed that maturing myeloid cells were being lost through accelerated apoptosis of maturing neutrophils in the marrow. The authors concluded that serpinB1 is required for maintenance of a healthy reserve of marrow neutrophils and a normal acute immune response [5].

This paper provides new and fascinating insights for understanding the mechanism for neutropenia. It also suggests opportunities to investigate potential therapies for patients with neutropenia and prompts several questions. As inhibition of the activity of intracellular serine proteases is the only known function of serpinB1, the findings reported by Benarafa et al. [5] suggest that uninhibited serine proteases perturbed neutrophil production severely. The SERPINB1−/− mice used in their work have accelerated apoptosis of myeloid cells, a finding suggesting that uninhibited serine proteases or mutant neutrophil elastase perturb myelopoiesis by similar mechanisms. It is now important to determine whether the defect in the SERPINB1−/− mice is, indeed, attributable to uninhibited activity of normal neutrophil elastase, other neutrophil proteases, or another mechanism. ″Double-knockout″ studies in mice deficient in neutrophil elastase and serpinB1 might provide an answer.

This report provides evidence regarding the intracellular mechanisms for the apoptosis of myeloid cells and indicates that other studies are ongoing. The key antiapoptotic proteins, Mcl-1, Bcl-XL, and A1/Bfl-I, are apparently not involved. A more precise understanding of the mechanisms of cell death is important for development of targeted therapies for neutropenia. It is also important to discover whether only cells of the neutrophil lineage are involved or whether monocytes are also affected. In cyclic and congenital neutropenia, patients failed to produce neutrophils, but they can produce monocytes; in fact, they overproduce monocytes and have significantly elevated blood monocyte counts. Neutropenia with monocytosis is probably attributable to differences in the expression of ELANE in the two lineages. Benarafa et al. [5] reported that human bone marrow monocytes contain substantially less serpinB1 than marrow neutrophils, suggesting that the expression of serpinB1 and the serine proteases are closely coordinated.

This report shows the importance of the marrow neutrophil reserves in the normal response to infections. Compared with humans, healthy mice are always neutropenic, but they have a bigger marrow neutrophil reserve, and their mature neutrophils in the marrow and blood look like human band neutrophils. These differences are well known, but they are critical for considering the clinical inferences that can be made from this report. For example, although theSERPINB1−/− mice were not neutropenic, human SERPINB1−/− might cause neutropenia because of physiological differences between the species. If some but not all mutations in SERPINB1 cause neutropenia, we might gain a better understanding about how serpinB1 normally inhibits the neutrophil’s serine proteases.

We do not know if some or all of the mutant neutrophil elastases can be inhibited by serpinB1. We do not know whether cyclic or congenital neutropenia are attributable to defects in this interaction. However, we do know that there are chemical inhibitors of neutrophil elastase that can abrogate apoptosis of myeloid cells in a cellular model for congenital neutropenia [6]. It would be interesting to see if these chemical inhibitors can replace the natural inhibitor and normalize neutrophil production in the SERPINB1−/− mice. This would provide evidence to support use of chemical protease inhibitors as a treatment for cyclic and congenital neutropenia.

Concerns with the use of G-CSF for the treatment of cyclic and congenital neutropenia are how and why some of these patients are at risk of developing leukemia. Are the SERPINB1−/− mice with a hyperproliferative marrow and high G-CSF levels also at risk of developing myeloid leukemia?

This is a very provocative paper, and much will be learned from further studies of the SERPINB1−/− mice.

 

SerpinB1 is critical for neutrophil survival through cell-autonomous inhibition of cathepsin G

Mathias Baumann1,2, Christine T. N. Pham3, and Charaf Benarafa1

Blood May 9, 2013; 121(19)   http://www.bloodjournal.org/content/121/19/3900

Key Points

  • Serine protease inhibitor serpinB1 protects neutrophils by inhibition of their own azurophil granule protease cathepsin G.
  • Granule permeabilization in neutrophils leads to cathepsin G–mediated death upstream and independent of apoptotic caspases.

Abstract

Bone marrow (BM) holds a large reserve of polymorphonuclear neutrophils (PMNs) that are rapidly mobilized to the circulation and tissues in response to danger signals. SerpinB1 is a potent inhibitor of neutrophil serine proteases neutrophil elastase (NE) and cathepsin G (CG). SerpinB1 deficiency (sB1−/−) results in a severe reduction of the BM PMN reserve and failure to clear bacterial infection. Using BM chimera, we found that serpinB1 deficiency in BM cells was necessary and sufficient to reproduce the BM neutropenia ofsB1−/− mice. Moreover, we showed that genetic deletion of CG, but not NE, fully rescued the BM neutropenia in sB1−/− mice. In mixed BM chimera and in vitro survival studies, we showed that CG modulates sB1−/− PMN survival through a cell-intrinsic pathway. In addition, membrane permeabilization by lysosomotropic agent L-leucyl-L-leucine methyl ester that allows cytosolic release of granule contents was sufficient to induce rapid PMN death through a CG-dependent pathway. CG-mediated PMN cytotoxicity was only partly blocked by caspase inhibition, suggesting that CG cleaves a distinct set of targets during apoptosis. In conclusion, we have unveiled a new cytotoxic function for the serine protease CG and showed that serpinB1 is critical for maintaining PMN survival by antagonizing intracellular CG activity.

Introduction

Polymorphonuclear neutrophil (PMN) granulocytes are essential components of the innate immune response to infection. PMNs are relatively short-lived leukocytes that originate from hematopoietic stem cells in the bone marrow (BM) in a process called granulopoiesis. Granulopoiesis proceeds through a proliferative phase followed by a maturation phase. After maturation, the BM retains a large reserve of mature PMNs, which includes over 90% of the mature PMNs in the body while only a small proportion (1%-5%) is in the blood.1,2 Even in noninflammatory conditions, granulopoiesis is remarkable as >1011 PMNs are produced daily in an adult human, only to be disposed of, largely unused, a few hours later.3 There is evidence that the majority of PMNs produced never reach circulation and die within the BM.4 Congenital or acquired forms of neutropenia are associated with the highest risks of bacterial and fungal infection,5 indicating a strong evolutionary pressure to maintain granulopoiesis at high levels and sustain a large mobilizable pool of PMNs in the BM.

In steady state, PMNs die by apoptosis, a form of programmed cell death that allows for the safe disposal of aging PMNs and their potentially toxic cargo. Like in other cells, caspases participate in the initiation, amplification, and execution steps of apoptosis in PMNs.6,7 Interestingly, noncaspase cysteine proteases calpain and cathepsin D were reported to induce PMN apoptosis through activation of caspases.811 In addition, PMNs carry a unique set of serine proteases (neutrophil serine proteases [NSPs]) including elastase (NE), cathepsin G (CG), and proteinase-3 (PR3) stored active in primary granules. There is strong evidence for a role of NSPs in killing pathogens and inducing tissue injury when released extracellularly.1214 In contrast, the function of NSPs in PMN homeostasis and cell death remains elusive. In particular, no defects in granulopoiesis or PMN homeostasis have been reported in mice deficient in cathepsin G (CG−/−),15 neutrophil elastase (NE−/−),16,17 or dipeptidylpeptidase I (DPPI−/−), which lack active NSPs.18 We have recently shown that mice lacking the serine protease inhibitor serpinB1 (sB1−/−) have reduced PMN survival in the lungs following Pseudomonas infection and that these mice have a profound reduction in mature PMN numbers in the BM.19,20SerpinB1, also known as monocyte NE inhibitor, is expressed at high levels in the cytoplasm of PMNs and is one of the most potent inhibitors of NE, CG, and PR3.21,22 In this study, we tested the hypothesis that serpinB1 promotes PMN survival by inhibiting 1 or several NSPs, and we discovered a novel regulatory pathway in PMN homeostasis in vivo.

 

http://d3md5dngttnvbj.cloudfront.net/content/bloodjournal/121/19/3900/F1.medium.gif

Figure 1

Defective PMN reserve in BM chimera depends on serpinB1 deficiency in the hematopoietic compartment. Flow cytometry analysis of major BM leukocyte subsets of lethally irradiated mice was performed 8 to 10 weeks after BM transfer. (A) Irradiated WT (CD45.1) mice were transferred with WT (●) or sB1−/− (○) BM cells. (B) Irradiated WT (●) andsB1−/− (○) mice both CD45.2 were transferred with WT (CD45.1) BM cells. Each circle represents leukocyte numbers for 1 mouse and horizontal line indicates the median. Median subsets numbers were compared by the Mann-Whitney test (*P < .05; ***P < .001).

CG regulates neutrophil numbers in the BM

Because serpinB1 is an efficient inhibitor of NE, CG, and PR3, we then examined PMN numbers in mice deficient in 1 or several NSPs in combination with serpinB1 deletion. As expected, sB1−/− mice had significantly reduced numbers and percentage of mature PMNs in the BM compared with WT and heterozygous sB1+/− mice. In addition, PMN numbers were normal in mice deficient in either DPPI, NE, or CG (Figure 2A). DPPI is not inhibited by serpinB1 but is required for the activation of all NSPs, and no NSP activity is detectable in DPPI−/− mice.18,23 PMN counts in DPPI−/−.sB1−/− BM were significantly higher than in sB1−/− BM, suggesting that 1 or several NSPs contribute to the PMN survival defect. To examine the role of NSPs in this process, we crossed several NSP-deficient strains with sB1−/− mice. We found that NE.CG.sB1−/− mice had normal PMN numbers indicating that these NSPs play a key role in the defective phenotype of sB1−/− PMNs (Figure 2A). Furthermore, CG.sB1−/− mice showed normal PMN numbers whereasNE.sB1−/− mice retained the BM neutropenia phenotype indicating that CG, but not NE, plays a significant role in the death of sB1−/− PMNs (Figure 2A). In addition, the double-deficient NE.sB1−/− mice had significantly lower BM myelocyte numbers than sB1−/− mice while the myelocyte numbers in singly deficient NE−/− and sB1−/− BM were normal (Figure 2B). These results suggest that NE may promote myeloid cell proliferation, an activity that is revealed only when serpinB1 is absent. This complex interaction between sB1 and NE requires further investigation. On the other hand, B-cell and monocyte numbers and relative percentage in the BM were largely similar in all genotypes (supplemental Figure 2). Total numbers of blood leukocytes, erythrocytes, and platelets were normal in mice deficient in NSPs and/or serpinB1 (supplemental Figure 3). PMN numbers in blood were normal insB1−/− mice in steady state and combined deficiency of NSPs did not significantly alter these numbers (Figure 2C). Taken together, our results indicate that serpinB1 likely sustains the survival of postmitotic PMNs through its interaction with CG.

Figure 2

PMN and myelocyte numbers in BM and blood of mice deficient in NSPs and serpinB1.

http://d3md5dngttnvbj.cloudfront.net/content/bloodjournal/121/19/3900/F2.medium.gif

CG-mediated PMN death proceeds independent of caspase activity

Figure 4

sB1−/− PMN death mediated by CG does not require caspase activity

http://d3md5dngttnvbj.cloudfront.net/content/bloodjournal/121/19/3900/F4.medium.gif

Granule membrane permeabilization induces CG-mediated death in PMNs

To test whether granule disruption contributes to the serpinB1-regulated CG-dependent cell death, BM cells were treated with the lysosomotropic agent LLME. LLME accumulates in lysosomes where the acyl transferase activity of DPPI generates hydrophobic (Leu-Leu)n-OMe polymers that induce lysosomal membrane permeabilization (LMP) and cytotoxicity in granule-bearing cells such as cytotoxic T lymphocytes, NK cells, and myeloid cells.29,30

Figure 5

LMP induces CG-mediated death in PMNs

http://d3md5dngttnvbj.cloudfront.net/content/bloodjournal/121/19/3900/F5.medium.gif

G-CSF therapy increases sB1−/− PMN numbers via enhanced granulopoiesis

G-CSF therapy is an effective long-term treatment in many cases of severe congenital neutropenia and it is also used to prevent chemotherapy-induced febrile neutropenia by enhancing PMN production. In addition, G-CSF delays neutrophil apoptosis by differentially regulating proapoptotic and antiapoptotic factors.10 To test whether G-CSF could rescue sB1−/− PMN survival defect, WT and sB1−/− mice were treated with therapeutic doses of G-CSF or saline for 5 days and BM and blood PMNs were analyzed 24 hours after the last injection. Total counts of myelocytes and PMNs were significantly increased in the BM of treated mice compared with their respective untreated genotype controls (Figure 6A-B). The increase in myelocyte numbers was identical in G-CSF–treated WT and sB1−/− mice, indicating that G-CSF–induced granulopoiesis proceeds normally in sB1−/−myeloid progenitors (Figure 6B).

Figure 6

In vivo G-CSF therapy increases PMN numbers in BM of sB1−/− mice.

 

SerpinB1 is a member of the clade B serpins, a subfamily composed of leaderless proteins with nucleocytoplasmic localization. Clade B serpins are often expressed in cells that also carry target proteases, which led to the hypothesis that intracellular serpins protect against misdirected granule proteases and/or protect bystander cells from released proteases.31 We previously reported that deficiency in serpinB1 is associated with reduced PMN survival in the BM and at inflammatory sites.19,20 The evidence presented here demonstrates that the cytoprotective function of serpinB1 in PMNs is based on the inhibition of granule protease CG. Deficiency in CG was sufficient to rescue the defect of sB1−/− mice as illustrated by normal PMN counts in the BM of double knockout CG.sB1−/− mice. We also showed that the protease-serpin interaction occurred within PMNs. Indeed, WT PMNs had a greater survival over sB1−/− PMNs in mixed BM chimera, whereas the survival of CG.sB1−/− PMNs was similar to WT PMNs after BM transfer. SerpinB1 is an ancestral clade B serpin with a conserved specificity determining reactive center loop in all vertebrates.32 Furthermore, human and mouse serpinB1 have the same specificity for chymotrypsin-like and elastase-like serine proteases.21,22 Likewise, human and mouse CG have identical substrate specificities and the phenotype of CG−/− murine PMN can be rescued by human CG.33 Therefore, it is highly likely that the antagonistic functions of CG and serpinB1 in cellular homeostasis observed in mice can be extended to other species.

Extracellular CG was previously reported to promote detachment-induced apoptosis (anoikis) in human and mouse cardiomyocytes.34 This activity is mediated through the shedding and transactivation of epidermal growth factor receptor and downregulation of focal adhesion signaling.35,36 In our study, exogenous human CG also induced PMN death in vitro but these effects were not enhanced in sB1−/− PMNs and the neutropenia associated with serpinB1 deficiency was principally cell intrinsic. How intracellular CG induces PMN death remains to be fully investigated. However, our studies provide some indications on the potential pathways. Like other NSPs, the expression of CG is transcriptionally restricted to the promyelocyte stage during PMN development and NSPs are then stored in active form in primary azurophil granules.37 Because serpinB1 is equally efficient at inhibiting NE, CG, and PR3, it was surprising that deletion of CG alone was sufficient to achieve a complete reversal of the PMN survival defect in CG.sB1−/− mice. A possible explanation would be that CG gains access to targets more readily than other granule proteases. There is evidence that binding to serglycin proteoglycans differs between NE and CG resulting in altered sorting of NE but not CG into granules of serglycin-deficient PMNs.38 Different interactions with granule matrix may thus contribute to differential release of CG from the granules compared with other NSPs. However, because sB1−/− PMNs have similar levels of CG and NE as WT PMNs20 and because LLME-induced granule permeabilization likely releases all granule contents equally, we favor an alternative interpretation where CG specifically targets essential cellular components that are not cleaved by the other serpinB1-inhibitable granule proteases. Upon granule permeabilization, we found that CG can induce cell death upstream of caspases as well as independent of caspases. CG was previously shown to activate caspase-7 in vitro and it functions at neutral pH, which is consistent with a physiological role in the nucleocytoplasmic environment.39 Cell death induced by lysosomal/granule membrane permeabilization has previously been linked to cysteine cathepsins in other cell types. However, these proteases appear to depend on caspase activation to trigger apoptosis and they function poorly at neutral pH, questioning their potential role as regulators of cell death.40 In contrast, CG-mediated cell death is not completely blocked by caspase inhibition, which is a property reminiscent of granzymes in cytotoxic T cells.41 In fact, CG is phylogenetically most closely related to serine proteases granzyme B and H.42 Granzymes have numerous nuclear, mitochondrial, and cytoplasmic target proteins leading to cell death41 and we anticipate that this may also be the case for CG.

……

G-CSF therapy is successfully used to treat most congenital and acquired neutropenia through increased granulopoiesis, mobilization from the BM, and increased survival of PMNs. Prosurvival effects of G-CSF include the upregulation of antiapoptotic Bcl-2 family members, which act upstream of the mitochondria and the activation of effector caspases. In sB1−/− mice, G-CSF levels in serum are fourfold higher than in WT mice in steady state and this is accompanied by an upregulation of the antiapoptotic Bcl-2 family member Mcl-1 in sB1−/− PMNs.19 Here, G-CSF therapy significantly increased granulopoiesis in both WT and sB1−/− mice. However, the PMN numbers in treated sB1−/− BM and blood were significantly lower than those of treated WT mice, indicating only a partial rescue of the survival defect. This is consistent with our findings that CG-mediated death can proceed independent of caspases and can thus bypass antiapoptotic effects mediated by G-CSF.

CG has largely been studied in association with antimicrobial and inflammatory functions due to its presence in PMNs.1214,49 In this context, we have previously shown that serpinB1 contributes to prevent increased mortality and morbidity associated with production of inflammatory cytokines upon infection with Pseudomonas aeruginosa and influenza A virus.20,50 In this study, we demonstrate that serpinB1 inhibition of the primary granule protease CG in PMNs is essential for PMN survival and this ultimately regulates PMN numbers in vivo. Our findings also extend the roles of CG from antimicrobial and immunoregulatory functions to a novel role in inducing cell death.

 

Neutrophil Elastase, Proteinase 3, and Cathepsin G as Therapeutic Targets in Human Diseases

Brice KorkmazMarshall S. HorwitzDieter E. Jenne and Francis Gauthier
Pharma Rev Dec 2010; 62(4):726-759  http://dx.doi.org:/10.1124/pr.110.002733

Polymorphonuclear neutrophils are the first cells recruited to inflammatory sites and form the earliest line of defense against invading microorganisms. Neutrophil elastase, proteinase 3, and cathepsin G are three hematopoietic serine proteases stored in large quantities in neutrophil cytoplasmic azurophilic granules. They act in combination with reactive oxygen species to help degrade engulfed microorganisms inside phagolysosomes. These proteases are also externalized in an active form during neutrophil activation at inflammatory sites, thus contributing to the regulation of inflammatory and immune responses. As multifunctional proteases, they also play a regulatory role in noninfectious inflammatory diseases. Mutations in the ELA2/ELANE gene, encoding neutrophil elastase, are the cause of human congenital neutropenia. Neutrophil membrane-bound proteinase 3 serves as an autoantigen in Wegener granulomatosis, a systemic autoimmune vasculitis. All three proteases are affected by mutations of the gene (CTSC) encoding dipeptidyl peptidase I, a protease required for activation of their proform before storage in cytoplasmic granules. Mutations of CTSC cause Papillon-Lefèvre syndrome. Because of their roles in host defense and disease, elastase, proteinase 3, and cathepsin G are of interest as potential therapeutic targets. In this review, we describe the physicochemical functions of these proteases, toward a goal of better delineating their role in human diseases and identifying new therapeutic strategies based on the modulation of their bioavailability and activity. We also describe how nonhuman primate experimental models could assist with testing the efficacy of proposed therapeutic strategies.

 

Human polymorphonuclear neutrophils represent 35 to 75% of the population of circulating leukocytes and are the most abundant type of white blood cell in mammals (Borregaard et al., 2005). They are classified as granulocytes because of their intracytoplasmic granule content and are characterized by a multilobular nucleus. Neutrophils develop from pluripotent stem cells in the bone marrow and are released into the bloodstream where they reach a concentration of 1.5 to 5 × 109 cells/liter. Their half-life in the circulation is only on the order of a few hours. They play an essential role in innate immune defense against invading pathogens and are among the primary mediators of inflammatory response. During the acute phase of inflammation, neutrophils are the first inflammatory cells to leave the vasculature, where they migrate toward sites of inflammation, following a gradient of inflammatory stimuli. They are responsible for short-term phagocytosis during the initial stages of infection (Borregaard and Cowland, 1997Hampton et al., 1998Segal, 2005). Neutrophils use complementary oxidative and nonoxidative pathways to defend the host against invading pathogens (Kobayashi et al., 2005).

The three serine proteases neutrophil elastase (NE1), proteinase 3 (PR3), and cathepsin G (CG) are major components of neutrophil azurophilic granules and participate in the nonoxidative pathway of intracellular and extracellular pathogen destruction. These neutrophil serine proteases (NSPs) act intracellularly within phagolysosomes to digest phagocytized microorganisms in combination with microbicidal peptides and the membrane-associated NADPH oxidase system, which produces reactive oxygen metabolites (Segal, 2005). An additional extracellular antimicrobial mechanism, neutrophil extracellular traps (NET), has been described that is made of a web-like structure of DNA secreted by activated neutrophils (Papayannopoulos and Zychlinsky, 2009) (Fig. 1). NETs are composed of chromatin bound to positively charged molecules, such as histones and NSPs, and serve as physical barriers that kill pathogens extracellularly, thus preventing further spreading. NET-associated NSPs participate in pathogen killing by degrading bacterial virulence factors extracellularly (Brinkmann et al., 2004;Papayannopoulos and Zychlinsky, 2009).

http://pharmrev.aspetjournals.org/content/62/4/726/F1.small.gif

Fig. 1.

Polymorphonuclear neutrophil. Quiescent (A) and chemically activated (B) neutrophils purified from peripheral blood. C, PMA-activated neutrophils embedded within NET and neutrophil spreading on insoluble elastin.

In addition to their involvement in pathogen destruction and the regulation of proinflammatory processes, NSPs are also involved in a variety of inflammatory human conditions, including chronic lung diseases (chronic obstructive pulmonary disease, cystic fibrosis, acute lung injury, and acute respiratory distress syndrome) (Lee and Downey, 2001Shapiro, 2002Moraes et al., 2003Owen, 2008b). In these disorders, accumulation and activation of neutrophils in the airways result in excessive secretion of active NSPs, thus causing lung matrix destruction and inflammation. NSPs are also involved in other human disorders as a consequence of gene mutations, altered cellular trafficking, or, for PR3, autoimmune disease. Mutations in the ELA2/ELANE gene encoding HNE are the cause of human cyclic neutropenia and severe congenital neutropenia (Horwitz et al., 19992007). Neutrophil membrane-bound proteinase 3 (mPR3) is the major target antigen of anti-neutrophil cytoplasmic autoantibodies (ANCA), which are associated with Wegener granulomatosis (Jenne et al., 1990). All three proteases are affected by mutation of the gene (CTSC) encoding dipeptidyl peptidase I (DPPI), which activates several granular hematopoietic serine proteases (Pham and Ley, 1999Adkison et al., 2002). Mutations of CTSC cause Papillon-Lefèvre syndrome and palmoplantar keratosis (Hart et al., 1999Toomes et al., 1999).

…….

Fully processed mature HNE, PR3, and CG isolated from azurophilic granules contain, respectively, 218 (Bode et al., 1986Sinha et al., 1987), 222 (Campanelli et al., 1990b), and 235 (Salvesen et al., 1987Hof et al., 1996) residues. They are present in several isoforms depending on their carbohydrate content, with apparent mass of 29 to 33 kDa upon SDS-polyacrylamide gel electrophoresis (Twumasi and Liener, 1977Watorek et al., 1993). HNE and PR3 display two sites of N-glycosylation, whereas CG possesses only one. NSPs are stored mainly in neutrophil azurophilic granules, but HNE is also localized in the nuclear envelope, as revealed by immunostaining and electron microscopy (Clark et al., 1980;Benson et al., 2003), whereas PR3 is also found in secretory vesicles (Witko-Sarsat et al., 1999a). Upon neutrophil activation, granular HNE, PR3, and CG are secreted extracellularly, although some molecules nevertheless remain at the cell surface (Owen and Campbell, 1999Owen, 2008a). The mechanism through which NSPs are sorted from the trans-Golgi network to the granules has not been completely defined, even though an intracellular proteoglycan, serglycin, has been identified as playing a role in elastase sorting and packaging into azurophilic granules (Niemann et al., 2007). Unlike HNE and CG, PR3 is constitutively expressed on the membranes of freshly isolated neutrophils (Csernok et al., 1990Halbwachs-Mecarelli et al., 1995). Stimulation of neutrophils at inflammatory sites triggers intracytoplasmic granules to translocate to the phagosomes and plasma membrane, thereby liberating their contents. The first step of the translocation to the target membrane depends on cytoskeleton remodeling and microtubule assembly (Burgoyne and Morgan, 2003). This is followed by a second step of granule tethering and docking, which are dependent on the sequential intervention of SNARE proteins (Jog et al., 2007).

…….

Exposure of neutrophils to cytokines (TNF-α), chemoattractants (platelet-activating factor, formyl-Met-Leu-Phe, or IL-8), or bacterial lipopolysaccharide leads to rapid granule translocation to the cell surface with secretion of HNE, PR3, and CG into the extracellular medium (Owen and Campbell, 1999). A fraction of secreted HNE, PR3, and CG is detected at the surface of activated neutrophils (Owen et al., 1995a1997Campbell et al., 2000). Resting purified neutrophils from peripheral blood express variable amounts of PR3 on their surface. A bimodal, apparently genetically determined, distribution has been observed with two populations of quiescent neutrophils that express or do not express the protease at their surface (Halbwachs-Mecarelli et al., 1995Schreiber et al., 2003). The percentage of mPR3-positive neutrophils ranges from 0 to 100% of the total neutrophil population within individuals. Furthermore, the percentage of mPR3-positive neutrophils remains stable over time and is not affected by neutrophil activation (Halbwachs-Mecarelli et al., 1995).

The mechanism through which HNE and CG are associated with the outer surface of the plasma membrane of neutrophils mainly involves electrostatic interactions with the sulfate groups of chondroitin sulfate- and heparan sulfate-containing proteoglycans (Campbell and Owen, 2007). These two proteases are released from neutrophil cell surfaces by high concentrations of salt (Owen et al., 1995b1997;Korkmaz et al., 2005a) and after treatment with chondroitinase ABC and heparinase (Campbell and Owen, 2007). Membrane PR3 is not solubilized by high salt concentrations, which means that its membrane association is not charge dependant (Witko-Sarsat et al., 1999aKorkmaz et al., 2009). Unlike HNE and CG, PR3 bears at its surface a hydrophobic patch formed by residues Phe166, Ile217, Trp218, Leu223, and Phe224 that is involved in membrane binding (Goldmann et al., 1999Hajjar et al., 2008) (Fig. 3B). Several membrane partners of PR3 have been identified, including CD16/FcγRIIIb (David et al., 2005Fridlich et al., 2006), phospholipid scramblase-1, a myristoylated membrane protein with translocase activity present in lipid rafts (Kantari et al., 2007), CD11b/CD18 (David et al., 2003), and human neutrophil antigen NB1/CD177 (von Vietinghoff et al., 2007Hu et al., 2009), a 58- to 64-kDa glycosyl-phosphatidylinositol anchored surface receptor belonging to the urokinase plasminogen activator receptor superfamily (Stroncek, 2007). NB1 shows a bimodal distribution that superimposes with that of PR3 on purified blood neutrophils (Bauer et al., 2007). Active, mature forms of PR3 but not pro-PR3 can bind to the surface of NB1-transfected human embryonic kidney 293 cells (von Vietinghoff et al., 2008) and Chinese hamster ovary cells (Korkmaz et al., 2008b). Interaction involves the hydrophobic patch of PR3 because specific amino acid substitutions disrupting this patch in the closely related gibbon PR3 prevent binding to NB1-transfected cells (Korkmaz et al., 2008b). Decreased interaction of pro-PR3 with NB1-transfected cells is explained by the topological changes affecting the activation domain containing the hydrophobic patch residues. Together, these results support the hydrophobic nature of PR3-membrane interaction.

……..

Roles in Inflammatory Process Regulation

NSPs are abundantly secreted into the extracellular environment upon neutrophil activation at inflammatory sites. A fraction of the released proteases remain bound in an active form on the external surface of the plasma membrane so that both soluble and membrane-bound NSPs are able to proteolytically regulate the activities of a variety of chemokines, cytokines, growth factors, and cell surface receptors. Secreted proteases also activate lymphocytes and cleave apoptotic and adhesion molecules (Bank and Ansorge, 2001Pham, 2006Meyer-Hoffert, 2009). Thus, they retain pro- and anti-inflammatory activities, resulting in a modulation of the immune response at sites of inflammation.

…….

Processing of Cytokines, Chemokines, and Growth Factors.

Processing and Activation of Cellular Receptors.

Induction of Apoptosis by Proteinase 3.

Physiological Inhibitors of Elastase, Proteinase 3, and Cathepsin G

During phagocytosis and neutrophil turnover, HNE, PR3, and CG are released into the extracellular space as active proteases. The proteolytic activity of HNE, PR3, and CG seems to be tightly regulated in the extracellular and pericellular space to avoid degradation of connective tissue proteins including elastin, collagen, and proteoglycans (Janoff, 1985). Protein inhibitors that belong to three main families, the serpins, the chelonianins, and the macroglobulins, ultimately control proteolytic activity of HNE, PR3, and CG activities. The individual contributions of these families depend on their tissue localization and that of their target proteases. The main characteristics of HNE, PR3, and CG physiological inhibitors are presented in Table 2.

 

Serine Protease Inhibitors

Serpins are the largest and most diverse family of protease inhibitors; more than 1000 members have been identified in human, plant, fungi, bacteria, archaea, and certain viruses (Silverman et al., 2001Mangan et al., 2008). They share a similar highly conserved tertiary structure and similar molecular weight of approximately 50 kDa. Human serpins belong to the first nine clades (A–I) of the 16 that have been described based on phylogenic relationships (Irving et al., 2000Silverman et al., 2001Mangan et al., 2008). For historical reasons, α1-protease inhibitor (α1-PI) was assigned to the first clade. Clade B, also known as the ov-serpin clan because of the similarity of its members to ovalbumin (a protein that belongs to the serpin family but lacks inhibitory activity), is the second largest clan in humans, with 15 members identified so far. Ov-serpin clan members are generally located in the cytoplasm and, to a lesser extent, on the cell surface and nucleus (Remold-O’Donnell, 1993).

Serpins play important regulatory functions in intracellular and extracellular proteolytic events, including blood coagulation, complement activation, fibrinolysis, cell migration, angiogenesis, and apoptosis (Potempa et al., 1994). Serpin dysfunction is known to contribute to diseases such as emphysema, thrombosis, angioedema, and cancer (Carrell and Lomas, 1997Lomas and Carrell, 2002). Most inhibitory serpins target trypsin-/chymotrypsin-like serine proteases, but some, termed “cross-class inhibitors,” have been shown to target cysteine proteases (Annand et al., 1999). The crystal structure of the prototype plasma inhibitor α1-PI revealed the archetype native serpin fold (Loebermann et al., 1984). All serpins typically have three β-sheets (termed A, B, and C) and eight or nine α-helices (hA–hI) arranged in a stressed configuration. The so-called reactive center loop (RCL) of inhibitory molecules determines specificity and forms the initial encounter complex with the target protease (Potempa et al., 1994Silverman et al., 2001). Serpins inhibit proteases by a suicide substrate inhibition mechanism. The protease initially recognizes the serpin as a potential substrate using residues of the reactive center loop and cleaves it between P1 and P1′ This cleavage allows insertion of the cleaved RCL into the β-sheet A of the serpin, dragging the protease with it and moving it over 71 Å to the distal end of the serpin to form a 1:1 stoichiometric covalent inhibitory complex (Huntington et al., 2000). Such cleavage generates a ∼4-kDa C-terminal fragment that remains noncovalently bound to the cleaved serpin. Displacement of the covalently attached active site serine residue from its catalytic partner histidine explains the loss of catalytic function in the covalent complex. The distortion of the catalytic site structure prevents the release of the protease from the complex, and the structural disorder induces its proteolytic inactivation (Huntington et al., 2000). Covalent complex formation between serpin and serine proteases triggers a number of conformational changes, particularly in the activation domain loops of the bound protease (Dementiev et al., 2006).

………

Pathophysiology of Elastase, Proteinase 3 and Cathepsin G in Human Diseases

In many instances, the initiation and propagation of lung damage is a consequence of an exaggerated inappropriate inflammatory response, which includes the release of proteases and leukocyte-derived cytotoxic products (Owen, 2008b;Roghanian and Sallenave, 2008). Inflammation is a physiological protective response to injury or infection consisting of endothelial activation, leukocyte recruitment and activation, vasodilation, and increased vascular permeability. Although designed to curtail tissue injury and facilitate repair, the inflammatory response sometimes results in further injury and organ dysfunction. Inflammatory chronic lung diseases, chronic obstructive pulmonary disease, acute lung injury, acute respiratory distress syndrome, and cystic fibrosis are syndromes of severe pulmonary dysfunction resulting from a massive inflammatory response and affecting millions of people worldwide. The histological hallmark of these chronic inflammatory lung diseases is the accumulation of neutrophils in the microvasculature of the lung. Neutrophils are crucial to the innate immune response, and their activation leads to the release of multiple cytotoxic products, including reactive oxygen species and proteases (serine, cysteine, and metalloproteases). The physiological balance between proteases and antiproteases is required for the maintenance of the lung’s connective tissue, and an imbalance in favor of proteases results in lung injury (Umeki et al., 1988Tetley, 1993). A number of studies in animal and cell culture models have demonstrated a contribution of HNE and related NSPs to the development of chronic inflammatory lung diseases. Available preclinical and clinical data suggest that inhibition of NSP in lung diseases suppresses or attenuates the contribution of NSP to pathogenesis (Chughtai and O’Riordan, 2004Voynow et al., 2008Quinn et al., 2010). HNE could also participate in fibrotic lung remodeling by playing a focused role in the conversion of latent transforming growth factor-β into its biologically active form (Chua and Laurent, 2006Lungarella et al., 2008).

Anti-Neutrophil Cytoplasmic Autoantibody-Associated Vasculitides

ANCA-associated vasculitides encompasses a variety of diseases characterized by inflammation of blood vessels and by the presence of autoantibodies directed against neutrophil constituents. These autoantibodies are known as ANCAs (Kallenberg et al., 2006). In Wegener granulomatosis (WG), antibodies are mostly directed against PR3. WG is a relatively uncommon chronic inflammatory disorder first described in 1931 by Heinz Karl Ernst Klinger as a variant of polyarteritis nodosa (Klinger, 1931). In 1936, the German pathologist Friedrich Wegener described the disease as a distinct pathological entity (Wegener, 19361939). WG is characterized by necrotizing granulomatous inflammation and vasculitis of small vessels and can affect any organ (Fauci and Wolff, 1973Sarraf and Sneller, 2005). The most common sites of involvement are the upper and lower respiratory tract and the kidneys. WG affects approximately 1 in 20,000 people; it can occur in persons of any age but most often affects those aged 40 to 60 years (Walton, 1958Cotch et al., 1996). Approximately 90% of patients have cold or sinusitis symptoms that fail to respond to the usual therapeutic measures and that last considerably longer than the usual upper respiratory tract infection. Lung involvement occurs in approximately 85% of the patients. Other symptoms include nasal membrane ulcerations and crusting, saddle-nose deformity, inflammation of the ear with hearing problems, inflammation of the eye with sight problems, and cough (with or without hemoptysis).

Hereditary Neutropenias

Neutropenia is a hematological disorder characterized by an abnormally low number of neutrophils (Horwitz et al., 2007). The normal neutrophil count fluctuates across human populations and within individual patients in response to infection but typically lies in the range of 1.5 to 5 × 109 cells/liter. Neutropenia is categorized as severe when the cell count falls below 0.5 × 109 cells/liter. Hence, patients with neutropenia are more susceptible to bacterial infections and, without prompt medical attention, the condition may become life-threatening. Common causes of neutropenia include cancer chemotherapy, drug reactions, autoimmune diseases, and hereditary disorders (Berliner et al., 2004Schwartzberg, 2006).

Papillon-Lefèvre Syndrome

……….

New Strategies for Fighting Neutrophil Serine Protease-Related Human Diseases

Administration of therapeutic inhibitors to control unwanted proteolysis at inflammation sites has been tested as a therapy for a variety of inflammatory and infectious lung diseases (Chughtai and O’Riordan, 2004). Depending on the size and chemical nature of the inhibitors, they may be administered orally, intravenously, or by an aerosol route. Whatever the mode of administration, the access of therapeutic inhibitors to active proteases is often hampered by physicochemical constraints in the extravascular space and/or by the partitioning of proteases between soluble and solid phases.

……….

Concluding Remarks

NSPs were first recognized as protein-degrading enzymes but have now proven to be multifunctional components participating in a variety of pathophysiological processes. Thus, they appear as potential therapeutic targets for drugs that inhibit their active site or impair activation from their precursor. Overall, the available preclinical and clinical data suggest that inhibition of NSPs using therapeutic inhibitors would suppress or attenuate deleterious effects of inflammatory diseases, including lung diseases. Depending on the size and chemical nature of inhibitors, those may be administered orally, intravenously, or by aerosolization. But the results obtained until now have not been fully convincing because of the poor knowledge of the biological function of each protease, their spatiotemporal regulation during the course of the disease, the physicochemical constraints associated with inhibitor administration, or the use of animal models in which NSP regulation and specificity differ from those in human. Two different and complementary approaches may help bypass these putative problems. One is to target active proteases by inhibitors at the inflammatory site in animal models in which lung anatomy and physiology are close to those in human to allow in vitro and in vivo assays of human-directed drugs/inhibitors. The other is to prevent neutrophil accumulation at inflammatory sites by impairing production of proteolytically active NSPs using an inhibitor of their maturation protease, DPPI. Preventing neutrophil accumulation at the inflammatory sites by therapeutic inhibition of DPPI represents an original and novel approach, the exploration of which has just started (Méthot et al., 2008). Thus pharmacological inactivation of DPPI in human neutrophils could well reduce membrane binding of PR3 and, as a consequence, neutrophil priming by pathogenic auto-antibodies in WG. In addition, it has been recognized that the intracellular level of NSPs depends on their correct intracellular trafficking. In the future, pharmacological targeting of molecules specifically involved in the correct intracellular trafficking of each NSP could possibly regulate their production and activity, a feature that could be exploited as a therapeutic strategy for inflammatory diseases.

…….

 

 

 

 

 

 

 

 

Read Full Post »

von Willebrand Factor

Larry H. Bernstein, MD, FCAP, Curator

LPBI

 

FDA approves first recombinant von Willebrand factor to treat bleeding episodes

Dr. Anthony Melvin Castro

 

 

12/08/2015 02:44
The U.S. Food and Drug Administration today approved Vonvendi, von Willebrand factor (Recombinant), for use in adults 18 years of age and older who have von Willebrand disease (VWD). Vonvendi is the first FDA-approved recombinant von Willebrand factor, and is approved for the on-demand (as needed) treatment and control of bleeding episodes in adults diagnosed with VWD.
Company Baxalta Inc.
Description Recombinant human von Willebrand factor (vWF)
Molecular Target von Willebrand factor (vWF)
Mechanism of Action
Therapeutic Modality Biologic: Protein
Latest Stage of Development Registration
Standard Indication Bleeding
Indication Details Treat and prevent bleeding episodes in von Willebrand disease (vWD) patients; Treat von Willebrand disease (vWD)
Regulatory Designation U.S. – Orphan Drug (Treat and prevent bleeding episodes in von Willebrand disease (vWD) patients);
EU – Orphan Drug (Treat and prevent bleeding episodes in von Willebrand disease (vWD) patients);
Japan – Orphan Drug (Treat and prevent bleeding episodes in von Willebrand disease (vWD) patients)

 

The U.S. Food and Drug Administration today approved Vonvendi, von Willebrand factor (Recombinant), for use in adults 18 years of age and older who have von Willebrand disease (VWD). Vonvendi is the first FDA-approved recombinant von Willebrand factor, and is approved for the on-demand (as needed) treatment and control of bleeding episodes in adults diagnosed with VWD.

VWD is the most common inherited bleeding disorder, affecting approximately 1 percent of the U.S. population. Men and women are equally affected by VWD, which is caused by a deficiency or defect in von Willebrand factor, a protein that is critical for normal blood clotting. Patients with VWD can develop severe bleeding from the nose, gums, and intestines, as well as into muscles and joints. Women with VWD may have heavy menstrual periods lasting longer than average and may experience excessive bleeding after childbirth.

“Patients with heritable bleeding disorders should meet with their health care provider to discuss appropriate measures to reduce blood loss,” said Karen Midthun, M.D., director of the FDA’s Center for Biologics Evaluation and Research. “The approval of Vonvendi provides an additional therapeutic option for the treatment of bleeding episodes in patients with von Willebrand disease.”

The safety and efficacy of Vonvendi were evaluated in two clinical trials of 69 adult participants with VWD. These trials demonstrated that Vonvendi was safe and effective for the on-demand treatment and control of bleeding episodes from a variety of different sites in the body. No safety concerns were identified in the trials. The most common adverse reaction observed was generalized pruritus (itching).

The FDA granted Vonvendi orphan product designation for these uses.Orphan product designation is given to drugs intended to treat rare diseases in order to promote their development.

Vonvendi is manufactured by Baxalta U.S., Inc., based in Westlake Village, California.

 

von Willebrand Disease

Author: Eleanor S Pollak; Chief Editor: Srikanth Nagalla

Von Willebrand disease (vWD) is a common, inherited, genetically and clinically heterogeneous hemorrhagic disorder caused by a deficiency or dysfunction of the protein termed von Willebrand factor (vWF). Consequently, defective vWF interaction between platelets and the vessel wall impairs primary hemostasis.

vWF, a large, multimeric glycoprotein, circulates in blood plasma at concentrations of approximately 10 mg/mL. In response to numerous stimuli, vWF is released from storage granules in platelets and endothelial cells. It performs two major roles in hemostasis. First, it mediates the adhesion of platelets to sites of vascular injury. Second, it binds and stabilizes the procoagulant protein factor VIII (FVIII). (See Etiology.)

vWD is divided into three major categories: (1) partial quantitative deficiency (type I), (2) qualitative deficiency (type II), and (3) total deficiency (type III). vWD type II is further divided into four variants (IIA, IIB, IIN, IIM), based on characteristics of dysfunctional vWF. These categories correspond to distinct molecular mechanisms, with corresponding clinical features and therapeutic recommendations.

For discussion of vWD in children, see Pediatric Von Willebrand Disease.

http://emedicine.medscape.com/article/206996-overview

 

 

Read Full Post »

Pharmacogenomics visited for Anticoagulant Therapy

Reporter: Demet Sag, PhD


pharmacogenetics algorithm
pharmacogenetics anti-coagulant theraphy

Read Full Post »

News Picks | Hs-Troponin T, Silent Cerebral Ischemia and Complications in Afib

Reporter: Aviva Lev-Ari, PhD, RN

View Video

https://www.youtube.com/v/W3X3bMT_F-M?fs=1&hl=fr_FR

High-sensitivity troponin T outperformed other assays in chest pain patients. Silent cerebral ischemia in Afib. Acute cardioversion.

Sourced through Scoop.it from: www.youtube.com

See on Scoop.itCardiovascular and vascular imaging

Read Full Post »

No evidence to change current transfusion practices for adults undergoing complex cardiac surgery: RECESS evaluated 1,098 cardiac surgery patients received red blood cell units stored for short or long periods

Reporter: Aviva Lev-Ari, PhD, RN

No evidence to change current transfusion practices for adults undergoing complex cardiac surgery

A National Institutes of Health-funded study found no statistical difference in the primary clinical measure — which assessed changes in function of six organs from before to seven days after surgery — between complex cardiac surgery patients receiving transfusions of red blood cell units stored for short (up to 10 days) versus long (21 or more days) periods. These findings indicate there is no need to alter how hospitals currently transfuse blood in adults going through complex cardiac surgical procedures.

Results of the Red Cell Storage Duration Study (RECESS), supported by the NIH’s National Heart, Lung, and Blood Institute (NHLBI), appear today in the New England Journal of Medicine.

In the United States, red blood cell units can be stored up to 42 days after collection. Basic research has documented changes in red blood cell units the longer that they are stored. Some studies, primarily observational, have found an association between the transfusion of blood stored for a longer duration and increased morbidity and mortality. However, the clinical significance of these findings is difficult to determine due to study-design limitations.

RECESS was a multicenter trial conducted at more than two dozen U.S. hospitals from January 2010 to January 2014 by the NHLBI-funded Transfusion Medicine and Hemostasis Clinical Trial Network (TMH CTN). The TMH CTN includes 17 core clinical centers and a data coordinating center. Patients were enrolled at most TMH CTN core clinical centers and some non-network centers.

RECESS evaluated 1,098 cardiac surgery patients who were randomized to receive red blood cell units stored for short or long periods. Patients in the longer storage period group received their transfusions using current care practices.

There was no statistical difference in the change in the primary clinical measure, the Multiple Organ Dysfunction Score (MODS), or mortality from before cardiac surgery to seven or 28 days after the operation for both transfusion groups.  The MODS was evaluated because it is an objective and validated way to assess small changes in six organ systems, which includes respiratory, renal, hepatic, cardiovascular, hematologic and neurologic. There were no statistical differences in the mean number of serious and non-serious adverse events between the two groups.

“RECESS contributes to a long-standing question about whether red blood cell storage duration impacts a patient’s clinical outcome after transfusion.” said Keith Hoots, M.D., director of the NHLBI Division of Blood Diseases and Resources. “These findings are reassuring because they do not support the need to modify transfusion practices in adult patients undergoing complex cardiac surgery. In particular, there does not appear to be something gained by only transfusing red blood products stored for ten days or less.”

Because very few RECESS patients were under 18 years of age, findings primarily apply to adult patients undergoing complex cardiac surgery.

Centers that Participated in RECESS

TMH CTN Core Clinical Centers

  • BloodCenter of Wisconsin, Milwaukee
  • Children’s Hospital, Boston
  • Weill Cornell Medical College, Cornell University, New York City
  • Duke University, Durham, North Carolina
  • Emory University, Atlanta
  • Johns Hopkins Hospital, Baltimore
  • Massachusetts General Hospital, Boston
  • Puget Sound Blood Center, Seattle
  • University of Iowa, Iowa City
  • University of Maryland, Baltimore
  • University of Minnesota, Minneapolis
  • University of North Carolina, Chapel Hill
  • University of Oklahoma Health Sciences Center, Oklahoma City/UT Southwestern Medical Center, Dallas
  • University of Pittsburgh

TMH CTN Data Coordinating Center

  • New England Research Institutes, Watertown, Massachusetts

Non-Network Centers

  • Mayo Clinic, Rochester, Minnesota
  • Vanderbilt University, Nashville, Tennessee
  • Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey
  • St. Luke’s Episcopal — Texas Heart Institute, Houston
  • Baystate Medical Center, Springfield, Massachusetts
  • Indiana/Ohio Heart, Fort Wayne, Indiana
  • Indiana/Ohio Heart, St. Joseph Hospital, Fort Wayne, Indiana
  • University of Florida, Gainesville
  • St. Elizabeth’s Medical Center, Brighton, Massachusetts,
  • Newark Beth Israel Medical Center, New Jersey
  • Aspirus Heart and Vascular Institute, Wausau, Wisconsin
  • Sanford Heart Center, Fargo, North Dakota
  • Columbia University Medical Center, New York City

The National Heart, Lung, and Blood Institute (NHLBI) plans, conducts, and supports research related to the causes, prevention, diagnosis, and treatment of heart, blood vessel, lung, and blood diseases, and sleep disorders. More information about NHLBI is available at http://www.nhlbi.nih.gov.

About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH…Turning Discovery Into Health®

Related Resources

SOURCE

http://www.nih.gov/news/health/apr2015/nhlbi-08.htm

Read Full Post »

Researchers unlock the mysteries of how cells rush to a wound and heal it

Reporter: Aviva Lev-Ari, PhD, RN

 

 

A multidisciplinary research team has discovered how cells know to rush to a wound and heal it — opening the door to new treatments for diabetes, heart disease and cancer. The findings shed light on the mechanisms of cell migration, particularly in the wound-healing process. The results represent a major advancement for regenerative medicine, in which biomedical engineers and other researchers manipulate cells’ form and function to create new tissues, and even organs, to repair, restore or replace those damaged by injury or disease.

 

The answer, it turns out, involves delicate interactions between biomechanical stress, or force, which living cells exert on one another, and biochemical signaling. The University of Arizona researchers discovered that when mechanical force disappears — for example at a wound site where cells have been destroyed, leaving empty, cell-free space — a protein molecule, known as DII4, coordinates nearby cells to migrate to a wound site and collectively cover it with new tissue. What’s more, they found, this process causes identical cells to specialize into leader and follower cells. Researchers had previously assumed leader cells formed randomly. “The results significantly increase our understanding of how tissue regeneration is regulated and advance our ability to guide these processes,” said Pak Kin Wong, UA associate professor of mechanical and aerospace engineering and lead investigator of the research.

 

Wong’s team observed that when cells collectively migrate toward a wound, leader cells expressing a form of messenger RNA, or mRNA, genetic code specific to the DII4 protein emerge at the front of the pack, or migrating tip. The leader cells, in turn, send signals to follower cells, which do not express the genetic messenger. This elaborate autoregulatory system remains activated until new tissue has covered a wound.

 

The same migration processes for wound healing and tissue development also apply to cancer spreading, the researchers noted. The combination of mechanical force and genetic signaling stimulates cancer cells to collectively migrate and invade healthy tissue.

 

Biologists have known of the existence of leader cells and the DII4 protein for some years and have suspected they might be important in collective cell migration. But precisely how leader cells formed, what controlled their behavior, and their genetic makeup were all mysteries — until now. “Knowing the genetic makeup of leader cells and understanding their formation and behavior gives us the ability to alter cell migration,” Wong said.

 

With this new knowledge, researchers can re-create, at the cellular and molecular levels, the chain of events that brings about the formation of human tissue. Bioengineers now have the information they need to direct normal cells to heal damaged tissue, or prevent cancer cells from invading healthy tissue.

Source: www.eurekalert.org

See on Scoop.itCardiovascular and vascular imaging

Read Full Post »

Allogeneic Transfusion Reactions

Writer and Curator: Larry H. Bernstein, MD, FCAP 

 

Introduction

Transfusion Medicine owes much to the discovery of the ABO Blood Groups
by Landsteiner. This was a landmark in the history of immunology.  The next
important discovery was the RhD system in immune hemolytic anemia of the
newborn, which was important in the history of neonatology.  As blood banking
became critical in the preparation, storage, transport, and transfusion of blood
during the Second World War, there was the elucidation of the Kell, MNSs,
Kidd, Duffy, Lewis, and other red cell antigenic systems.  The type and screen
for antibodies, and for red cell compatibility in the crossmatch became routine,
and a formal classification of the antigenic components was created.
Incompatibilities in transfusion mediated reactions were expressed as
allogeneic transfusion reactions.  The red cell was not the only component,
as whole blood was ultimately broken into red cell units, plasma, and platelets,
and eventually a neutrophilic component.  With the development of solid organ
transplantation, the definition of the HLA antigen was a large focus for
compatibility.  Today, the traditional problems of transfusion immuno-compatibility have become displaced in large measure by transplantation
issues.  This piece and that which follows will address allogeneic
transplantation reactions and graft-versus-host disease.

Blood Groups

Although all blood is made of the same basic elements, not all blood is
alike. In fact, there are eight different common blood types, which are
determined by the presence or absence of certain antigens – substances that can trigger an immune response if they are foreign
to the body. Since some antigens can trigger a patient’s immune system
to attack the transfused blood, safe blood transfusions depend on careful
blood typing and cross-matching.

There are four major blood groups determined by the presence or absence
of two antigens – A and B – on the surface of red blood cells:

  • Group A – has only the A antigen on red cells (and B antibody in the plasma)
  • Group B – has only the B antigen on red cells (and A antibody in the plasma)
  • Group AB – has both A and B antigens on red cells (but neither A nor B
    antibody in the plasma)
  • Group O – has neither A nor B antigens on red cells (but both A and B
    antibody are in the plasma)

There are very specific ways in which blood types must be matched for a
safe transfusion. See the chart below:

http://www.redcrossblood.org/sites/arc/files/images/ab_top.gif

In addition to the A and B antigens, there is a third antigen called the
Rh factor, which can be either present (+) or absent ( – ). In general,
Rh negative blood is given to Rh-negative patients, and Rh positive blood
or Rh negative blood may be given to Rh positive patients.

O positive is the most common blood type. Not all ethnic groups have the
same mix of these blood types. Hispanic people, for example, have a relatively
high number of O’s, while Asian people have a relatively high number of B’s.
The mix of the different blood types in the U.S. population is:

Caucasians African American Hispanic Asian
O + 37% 47% 53% 39%
O – 8% 4% 4% 1%
A + 33% 24% 29% 27%
A – 7% 2% 2% 0.5%
B + 9% 18% 9% 25%
B – 2% 1% 1% 0.4%
AB + 3% 4% 2% 7%
AB – 1% 0.3% 0.2% 0.1%

Some patients require a closer blood match than that provided by the ABO
positive/negative blood typing. For example, sometimes if the donor and
recipient are from the same ethnic background the chance of a reaction
can be reduced. That’s why an African-American blood donation may be
the best hope for the needs of patients with sickle cell disease, 98 percent
of whom are of African-American descent.

http://www.redcrossblood.org/learn-about-blood/blood-types

Whether your blood group is type A, B, AB or O is based on the blood types
of your mother and father.

This chart shows the potential blood types you may inherit.

Parent 1 AB AB AB AB B A A O O O
Parent 2 AB B A O B B A B A O
Possible
blood
type
of
child
O X X X X X X
A X X X X X X X
B X X X X X X X
AB X X X X

A blood type (also called a blood group) is a classification of blood based on
the presence or absence of inherited antigenic substances on the surface of
red blood cells (RBCs). These antigens may be proteins, carbohydrates,
glycoproteins, or glycolipids, depending on the blood group system. Some of
these antigens are also present on the surface of other types of cells of
various tissues. Several of these red blood cell surface antigens can stem
from one allele (or very closely linked genes) and collectively form a blood
group system. Blood types are inherited and represent contributions from
both parents. A total of 33 human blood group systems are now recognized
by the International Society of Blood Transfusion (ISBT). The two most
important ones are ABO and the RhD antigen; they determine someone’s
blood type (A, B, AB and O, with +, − or Null denoting RhD status).

Many pregnant women carry a fetus with a blood type which is different from
their own, and the mother can form antibodies against fetal RBCs. Sometimes
these maternal antibodies are IgG, a small immunoglobulin, which can cross
the placenta and cause hemolysis of fetal RBCs, which in turn can lead to
hemolytic disease of the newborn called erythroblastosis fetalis, an illness
of low fetal blood counts that ranges from mild to severe. Sometimes this is
lethal for the fetus; in these cases it is called hydrops fetalis.

ABO_blood_type.svg

ABO_blood_type.svg

http://upload.wikimedia.org/wikipedia/commons/thumb/3/32/ABO_blood_type.svg/824px-ABO_blood_type.svg.png

Blood type (or blood group) is determined, in part, by the ABO blood group antigens

A complete blood type would describe a full set of 30 substances on the surface
of RBCs, and an individual’s blood type is one of many possible combinations
of blood-group antigens. Across the 33 blood groups, over 600 different blood-
group antigens have been found, but many of these are very rare, some being
found mainly in certain ethnic groups.

Almost always, an individual has the same blood group for life, but very rarely
an individual’s blood type changes through addition or suppression of an
antigen in infection, malignancy, or autoimmune disease. Another more
common cause in blood type change is a bone marrow transplant. Bone-marrow transplants are performed for many leukemias and lymphomas,
among other diseases. If a person receives bone marrow from someone
who is a different ABO type (e.g., a type A patient receives a type O bone
marrow), the patient’s blood type will eventually convert to the donor’s type.

Some blood types are associated with inheritance of other diseases; for example,
the Kell antigen is sometimes associated with McLeod syndrome. Certain
blood types may affect susceptibility to infections, an example being the
resistance to specific malaria species seen in individuals lacking the Duffy
antigen. The Duffy antigen, presumably as a result of natural selection, is
less common in ethnic groups from areas with a high incidence of malaria.

The Rh system (Rh meaning Rhesus) is the second most significant blood-
group system in human-blood transfusion with currently 50 antigens.
The most significant Rh antigen is the D antigen, because it is the most
likely to provoke an immune system response of the five main Rh antigens.
It is common for D-negative individuals not to have any anti-D IgG or
IgM antibodies, because anti-D antibodies are not usually produced
by sensitization against environmental substances. However, D-negative
individuals can produce IgG anti-D antibodies following a sensitizing event:
possibly a fetomaternal transfusion of blood from a fetus in pregnancy or
occasionally a blood transfusion with D positive RBCs. Rh disease can
develop in these cases. Rh negative blood types are much less common
in proportion of Asian populations (0.3%) than they are in White (15%).
The presence or absence of the Rh antigens is signified by the + or − sign,
so that for example the A− group does not have any of the Rh antigens.

http://en.wikipedia.org/wiki/Blood_type

Allogeneic blood transfusions: benefit, risks and clinical indications
in countries with a low or high human development index

Carlos Marcucci, Caveh Madjdpour and Donat R. Spahn
Br Med Bull (2004) 70 (1): 15-28. http://dx.doi.org:/10.1093/bmb/ldh023

The risks associated with allogeneic red blood cell (RBC) transfusions differ
significantly between countries with low and high human development indexes
(HDIs). In countries with a low HDI, the risk of infection (HIV, HBV, HCV and
malaria) is elevated. In contrast, in countries with a high HDI, immunological
reactions (hemolytic transfusion reactions, alloimmunization and immuno-suppression) are predominant. Therefore the overall risk associated with RBC
transfusions in low HDI countries is much more significant than that in high HDI
countries. In view of these risks, the limited efficacy of RBC transfusion and its
high costs, this procedure should be used sparingly and rationally.

Red blood cell (RBC) transfusions originating from an unrelated donor are known
as allogeneic RBC transfusions. In the West, i.e. in countries with a high human
development index (HDI), which is an index based on life expectancy, literacy,
enrolment in further education and per capita income, >50% of RBC transfusions
are used in trauma and surgery to compensate for major blood loss.

RBC transfusions are certainly beneficial in specific situations, but are accompanied
by many risks and side effects. Several recent studies have suggested that RBC
transfusions are associated with major adverse outcomes and high costs. In addition,
RBC transfusions are a limited resource and blood shortages can occur at times.

The risk of viral transmission via RBC transfusions has decreased considerably
in recent years in high HDI countries, although new transfusion-transmitted
viruses have been discovered.14 In contrast, in countries with medium or low
HDIs, the risk of transmission of infectious diseases may still be extremely high.

Most reviews consider risks on transfusion-transmissible infections and
immunological reactions, associated with RBC transfusions, that are only
applicable to Western countries, i.e. countries with a high HDI. Although 83%
of the global population live in countries with medium and low HDIs, they
have access to only 40% of the global blood supply. Most notably, all blood
donations in high HDI countries are screened for transfusion-transmissible
infections, whereas only 57% of blood donations in medium and low HDI
countries are tested. In addition, the tests used for blood screening are
not always comparable. For example, only four of the 19 countries
participating in the ‘Workshop of the Directors of National Blood Transfusion
Services’, held in Harare, Zimbabwe, in 2000, used p24 antigen testing for
HIV blood screening.18 Moreover, the blood donation rate per 1000 population
is almost 20 times higher in developed countries than in countries with a low HDI.
Regular non-remunerated volunteers, who are the safest donors, provide 98%
of donations in high HDI countries. In contrast, such donors are a minority in
low HDI countries where up to 60% of donated blood comes from relatives of
the anemic patient or from paid donors.

Acute extravascular hemolytic transfusion reaction due to
anti-Kpa antibody missed by electronic crossmatch

Ruth Padmore, Philip Berardi, …, Doris Neurath, Elianna Saidenberg
Transfusion and Apheresis Science 51 (2014) 168–171
http://dx.doi.org/10.1016/j.transci.2014.08.011

Background: Kpa antigen is a low incidence red blood cell antigen within the Kell
system. Anti-Kpa alloantibody may be associated with acute and delayed hemolytic
transfusion reactions.
Case Study: We report a case of a clinically significant acute extravascular
hemolytic transfusion reaction mediated by previously unrecognized (and
undetected) anti-Kpa alloantibody. This reaction occurred in a patient who
met all criteria for electronic crossmatch, resulting in the transfusion of an
incompatible red cell unit.
Results: Post-transfusion investigation showed the transfused red cell unit
was crossmatch compatible at the immediate spin phase but was 3 + incompatible
at the antiglobulin phase.No evidence of intravascular hemolysis was observed
upon visual comparison of the pre and post-transfusion peripheral blood plasma.
Further testing showed the presence of anti-Kpa antibody. The clinical course
of the patient included acute febrile and systemic reaction.
Conclusion: Acute extravascular hemolytic transfusion reaction may occur due
to undetected anti-Kpa alloantibody. Various strategies for crossmatching are
discussed in the context of antibodies to low incidence antigens.

Transfusion-related mortality: the ongoing risks of allogeneic blood
transfusion and the available strategies for their prevention

Eleftherios C. Vamvakas and Morris A. Blajchman
Blood. 2009; 113: 3406-3417
http://dx.doi.org:/10.1182/blood-2008-10-167643

As the risks of allogeneic blood transfusion (ABT)–transmitted viruses were
reduced to exceedingly low levels in the US, transfusion-related acute lung injury
(TRALI), hemolytic transfusion reactions (HTRs), and transfusion-associated
sepsis (TAS) emerged as the leading causes of ABT related deaths. Since 2004,
preventive measures for TRALI and TAS have been implemented, but their
implementation remains incomplete. Infectious causes of ABT-related deaths
currently account for less than 15% of all transfusion-related mortality, but the
possibility remains that a new transfusion-transmitted agent causing a fatal
infectious disease may emerge in the future. Aside from these established
complications of ABT, randomized controlled trials comparing recipients of
non–white blood cell (WBC)–reduced versus WBC-reduced blood components
in cardiac surgery have documented increased mortality in association with
the use of non-WBC–reduced ABT. ABT-related mortality can thus be further
reduced by universally applying the policies of avoiding prospective donors
alloimmunized to WBC antigens from donating plasma products, adopting
strategies to prevent HTRs, WBC-reducing components transfused to patients
undergoing cardiac surgery, reducing exposure to allogeneic donors through
conservative transfusion guidelines and avoidance of product pooling, and
implementing pathogen-reduction technologies to address the residual risk of TAS as well as the potential risk of a transfusion transmitted agent to emerge
in the foreseeable future.

Red blood cell-incompatible allogeneic hematopoietic progenitor cell
transplantation

S D Rowley, M L Donato and P Bhattacharyya
Bone Marrow Transplantation (2011) 46, 1167–1185; http://dx.doi.org:/10.1038/bmt.2011.135

Transplantation of hematopoietic progenitor cells from red cell-incompatible
donors occurs in 30–50% of patients. Immediate and delayed hemolytic
transfusion reactions are expected complications of red cell-disparate
transplantation and both ABO and other red cell systems such as Kidd
and rhesus can be involved. The immunohematological consequences of
red cell-incompatible transplantation include delayed red blood cell recovery,
pure red cell aplasia and delayed hemolysis from viable lymphocytes carried
in the graft (‘passenger lymphocytes’). The risks of these reactions, which
may be abrupt in onset and fatal, are ameliorated by graft processing and
proper blood component support. Red blood cell antigens are expressed on
endothelial and epithelial tissues in the body and could serve to increase
the risk of GvHD. Mouse models indicate that blood cell antigens may
function as minor histocompatibility antigens affecting engraftment. Similar
observations have been found in early studies of human transplantation
for transfused recipients, although current conditioning and immuno-suppressive regimens appear to overcome this affect. No deleterious effects
from the use of red cell-incompatible hematopoietic grafts on transplant
outcomes, such as granulocyte and platelet engraftments, the incidences
of acute or chronic GvHD, relapse risk or OS, have been consistently
demonstrated. Most studies, however, include limited number of patients,
varying diagnoses and differing treatment regimens, complicating the
detection of an effect of ABO-incompatible transplantation. Classification
of patients by ABO phenotype ignoring the allelic differences of these
antigens also may obscure the effect of red cell-incompatible transplantation
on transplant outcomes.

Severe hemolytic transfusion reaction due to anti-A1 following allogeneic
stem cell transplantation with minor ABO incompatibility

Çiğdem Akalın Akkok, Håkon Haugaa, Anders Galgerud, Lorentz Brinch
Transfusion and Apheresis Science 2013; 48(1), Pages 63–66
http://dx.doi.org/10.1016/j.transci.2012.07.006

Blood components should be compatible both with the recipient and the
donor in the ABO incompatible allogeneic stem cell transplantation setting.
A patient with blood type A2 received peripheral blood stem cells from a
blood type O donor. The patient was in critical condition due to treatment-
related toxicity. He had acquired anti-A1 that was unfortunately overlooked.
Following transfusion of A1 red blood cells in error, he developed a severe
hemolytic transfusion reaction. Anti-A1 is rarely clinically significant.
We discuss the role of passenger lymphocytes in development of the anti-A1, and stress the importance of investigating unusual/atypical reactions
in blood typing.

Transfusion Support of Allogeneic Stem Cell Transplant Recipients

Kate Chipperfield MD FRCPC  21 Feb 2012

After this session, the learner will be able to:

  1. Provide an overview of transfusion issues in allogeneic stem cell transplant.
  2. Discuss the potential consequences of ABO mismatch between recipient
    and donor.
  3. Understand the rationale for ABO/D group selection of blood product support
    peri-stem cell transplant.
  4. Appreciate the special impact of umbilical cord blood stem cell transplant.
  5. Briefly outline variable practices in transfusion support of stem cell
    transplantation.

Pre-transplant

  • Leukocyte Reduction

– reduction in HLA Alloimmunization (TRAP study)

– reduction in CMV infection in seronegative candidates*

  • Avoidance of directed donations
  • Irradiation of cellular blood products

– Only from start of SCT conditioning (to end of GVHD prophylaxis or
lymphs >1 x 109/L)

  • Issues with this

– as soon as identified as potential SCT recipient*

– prevention of microchimerism in intended recipient (donor lymphocytes)

 

ABO and SCT

  • Any allogeneic SCT will be one of:

– ABO-Identical

– Major ABO Incompatible

– Minor ABO Incompatible

– Major and Minor incompatible (Bidirectional)

(more not shown)

Major ABO Blood Group Mismatch Increases the Risk for Graft Failure
after Unrelated Donor Hematopoietic Stem Cell Transplantation

Mats Remberger, E Watz, O Ringdén, J Mattsson, A Shanwell, A Wikman
Biology of Blood and Marrow Transplantation 13:675-682 (2007)
http://dx.doi.org:/10.1016/j.bbmt.2007.01.084

Two hundred twenty-four patients with leukemia transplanted with an unrelated
donor between 1991 and 2003 at the Karolinska University Hospital were
analyzed according to association between graft failure and ABO, RhD, MNSs,
and Kidd blood group antigen compatibility. Median age was 29 years
(range: 0-55). Conditioning consisted of total-body irridiation or busulfan-based myeloablative conditioning. A bone marrow graft was given to 152
patients, and 72 patients received peripheral blood stem cells. Most patients
received graft-versus-host disease prophylaxis with cyclosporine and MTX.
Graft failure (GF) was seen in 6 (2.7%) patients. In the multivariate analysis
major ABO mismatch (odds ratio [OR] 14.9, 95% confidence interval
[CI] 2.01-110, P = .008) and HLA-allele mismatch (6.42, 1.19-34.8, P = .03)
was significantly associated to GF. In patients with and without major ABO
mismatch the incidence of GF was 7.5% and 0.6% (P = .02), respectively.
Using an ABO major mismatched graft increases the risk for GF after
unrelated donor hematopoietic stem cell transplantation.

Perioperative transfusion-related acute lung injury: The Canadian
Blood Services experience

Asim Alam, Mary Huang, Qi-Long Yi, Yulia Lin, Barbara Hannach
Transfusion and Apheresis Science 50 (2014) 392–398
http://dx.doi.org/10.1016/j.transci.2014.04.008

Purpose: Transfusion-related acute lung injury (TRALI) is a devastating transfusion-associated adverse event. There is a paucity of data on the incidence and
characteristics of TRALI cases that occur perioperatively. We classified
suspected perioperative TRALI cases reported to Canadian Blood Services
between 2001 and 2012, and compared them to non-perioperative cases
to elucidate factors that may be associated with an increased risk of developing
TRALI in the perioperative setting. Methods: All suspected TRALI cases
reported to Canadian Blood Services (CBS) since 2001 were reviewed by
two experts or, from 2006 to 2012, the CBS TRALI Medical Review Group
(TMRG). These cases were classified based on the Canadian Consensus
Conference (CCC) definitions and detailed in a database. Two additional
reviewers further categorized them as occurring within 72 h from the onset of
surgery (perioperative) or not in that period (non-perioperative). Various
demographic and characteristic variables of each case were collected and
compared between groups. Results: Between 2001 and 2012, a total of
469 suspected TRALI cases were reported to Canadian Blood Services;
303 were determined to be within the TRALI diagnosis spectrum. Of those,
112 (38%) were identified as occurring during the perioperative period.
Patients who underwent cardiac surgery requiring cardiopulmonary bypass
(25.0%), general surgery (18.0%) and orthopedics patients (12.5%) represented
the three largest surgical groups. Perioperative TRALI cases comprised more
men (53.6% vs. 41.4%, p = 0.04) than non-perioperative patients. Perioperative
TRALI patients more often required supplemental O2 (14.3% vs. 3.1%, p = 0.0003),
mechanical ventilation (18.8% vs. 3.1%), or were in the ICU (14.3% vs. 3.7%,
p = 0.0043) prior to the onset of TRALI compared to non-perioperative TRALI
patients. The surgical patients were transfused on average more components
than non-perioperative patients (6.0 [SD = 8.3] vs. 3.6 [5.2] products per patient,
p = 0.0002).  Perioperative TRALI patients were transfused more plasma (152
vs. 105, p = 0.013) and cryoprecipitate (51 vs. 23, p < 0.01) than nonperioperative
TRALI patients. There was no difference between donor antibody test results
between the groups. Conclusion: CBS data has provided insight into the
nature of TRALI cases that occur perioperatively; this group represents a
large proportion of TRALI cases.

Platelet allo-antibodies identification strategies forpreventing and
managing platelet refractoriness

Basire, C.Picard
Transfusion Clinique et Biologique 21(2014)193–206
http://dx.doi.org/10.1016/j.tracli.2014.08.140

Platelet refractoriness is a serious complication for patients receiving recurrent
platelet transfusions ,which can be explained by non-immune and immune causes.
Human Leukocyte Antigens (HLA) allo-immunization, especially against HLA
class I, is the major cause for immune platelet refractoriness. To a lesser extent,
alloantibodies against specific Human Platelet Antigen (HPA) are also involved.
Pregnancy, transplantation and previous transfusions can lead to allo-immune reaction against platelet antigens. After transfusion, platelet count
is decreased by accelerated platelet destruction related to antibodies
fixation on incompatible platelet antigens. New laboratory tests for allo-antibodies identification were developed to improve sensibility and specificity,
especially with the LUMINEX® technology. The good use and interpretation
of these antibodies assays can improve strategies for platelet refractoriness
prevention and management with a patient adapted response. Compatible
platelets units can be selected according to their identity with recipient
typing or immune compatibility regarding HLA or HPA antibodies or HLA
epitope compatibility. Prospective studies are needed to further confirm the
clinical benefit of new allo-antibodies identification methods and consensus
strategies for immune platelet refractoriness management.

For Anti-HLA-Specific Donor Antibodies Detection By Flow Cytometry
Cytotoxic 
Crossmatches Comparison of Methods

Cervelli, F. Pisani, A. Aureli, R. Azzarone, ..,  A. Famulari, and F. Papola Transplantation Proceedings, 45, 2761e2764 (2013)
http://dx.doi.org/10.1016/j.transproceed.2013.07.023

Anti-HLA-specific donor antibodies induce rapid, irreversible destruction of
the transplant (hyperacute rejection) that today happens rarely due to
immunologic studies prospective crossmatch of patients awaiting the kidney
graft. The usual approach for pretransplant donor/recipient evaluation is
based on 2 methods: (1) the cytotoxic complement crossmatch (CDC) and
(2) the flow cytometric crossmatch  (FCX). The CDC crossmatch is positive
when complement-fixing antibodies are present, an absolute contra-
indication to kidney transplantation. The more sensitive FCX-positive
crossmatch detects low concentrations of unable to fix performed
antibodies complement. It is an  “index” of possible damage due to
accelerated rejection. The target of our study was to develop a cytotoxic
flow cytometry crossmatch (cFCX) that detected cytotoxic antibodies
move sensitively  than the traditional CDC method and also was less
subjective and more standardized for interpretation studying sera from
23 patients; the cFCX showed the requested efficiency characteristics even
in an emergency. In addition, the new method permitted one to calculate a
cutoff for positivity (average value of the negative control at + 2 standard
deviations), assuring an “objective” interpretation of the results that agreed
with the CDC but was more sensitive and accurate allowing solution of
ambiguous results for cases of “doubt”-positive CDC crossmatch.
Furthermore, our aim was to correlate the effect of the strength of the anti-HLA
antibodies determined by mean fluorescence intensity value of LabScreen
Single Antigen beads with results of CDC, cFCX, and FCX methods.

Allogeneic Stem Cell Transplants and Associated Incompatibities

Analysis of Donor and Recipient ABO Incompatibility and Antibody-
Associated Complications after Allogeneic Stem Cell Transplantation
with Reduced-Intensity Conditioning

Emma Watz, Mats Remberger, Olle Ringden, Joachim Lundahl, et al.
Biol Blood Marrow Transplant 20 (2014) 264e271
http://dx.doi.org/10.1016/j.bbmt.2013.11.011

Allogeneic hematopoietic stem cell transplantation (HSCT) can be performed
across the ABO blood group barrier. The impact of ABO incompatibility on
clinical outcome is controversial. A retrospective analysis of 310 patients who
underwent HSCT with reduced-intensity conditioning between 1998 and 2011
was performed to investigate the frequency and clinical implications of anti-RBC
antibodies in passenger lymphocyte syndrome (PLS) after minor ABO mismatch
(mm), persistent or recurring recipient type ABO antibodies (PRABO) after major
ABO mm HSCT, and autoimmune hemolytic anemia (AIHA). Transplantation
characteristics and clinical outcome were analyzed by univariate and multivariate
analysis for groups with or without anti-RBC antibodies. ABO blood group
incompatibility did not affect clinical outcome despite an increased requirement
of blood transfusion. Twelve patients with AIHA, 6 patients with PLS, and 12
patients with PRABO post-HSCT were identified. AIHA did not affect overall
survival (OS) or transplant-related mortality (TRM), but patients with AIHA had
a lower incidence of grades II to IV acute graft-versus-host disease (P < .05).
OS in the PLS group was 0% compared with 61% in the whole group receiving
minor ABO mm transplants (P < .001). Comparing PRABO patients with those
receiving a major ABO mm HSCT, the OS was 17% versus 73% (P <.002) and
TRM was 50% versus 21% (P < .03). At our center, PLS after minor ABO mm
and PRABO antibodies after major ABO mm HSCT are significant risk factors
for decreased OS and TRM. Our results suggest that occurrence of unexpected
ABO antibodies after HSCT warrant a wider investigation individual to find the
underlying cause.

Current Trends in Clinical Studies of Allogeneic Hematopoietic Stem Cell
Transplantation

Sophie Pilon, D Jedrysiak, D Sheppard, CN Bredeson, J Tay, DS Allan
Biol Blood Marrow Transplant 21 (2015) 364e381
http://dx.doi.org/10.1016/j.bbmt.2014.09.014

Allogeneic hematopoietic stem cell transplantation (HSCT) is a specialized
intervention performed at select centers worldwide. The extent to which
specific aspects of care in allogeneic HSCT have been studied and the
types of studies performed for different aspects of care remains incompletely
documented. Studies in allogeneic HSCT were systematically identified from
selected high-profile transplant journals between July 2010 and June 2011
and previously reported in a study addressing the definition of clinical outcomes
in HSCT. All articles were retrieved and assessed for study characteristics and
categorized by specific aspects of care related to allogeneic HSCT. One
hundred sixteen articles were retrieved and reviewed in detail by  investigators.
The most studied aspect of care was conditioning regimens. Transfusion
practices were the most understudied aspect of care. Interestingly, most
studies included both adult and pediatric patients. Studies involving all
hematological malignancies were encountered more often than disease-
specific studies. Geographically, most patients described in the published reports
were treated only in North America or only in Europe. Most studies were
retrospective (78), and 25 reported on multicenter registry data.  Of the 38
prospective studies, 8 were randomized controlled trials (RCTs) and
predominantly focused on prevention and treatment of graft-versus-host disease
(GVHD) and infections. Median follow-up was longer in retrospective registry
studies (54 months) and shortest in RCTs (32 months). The proportion of
positive outcomes in retrospective and prospective studies was remarkably
high (>80% for all categories) and not significantly different across all aspects
of care (P > .05). When comparing RCTs and registry data studies, this proportion
was similar and high (95% and 100%, respectively, P >.05). Our study highlights
the established and important role of retrospective registry studies for many
aspects of care and suggests RCTs may be most relevant for studies on
infectious complications and GVHD.

Efficacy and Long-Term Outcome of Treatment for Pure Red Cell Aplasia
after Allogeneic Stem Cell Transplantation from Major ABO-Incompatible
Donors

Makoto Hirokawa, T Fukuda, K Ohashi, …, H Sakamaki, for The PRCA
Collaborative Study Group
Biol Blood Marrow Transplant 19 (2013) 1026e1032
http://dx.doi.org/10.1016/j.bbmt.2013.04.004

No standard of care for pure red cell aplasia (PRCA) after major ABO-
incompatible hematopoietic stem cell transplantation (HSCT) has been
established. We conducted a retrospective cohort study to learn the
efficacy and outcome of treatment for PRCA. One hundred forty-five
recipients who showed delayed recovery of erythropoiesis and survived
>100 days after transplantation without early disease progression were
selected from 2846 records of major ABO-incompatible transplantation
in the registry database in Japan, and detailed data of 46 recipients
were collected. Treatment of PRCA, such as rapid tapering of calcineurin
inhibitors, corticosteroids, or additional immunosuppressants, was given
to 22 patients but not to the other 24 patients. The overall response rate
of the treatment group was 54.5%. The number of days from diagnosis of
PRCA to recovery of reticulocytes >1% and the cumulative number of red
blood cell transfusions were not significantly different between the 2 groups.
Infections accounted for the death of 7 of 11 patients in the treatment group.
Univariate analysis identified 5 variables influencing survival, including graft-
versus-host disease, disease progression, and treatment of PRCA; disease
progression remained as the only factor negatively affecting survival by
multivariate analysis. The present study could not provide supportive
evidence for the beneficial effects of treatment for PRCA after major
ABO-mismatched HSCT.

Current therapy of myelodysplastic syndromes

Amer M. Zeidan, Yuliya Linhares, Steven D. Gore
Blood Reviews 27 (2013) 243–259
http://dx.doi.org/10.1016/j.blre.2013.07.003

After being a neglected and poorly-understood disorder for many years, there
has been a recent explosion of data regarding the complex pathogenesis of
myelodysplastic syndromes (MDS). On the therapeutic front, the approval of
azacitidine, decitabine, and lenalidomide in the last decade was a major
breakthrough. Nonetheless, the responses to these agents are limited and
most patients progress within 2 years. Allogeneic stem cell transplantation
remains the only potentially curative therapy, but it is associated with significant
toxicity and limited efficacy. Lack or loss of response after standard therapies
is associated with dismal outcomes. Many unanswered questions remain
regarding the optimal use of current therapies including patient selection,
response prediction, therapy sequencing and combinations, and management
of resistance. It is hoped that the improved understanding of the underpinnings
of the complex mechanisms of pathogenesis will be translated into novel
therapeutic approaches and better prognostic/predictive tools that would
facilitate accurate risk-adaptive therapy.

Donor Selection for Killer Immunoglobulin-like Receptors B Haplotype
of the Centromeric Motifs Can Improve the Outcome after HLA-Identical
Sibling Hematopoietic Stem Cell Transplantation

Huifen Zhou, Xiaojing Bao, …, Miao Wang, Depei Wu, Jun He
Biol Blood Marrow Transplant 20 (2014) 98e105
http://dx.doi.org/10.1016/j.bbmt.2013.10.017

After hematopoietic stem cell transplantation (HSCT), natural killer (NK) cell
alloreactivity in HLA cells of recipients is regulated by killer immunoglobulin-like
receptors (KIRs) on donor NK cells. The effect of KIRs on HSCT outcomes
is controversial, particularly in those undergoing HLA-identical sibling HSCT.
In this study, effects of KIR and HLA genotypes on the HSCT outcome were
investigated in a 5-year retrospective study comprising 219 patient-donor pairs
undergoing HLA-identical sibling HSCT for myeloid and lymphoid malignancies.
We found that 39.7% (87 of 219) of these pairs, which were KIR mismatched,
had better overall survival (OS) and reduced grade III to IV acute graft-versus-
host disease (aGVHD), especially in acute myeloid leukemia (AML) patients.
Bx1 donor KIR genotype with haplotype B on a telomeric region was a risk
factor for the OS and relapse-free survival (RFS). Donor centromeric (c) and
telomeric (t) KIR haplotype analysis showed that donor KIR cB-tA/tB was
associated with improved OS and RFS compared with cA-tA or cA-tB.
Furthermore, donor KIR B haplotype of the centromeric motifs (Cen-B) was
an independent beneficial factor in improving OS and RFS and in protecting
from relapse after HSCT. In AML patients, the occurrence of a GVHD was
significantly lower in HLA-C1 group compared with that in HLA-C2 group,
although such effect was not observed in patients with acute lymphoblastic
leukemia or chronic myelogenous leukemia. Our results suggest that KIR
could impact outcome and donor KIR haplotype with Cen-B confer significant
survival benefits to HLA-identical sibling HSCT.

TEL-AML1 Corrupts Hematopoietic Stem Cells to Persist in the Bone
Marrow and Initiate Leukemia

Jeffrey W. Schindler, D Van Buren, A Foudi, O Krejci, J Qin, SH Orkin, and H Hock
Cell Stem Cell 5, 43–53, July 2, 2009
http://dx.doi.org:/10.1016/j.stem.2009.04.019

The initial steps in the pathogenesis of acute leukemia remain incompletely
understood. The TELAML1 gene fusion, the hallmark translocation in Childhood
Acute Lymphoblastic Leukemia and the first hit, occurs years before the clinical
disease, most often in utero. We have generated mice in which TEL-AML1
expression is driven from the endogenous promoter and can be targeted to
specific populations. TEL-AML1 renders mice prone to malignancy after
chemical mutagenesis when expressed in hematopoietic stem cells (HSCs),
but not in early lymphoid progenitors. We reveal that TEL-AML1 markedly
increases the number of HSCs and predominantly maintains them in the
quiescent (G0) stage of the cell cycle. TEL-AML1+ HSCs retain self renewal
properties and contribute to hematopoiesis, but fail to out-compete normal
HSCs. Our work shows that stem cells are susceptible to subversion by weak
oncogenes that can subtly alter their molecular program to provide a latent
reservoir for the accumulation of further mutations.

Factors Affecting the Outcome of Related Allogeneic Hematopoietic
Cell Transplantation in Patients with Fanconi Anemia

Mouhab Ayas, K Siddiqui, A Al-Jefri, , …, A Al-Musa, A Al-Seraihy
Biol Blood Marrow Transplant 20 (2014) 1599e1603
http://dx.doi.org/10.1016/j.bbmt.2014.06.016

Hematopoietic cell transplantation (HCT) can cure bone marrow failure in
patients with Fanconi Anemia (FA), and it is generally accepted that these
patients should receive low-intensity conditioning because of the underlying
DNA repair defect in their cells. Outcomes for recipients of matched related
HCT have generally been favorable, but only a few studies have scrutinized
the factors that may affect the eventual outcome of these patients. This
retrospective analysis of 94 pediatric patients with FA who underwent related
HCT at King Faisal Specialist Hospital & Research Center was carried out to
attempt to identify factors that may affect outcome. Results showed overall
survival (OS) probabilities of 92.5%, 89%, and 86% at 1, 5, and 10 years,
respectively. In univariate analysis, use of higher dose cyclophosphamide
(CY) (60 mg/kg) conditioning was associated with a better 10-year OS than
lower dose CY (20 mg/kg) conditioning (91% versus 82%, respectively;
P < .035), and use of radiation-containing regimens was associated with a
significantly lower 10-year OS than nonradiation regimens (76% versus 91%,
respectively; P < .005). Of the 4 regimens used in this study, the fludarabine-
based regimen was associated with the highest survival (95.2%; P < .034).
The use of the higher dose CY (60 mg/kg) was associated with a
significantly increased incidence of hemorrhagic cystitis (HC) (20% versus 5.6%
respectively; P < .049). Three patients (3%) developed squamous cell carcinoma
(2 oropharyngeal and 1 genitourinary), at 9.4, 5.4, and 13.3 years after HCT;
2 of them had radiation containing conditioning. In conclusion, our data suggest
that although using a higher dose CY (60 mg/kg)
conditioning regimen may be associated with better survival, it is also associated
with a significantly increased risk of HC. The addition of fludarabine to the low-dose
CY (20 mg/kg) is associated with the best survival. On the other hand, radiation-
containing regimens are associated with significantly lower survival.

Donor Cell Leukemia: A Review

Daniel H. Wiseman
Biol Blood Marrow Transplant 17: 771-789 (2011)
http://dx.doi.org:/10.1016/j.bbmt.2010.10.010

Relapse of acute leukemia following hematopoietic stem cell transplantation
(HSCT) usually represents return of an original disease clone, having evaded
eradication by pretransplant chemo-/radiotherapy, conditioning, or posttransplant
graft-versus-leukemia (GVL) effect. Rarely, acute leukemia can develop
de novo in engrafted cells of donor origin. Donor cell leukemia (DCL) was
first recognized in 1971, but for many years, the paucity of reported cases
suggested it to be a rare phenomenon. However, in recent years, an upsurge
in reported cases (in parallel with advances in molecular chimerism monitoring)
suggest that it may be significantly more common than previously appreciated;
emerging evidence suggests that DCL might represent up to 5% of all post-
transplant leukemia ‘‘relapses.’’ Recognition of DCL is important for several
reasons. Donor-derivation of the leukemic clone has implications when selecting
appropriate therapy, because seeking to enhance an allogeneic GVL effect
would intuitively not have the same role as in standard recipient-derived
relapses. There are also broader implications for donor selection and workup,
particularly given the growing popularity of nonmyeloblative HSCTand
corresponding rising age of the potential donor pool. Identification of DCL
raises potential concerns over future health of the donor, posing ethical
dilemmas regarding responsibilities toward donor notification (particularly
in the context of cord blood transplantation). The entity of DCL is also of
research interest, because it might provide a unique human model for studying
the mechanisms of leukemogenesis in vivo. This review presents and collates
all reported cases of DCL, and discusses the various strategies, controversies,
and pitfalls when investigating origin of posttransplant relapse. Putative etiologic
factors and mechanisms are proposed, and attempts made to address the
difficult ethical questions posed by discovery of donor-derived malignancy
within a HSCT recipient.

Feasible Outcomes of T Cell-Replete Haploidentical Stem Cell
Transplantation with Reduced-Intensity Conditioning in Patients
with Myelodysplastic Syndrome

Seung-Hwan Shin, Jung-Ho Kim, Young-Woo Jeon, …,, Woo-Sung Min,
Yoo-Jin Kim, Je-Hwan Lee
Biol Blood Marrow Transplant 21 (2015) 342e349
http://dx.doi.org/10.1016/j.bbmt.2014.10.031

Even with the recent optimization of haploidentical stem cell transplantation
(SCT), its role for patients with myelodysplastic syndrome (MDS) or acute
myeloid leukemia evolving from MDS (sAML) should be validated. We
analyzed the outcomes of consecutive 60 patients with MDS or sAML
who received T cell-replete haploidentical SCT after reduced-intensity
conditioning with fludarabine, busulfan, and rabbit antithymocyte globuline
800 cGy total body irradiation. Patients achieved a rapid neutrophil
engraftment after a median of 12 days (range, 8 to 23) and an early
immune reconstitution without high incidences of acute graft-versus-host
disease (GVHD) II to IV and chronic GVHD (36.7% and 48.3%, respectively).
After a median follow-up of 4 years, incidence of relapse and nonrelapse mortality
and rate of overall survival and disease-free survival was 34.8%, 23.3%, 46.8%,
and 41.9%, respectively. In multivariate analysis, the disease status at peak was
a significant predictor for relapse (lower-risk MDS versus higher-risk MDS or sAML;
hazard ratio [HR], 5.69; 95% confidence interval [CI], 1.45 to 22.29; P <.013)
and disease-free survival (HR, 4.44; 95% CI, 1.14 to 17.34; P <.032). Chronic
GVHD was an additional significant predictor for relapse (no versus yes; HR,
2.87; 95% CI, 1.03 to 7.51; P <.043). Our T cell-replete haploidentical SCT
may be a feasible option for patients with MDS and sAML without conventional
donors.

Extramedullary Relapse of Acute Leukemia after Allogeneic Hematopoietic
Stem Cell Transplantation: Different Characteristics between Acute
Myelogenous Leukemia and Acute Lymphoblastic Leukemia

Ling Ge, Fan Ye, X Mao, …, C Ruan, Depei Wu, Xiaowen Tang
Biol Blood Marrow Transplant 20 (2014) 1040e1047
http://dx.doi.org/10.1016/j.bbmt.2014.03.030

Extramedullary relapse (EMR) of acute leukemia (AL) after allogeneic
hematopoietic stem cell transplantation (allo-HSCT) is a contributor to post-
transplantation mortality and remains poorly understood, especially the
different characteristics of EMR in patients with acute myelogenous
leukemia (AML) and those with acute lymphoblastic leukemia (ALL).
To investigate the incidence, risk factors, and clinical outcomes of EMR
for AML and ALL, we performed a retrospective analysis of 362 patients
with AL who underwent allo-HSCT at the First affiliated Hospital of Soochow
University between January 2001 and March 2012. Compared with patients
with AML, those with ALL had a higher incidence of EMR (12.9% versus
4.6%; P < .009). The most common site of EMR was the central nervous
system, especially in the ALL group. Multivariate analyses identified the
leading risk factors for EMR in the patients with AML as advanced disease
status at HSCT, hyperleukocytosis at diagnosis, history of extramedullary
leukemia before HSCT, and a total body irradiationebased conditioning
regimen, and the top risk factors for EMR in the patients with ALL as
hyperleukocytosis at diagnosis, adverse cytogenetics, and transfusion
of peripheral blood stem cells. The prognosis for EMR of AL is poor,
and treatment options are very limited; however, the estimated 3-year
overall survival (OS) was significantly lower in patients with AML
compared with those with ALL (0 versus 18.5%; P < .000). The
characteristics of post-allo-HSCT EMR differed between the patients
with AML and those with ALL, possibly suggesting different pathogenetic
mechanisms for EMR of AML and EMR of ALL after allo-HSCT; further
investigation is needed.

French Multicenter 22-Year Experience in Stem Cell Transplantation
for Beta-Thalassemia Major: Lessons and Future Directions

Claire Galambrun, C Pondarré, Yves Bertrand, …,C Badens, I Thuret, for the
French Rare Disease Center for Thalassemia and the French Society of Bone
Marrow Transplantation
Biol Blood Marrow Transplant 19 (2013) 62e68
http://dx.doi.org/10.1016/j.bbmt.2012.08.005

Although hematopoietic stem cell transplantation (HSCT) offers curative
potential for beta-thalassemia major (beta-TM), it is associated with a
variable but significant incidence of graft rejection. We studied the French
national experience for improvement over time and the potential benefit
of antithymocyte globulin (ATG). Between December 1985 and December
2007, 108 patients with beta-TM underwent HSCT in 21 different French
transplantation centers. The majority of patients received a matched sibling
transplant (n = 96) and a busulfan- and cyclophosphamide-based conditioning
regimen (n = 95), also with ATG in 57 cases. Ninety five of the 108 patients
survived, with a median follow-up of 12 years. Probabilities of 15-year survival
and thalassemia-free survival after first HSCT were 86.8% and 69.4%, respectively.
Graft failure occurred in 24 patients, 11 of whom underwent a second HSCT.
The use of ATG was associated with a decrease in rejection rate from 35% to 10%.
Thalassemia-free survival improved significantly with time, reaching 83% in the
54 patients undergoing HSCT after 1994 (median time of HSCT). In view of the
increased risk of graft rejection after matched sibling HSCT, current French
national guidelines recommend, for all children at risk for beta-TM, the systematic
addition of ATG to the myeloablative conditioning regimen and special attention
to optimize transfusion and chelation therapy in the pretransplantation period.

Extramedullary Relapse of Acute Myelogenous Leukemia after
Allogeneic Hematopoietic Stem Cell Transplantation: Better
Prognosis Than Systemic Relapse

Melhem Solh, Todd E. DeFor, Daniel J. Weisdorf, Dan S. Kaufman
Biol Blood Marrow Transplant 18: 106-112 (2012)
http://dx.doi.org:/10.1016/j.bbmt.2011.05.023

Allogeneic hematopoietic cell transplantation (HSCT) is considered a curative
treatment for acute myelogenous leukemia (AML). Extramedullary relapse after
HSCT for AML is a rare event and is less well defined than systemic, hematologic
relapse. We retrospectively studied all patients with AML (n = 436) who underwent
HSCT at the University of Minnesota between  1996 and 2008 who developed
either a bone marrow (BM) or extramedullary (EM) relapse, and examined the
incidence and risk factors for BM and EM relapse. Of 128 patients who relapsed
post-HSCT, 25 had relapse in EM sites, either isolated (n = 13) or with  concurrent
BM relapse (n = 12). Relapse sites included bone (n = 1), central nervous system
(n=5 6), gastrointestinal (n=5 4), lymphatic (n = 4), skin (n = 5), genitourinary
(n=5 1), pulmonary (n = 1), and soft tissue (n = 3). The time to relapse was longer
in the EM sites (median, 328 days vs 168 days). Patients with EM relapse were
more likely to have had preceding acute graft-versus-host disease (GVHD) (77%
vs 49%; P = .03) or chronic GVHD (46% vs 15%; P < .02) compared with those
with BM relapse. The 6-month survival post-relapse was significantly better in
patients with isolated EM relapse (69%) compared with those with combined
EM and BM relapse (8%) or those with BM relapse alone (27%) (P <.01).
Compared with local therapy alone, systemic therapy yielded better 6-month
survival in patients with EM relapse. This study suggests differing pathogenesis
of BM relapse versus EM relapse of AML after allogeneic HSCT. GVHD and its
accompanying graft-versus-leukemia effect may better protect BM sites, but
patients with EM relapse have better responses to combined therapy and
improved survival compared with those with BM relapse.

Hematopoietic Cell Transplantation for Thalassemia: A Global
Perspective BMT Tandem Meeting 2013

Parinda A. Mehta, Lawrence B. Faulkner
Biol Blood Marrow Transplant 19 (2013) S70eS73
http://dx.doi.org/10.1016/j.bbmt.2012.10.025

Hematopoietic cell transplantation (HCT) remains the sole available curative
option for patients with β-thalassemia major. Expanded and improved supportive
therapies for thalassemia now routinely extend the life span of affected individuals
well into adulthood. Consequently, in regions of the world where this care is
readily available, HCT has been pursued infrequently, in part owing to concerns
about an expected lack of balance between risks and benefits. More recently,
however, recognition of significant health problems in older patients with
thalassemia, along with recognition of increased risks of graft-versus-host
disease (GVHD), graft rejection, and impaired organ function leading to inferior
HCT outcomes in this particular group, seem to be turning the wheels and tipping
the balance again in the direction of consideration for earlier HCTs. In contrast,
in countries where thalassemia is most prevalent (>100,000 new children born
each year in Middle East and southeast Asia), lack of supportive care standards
together with often insufficient access to dedicated health care facilities, results
in the majority of these children not reaching adulthood, further supporting the
need for expanded access to HCT for these patients. The cost of HCT is equivalent
to that of a few years of noncurative supportive care, such that HCT in low-risk
young children with a compatible sibling is justified not only medically and ethically
but also financially. International cooperation can play a major role in increasing
access to safe and affordable HCT in countries where there is a considerable
shortage of transplantation centers. In this article, we review the current status
of bone marrow transplantation for thalassemia major, with particular emphasis
on a global prospective.

Hematopoietic Stem Cell Transplantation in Autoimmune Diseases: The
Ahmedabad Experience

AV Vanikar, PR Modi, RD Patel, KV Kanodia, VR Shah, VB Trivedi, HL Trivedi
Transplantation Proceedings, 39, 703–708 (2007)
http://dx.doi.org:/10.1016/j.transproceed.2007.01.070

Introduction. Autoimmune disease represents a (AD) breakdown of natural
tolerance against autoreactive antigens leading to a high mortality and morbidity.
The reaction is usually polyclonal; T- and B-cell components of the hematopoietic
system are responsible for disease progression. Allogeneic/ autologous
hematopoietic stem cell transplantation (HSCT) are the current modalities
for treating drug-resistant AD. Patients and Methods. We present a single-
center retrospective evaluation of allogeneic HSCT with nonmyelo-ablative,
low-intensity conditioning in nine patients (five males, four females) with
pemphigus vulgaris (PV) and 27 patients with systemic lupus erythematosus
(SLE; 3 males, 24 females). The mean follow-up period was 4.24 years for PV
and 4.9 years for SLE. Cytokine-mobilized HSC from unmatched related donors,
with mean dose of 21.3108 nucleated cells/kg body weight (BW; mean CD34+
count, 6 x 106/kg BW) was administered in to the thymus as well as the portal and
peripheral circulations of recipients. Cyclosporine (4 + 1 mg/kg BW per day) and
prednisolone (10 mg/kg BW per day) were administered for 6 months to protect
mixed chimerism. A subset of patients with cross-gender donors were analyzed
for peripheral blood chimerism at 1 month post-HSCT and every 3 months
thereafter. Results. Sustained clinical remission with peripheral lymphohemato-
poietic chimerism of 0.7 + 0.3% was observed in PV, whereas SLE relapsed after
mean of 7.35 months of disease-free interval associated with fall in chimerism
from 5 + 3% to 0.08 + 0.03%. Conclusion. HSCT was effective to achieve early
clinical remission of PV; and in SLE relapsed after a 7.35-month disease-free
interval accompanied by a fall in mixed lymphohematopoietic chimerism.

Hematopoietic Stem Cell Transplantation in Children and Young Adults
with Secondary Myelodysplastic Syndrome and Acute Myelogenous
Leukemia after Aplastic Anemia

Ayami Yoshimi, B Strahm, I Baumann, I Furlan, S Schwarz, …, CM Niemeyer
Biol Blood Marrow Transplant 20 (2014) 421-434
http://dx.doi.org/10.1016/j.bbmt.2013.11.031

Secondary myelodysplastic syndrome and acute myelogenous leukemia
(sMDS/sAML) are the most serious secondary events occurring after immuno-
suppressive therapy in patients with aplastic anemia. Here we evaluate the
outcome of hematopoietic stem cell transplantation (HSCT) in 17 children
and young adults with sMDS/sAML after childhood aplastic anemia. The
median interval between the diagnosis of aplastic anemia and the development
of sMDS/sAML was 2.9 years (range, 1.2 to 13.0 years). At a median age of
13.1 years (range, 4.4 to 26.7 years), patients underwent HSCT with bone
marrow (n = 6) or peripheral blood stem cell (n = 11) grafts from HLA-
matched sibling donors (n = 2), mismatched family donors (n = 2), or
unrelated donors (n = 13). Monosomy 7 was detected in 13 patients. The
preparative regimen consisted of busulfan, cyclophosphamide, and melphalan
in 11 patients and other agents in 6 patients. All patients achieved neutrophil
engraftment. The cumulative incidence of grade II-IV acute graft-versus-host
disease (GVHD) was 47%, and that of chronic GVHD was 70%. Relapse
occurred in 1 patient. The major cause of death was transplant-related
complication (n = 9).Overall survival and event-free survival at 5 years after
HSCT were both 41%.In summary, this study indicates that HSCT is a curative
therapy for some patients with sMDS/sAML after aplastic anemia. Future
efforts should focus on reducing transplantation-related mortality.

Hematopoietic stem cells: An overview

Youssef Mohamed Mosaad
Transfusion and Apheresis Science 51 (2014) 68–82
http://dx.doi.org/10.1016/j.transci.2014.10.016

Considerable efforts have been made in recent years in understanding the
mechanisms that govern hematopoietic stem cell (HSC) origin, development,
differentiation, self-renewal, aging, trafficking, plasticity and trans-differentiation.
Hematopoiesis occurs in sequential waves in distinct anatomical locations during
development and these shifts in location are accompanied by changes in the
functional status of the stem cells and reflect the changing needs of the
developing organism. HSCs make a choice of either self-renewal or committing
to differentiation. The balance between self-renewal and differentiation is
considered to be critical to the maintenance of stem cell numbers. It is still
under debate if HSC can rejuvenate infinitely or if they do not possess ‘‘true”
self-renewal and undergo replicative senescence such as any other somatic
cell. Gene therapy applications that target HSCs offer a great potential for the
treatment of hematologic and immunologic diseases. However, the clinical
success has been limited by many factors. This review is intended to
summarize the recent advances made in the human HSC field, and will
review the hematopoietic stem cell from definition through development
to clinical applications.

HLA epitope based matching for transplantation

René J. Duquesnoy
Transplant Immunology 31 (2014) 1–6
http://dx.doi.org/10.1016/j.trim.2014.04.004

As important risk factors for transplant rejection and failure, HLA antibodies
are now recognized as being specific for epitopes which can be defined
structurally with amino acid differences between HLA alleles. Donor–recipient
compatibility should therefore be assessed at the epitope rather than the
antigen level. HLA Matchmaker is a computer algorithm that considers each
HLA antigen as a series of small configurations of polymorphic residues
referred to as eplets as essential components of HLA epitopes. It includes
epitopes on antigens encoded by all HLA-A, B, C, DR, DQ and DP loci as
well as MICA. HLA epitopes have two characteristics namely antigenicity, i.e.
the reactivity with antibody and immunogenicity, i.e. the ability of eliciting
an antibody response. This article addresses the relevance of determining
epitope-specificities of HLA antibodies, the effect of epitope structure on
technique-dependent antibody reactivity and the identification of acceptable
mismatches for sensitized patients considered for transplantation. Permissible
mismatching for non-sensitized patients aimed to prevent or reduce HLA
antibody responses could consider epitope loads of mismatched antigens and
the recently developed nonself-self paradigm of epitope immunogenicity.

Impact of HLA Mismatch Direction on the Outcome of Unrelated Bone
Marrow Transplantation: A Retrospective Analysis from the Japan
Society for Hematopoietic Cell Transplantation

Junya Kanda, T Ichinohe, S Fuji, Y Maeda, K Ohashi, …, Y Atsuta,
Y Kanda, on behalf of the HLA Working Group of the Japan Society
for Hematopoietic Cell Transplantation
Biol Blood Marrow Transplant 21 (2015) 305e311
http://dx.doi.org/10.1016/j.bbmt.2014.10.015

The relative desirability of an unrelated donor with a bidirectional 1-locus
mismatch (1MM-Bi), a 1-locus mismatch only in the graft-versus-host direction
(1MM-GVH), or a 1-locus mismatch only in the host versus-graft direction
(1MM-HVG) is not yet clear. We analyzed adult patients with leukemia or
myelodysplastic syndrome who received a first allogeneic stem cell transplant
from an HLA-A, -B, -C, and -DRB1 matched or 1-allele mismatched unrelated
donor in Japan. The effects of 1MM-Bi (n = 1020), 1MM-GVH (n = 83), and
1MM-HVG (n = 83) compared with a zero mismatch (0MM) (n = 2570)
were analyzed after adjusting for other significant variables. The risk of
grades III to IV acute graft-versus-host disease (GVHD) was higher with
marginal significance in the 1MM-GVH group than in the 0MM group
(hazard ratio, 1.85; P = .014). However, there was no significant difference
in overall or nonrelapse mortality between the 1MM-GVH and 0MM groups.
There was no significant difference in acute GVHD or overall or nonrelapse
mortality between the 1MM-HVG and 0MM groups. The risks of acute
GVHD and overall mortality were significantly higher in the 1MM-Bi group
than in the 0MM group. These findings indicate that unrelated donors with
1MM-GVH and 1MM-HVG are both good candidates for patients without an
HLA-matched unrelated donor in a Japanese cohort.

ABO incompatibility between donor and recipient and clinical
outcomes in allogeneic stem cell transplantation

James Goldman, Jane Liesveld, Diane Nichols, Joanna Heal, Neil Blumberg
Leukemia Research 27 (2003) 489–491 PII: S0145-2126(02)00259-X

We performed a retrospective, cohort study to evaluate the impact on recipient
survival of ABO incompatibility between recipient and donor after allogeneic
stem cell transplantation, primarily involving marrow-derived cells. No
statistically significant difference was noted in survival for 153 patients
with acute or chronic leukemia or myelodysplastic syndrome receiving
ABO identical or ABO mismatched allografts. Five patients who had
allografts that were bidirectionally incompatible (both donor cells and
plasma incompatible) did have significantly poorer survival than the other
recipients, similar to the experience reported in one other cohort study.
However, these patients had other risks for mortality, including being
older and receiving transplants from matched, unrelated donors. Our
data do not support a significant role for ABO donor–recipient matching in
allogeneic stem cell transplantation.

Allogeneic Hematopoietic Cell Transplantation Outcomes in
Acute Myeloid Leukemia: Similar Outcomes Regardless of
Donor Type

Erica D. Warlick, RP de Latour, R Shanley, …, Gerard Socie
Biol Blood Marrow Transplant 21 (2015) 357e363
http://dx.doi.org/10.1016/j.bbmt.2014.10.030

The use of alternative donor transplants is increasing as the transplantation-
eligible population ages and sibling donors are less available. We
evaluated the impact of donor source on transplantation outcomes for
adults with acute myeloid leukemia undergoing myeloablative (MA) or
reduced-intensity conditioning (RIC) transplantation. Between January 2000
and December 2010, 414 consecutive adult patients with acute myeloid
leukemia in remission received MA or RIC allogeneic transplantation from
either a matched related donor (n = 187), unrelated donor (n = 76), or
umbilical cord blood donor (n = 151) at the University of Minnesota or
Hôpital St. Louis in Paris. We noted similar 6-year overall survival
across donor types: matched related donor, 47% (95% confidence interval
[CI], 39% to 54%); umbilical cord blood, 36% (95% CI, 28% to 44%);
matched unrelated donor, 54% (95% CI, 40% to 66%); and mismatched
unrelated donor, 51% (95% CI, 28% to 70%) (P < .11). Survival differed
based on conditioning intensity and age, with 6-year survival of 57% (95% CI,
47% to 65%), 39% (95% CI, 28% to 49%), 23% (95% CI, 6% to 47%), 47%
(95% CI, 36% to 57%), and 28% (95% CI, 17% to 41%) for MA age 18 to 39,
MA age 40þ, or RIC ages 18 to 39, 40 to 56, and 57 to 74, respectively
(P < .01). Relapse was increased with RIC and lowest in younger patients
receiving MA conditioning (hazard ratio, 1.0 versus 2.5 or above for all RIC
age cohorts), P <.01. Transplantation-related mortality was similar across
donor types. In summary, our data support the use of alternative donors as
a graft source with MA or RIC for patients with acute myeloid leukemia
when a sibling donor is unavailable.

A Novel Reduced-Intensity Conditioning Regimen for Unrelated Umbilical
Cord Blood Transplantation in Children with Nonmalignant Diseases

Suhag H. Parikh, A Mendizabal, CL Benjamin, KV Komandur, J Antony, et al.
Biol Blood Marrow Transplant 20 (2014) 326e336
http://dx.doi.org/10.1016/j.bbmt.2013.11.021

Reduced-intensity conditioning (RIC) regimens have the potential to decrease
transplantation-related morbidity and mortality. However, engraftment
failure has been prohibitively high after RIC unrelated umbilical cord blood
transplantation (UCBT) in chemotherapy-naïve children with nonmalignant
diseases (NMD). Twenty-two children with a median age of 2.8 years, many
with severe comorbidities and prior viral infections, were enrolled in a novel RIC
protocol consisting of hydroxyurea, alemtuzumab, fludarabine, melphalan, and
thiotepa followed by single UCBT. Patients underwent transplantation for
inherited metabolic disorders (n = 8), primary immunodeficiencies (n = 9),
hemoglobinopathies (n = 4) and Diamond Blackfan anemia (n = 1). Most
umbilical cord blood (UCB) units were HLA-mismatched with median infused
total nucleated cell dose of 7.9 107/kg. No serious organ toxicities were
attributable to the regimen. The cumulative incidence of neutrophil engraftment
was 86.4% (95% confidence interval [CI], 65% to 100%) in a median of 20
days, with the majority sustaining > 95% donor chimerism at 1 year. Cumulative
incidence of acute graft-versus-host disease (GVHD) grades II to IV and III to IV
by day 180 was 27.3% (95% CI, 8.7% to 45.9%) and 13.6% (95 CI, 0% to 27.6%),
respectively. Cumulative incidence of extensive chronic GVHD was 9.1% (95%
CI, 0% to 20.8%). The primary causes of death were viral infections (n ¼ 3), acute
GVHD (n = 1) and transfusion reaction (n ¼ 1). One-year overall and event-free
survivals were 77.3% (95% CI, 53.7% to 89.8%) and 68.2% (95% CI, 44.6%
to 83.4%) with 31 months median follow-up. This is the first RIC protocol
demonstrating durable UCB engraftment in children with NMD. Future risk-
based modifications of this regimen could decrease the incidence of viral
infections. (www.clinicaltrials.gov/NCT00744692).

Read Full Post »

Pharmacogenomics

Writer and Curator: Larry H. Bernstein, MD, FCAP

 

Implementation and utilization of genetic testing in personalized medicine

NS Abul-Husn, AO Obeng, SC Sanderson, O Gottesman, S A Scott
Pharmacogenomics and Personalized Medicine 2014:7 227–240
http://dx.doi.org/10.2147/PGPM.S48887

Clinical genetic testing began over 30 years ago with the availability of mutation detection for sickle cell disease diagnosis. Since then, the field has dramatically transformed to include gene sequencing, high-throughput targeted genotyping, prenatal mutation detection, preimplantation genetic diagnosis, population-based carrier screening, and now genome-wide analyses using microarrays and next-generation sequencing. Despite these significant advances in molecular technologies and testing capabilities, clinical genetics laboratories historically have been centered on mutation detection for Mendelian disorders. However, the ongoing identification of deoxyribonucleic acid (DNA) sequence variants associated with common diseases prompted the availability of testing for personal disease risk estimation, and created commercial opportunities for direct-to-consumer genetic testing companies that assay these variants. This germline genetic risk, in conjunction with other clinical, family, and demographic variables, are the key components of the personalized medicine paradigm, which aims to apply personal genomic and other relevant data into a patient’s clinical assessment to more precisely guide medical management. However, genetic testing for disease risk estimation is an ongoing topic of debate, largely due to inconsistencies in the results, concerns over clinical validity and utility, and the variable mode of delivery when returning genetic results to patients in the absence of traditional counseling. A related class of genetic testing with analogous issues of clinical utility and acceptance is pharmacogenetic testing, which interrogates sequence variants implicated in interindividual drug response variability. Although clinical pharmacogenetic testing has not previously been widely adopted, advances in rapid turnaround time genetic testing technology and the recent implementation of preemptive genotyping programs at selected medical centers suggest that personalized medicine through pharmacogenetics is now a reality. This review aims to summarize the current state of implementing genetic testing for personalized medicine, with an emphasis on clinical pharmacogenetic testing.

Pharmacogenomic knowledge gaps and educational resource needs among physicians in selected specialties

Katherine A Johansen Taber, Barry D Dickinson
Pharmacogenomics and Personalized Medicine 2014:7 145–162
http://dx.doi.org/10.2147/PGPM.S63715

Background: The use of pharmacogenomic testing in the clinical setting has the potential to improve the safety and effectiveness of drug therapy, yet studies have revealed that physicians lack knowledge about the topic of pharmacogenomics, and are not prepared to implement it in the clinical setting. This study further explores the pharmacogenomic knowledge deficit and educational resource needs among physicians.
Materials and methods: Surveys of primary care physicians, cardiologists, and psychiatrists were conducted.
Results: Few physicians reported familiarity with the topic of pharmacogenomics, but more reported confidence in their knowledge about the influence of genetics on drug therapy. Only a small minority had undergone formal training in pharmacogenomics, and a majority reported being unsure what type of pharmacogenomic tests were appropriate to order for the clinical situation. Respondents indicated that an ideal pharmacogenomic educational resource should be electronic and include such components as how to interpret pharmacogenomic test results, recommendations for prescribing, population subgroups most likely to be affected, and contact information for laboratories offering pharmacogenomic testing.
Conclusion: Physicians continue to demonstrate pharmacogenomic knowledge gaps, and are unsure about how to use pharmacogenomic testing in clinical practice. Educational resources that are clinically oriented and easily accessible are preferred by physicians, and may best support appropriate clinical implementation of pharmacogenomics.

Developing genomic knowledge bases and databases to support clinical management: current perspectives

Vojtech Huser, Murat Sincan, James J Cimino
Pharmacogenomics and Personalized Medicine 2014:7 275–283
http://dx.doi.org/10.2147/PGPM.S49904

Personalized medicine, the ability to tailor diagnostic and treatment decisions for individual patients, is seen as the evolution of modern medicine. We characterize here the informatics resources available today or envisioned in the near future that can support clinical interpretation of genomic test results. We assume a clinical sequencing scenario (germline whole-exome sequencing) in which a clinical specialist, such as an endocrinologist, needs to tailor patient management decisions within his or her specialty (targeted findings) but relies on a genetic counselor to interpret off-target incidental findings. We characterize the genomic input data and list various types of knowledge bases that provide genomic knowledge for generating clinical decision support. We highlight the need for patient-level databases with detailed lifelong phenotype content in addition to genotype data and provide a list of recommendations for personalized medicine knowledge bases and databases. We conclude that no single knowledge base can currently support all aspects of personalized recommendations and that consolidation of several current resources into larger, more dynamic and collaborative knowledge bases may offer a future path forward.

 

Tumor Heterogeneity: Mechanisms and Bases for a Reliable Application of Molecular Marker Design

Salvador J. Diaz-Cano
Int. J. Mol. Sci. 2012, 13, 1951-2011; http://dx.doi.org/10.3390/ijms13021951

Tumor heterogeneity is a confusing finding in the assessment of neoplasms, potentially resulting in inaccurate diagnostic, prognostic and predictive tests. This tumor heterogeneity is not always a random and unpredictable phenomenon, whose knowledge helps designing better tests. The biologic reasons for this intratumoral heterogeneity would then be important to understand both the natural history of neoplasms and the selection of test samples for reliable analysis. The main factors contributing to intratumoral heterogeneity inducing gene abnormalities or modifying its expression include: the gradient ischemic level within neoplasms, the action of tumor microenvironment (bidirectional interaction between tumor cells and stroma), mechanisms of intercellular transference of genetic information (exosomes), and differential mechanisms of sequence-independent modifications of genetic material and proteins. The intratumoral heterogeneity is at the origin of tumor progression and it is also the byproduct of the selection process during progression. Any analysis of heterogeneity mechanisms must be integrated within the process of segregation of genetic changes in tumor cells during the clonal expansion and progression of neoplasms. The evaluation of these mechanisms must also consider the redundancy and pleiotropism of molecular pathways, for which appropriate surrogate markers would support the presence or not of heterogeneous genetics and the main mechanisms responsible. This knowledge would constitute a solid scientific background for future therapeutic planning.

Systematic evaluation of connectivity map for disease indications

Jie Cheng, Lun Yang, Vinod Kumar and Pankaj Agarwal
Genome Medicine 2014, 6:95 http://genomemedicine.com/content/6/12/95

Background: Connectivity map data and associated methodologies have become a valuable tool in understanding drug mechanism of action (MOA) and discovering new indications for drugs. One of the key ideas of connectivity map (CMAP) is to measure the connectivity between disease gene expression signatures and compound-induced gene expression profiles. Despite multiple impressive anecdotal validations, only a few systematic evaluations have assessed the accuracy of this aspect of CMAP, and most of these utilize drug-to-drug matching to transfer indications across the two drugs.
Methods: To assess CMAP methodologies in a more direct setting, namely the power of classifying known drug-disease relationships, we evaluated three CMAP-based methods on their prediction performance against a curated dataset of 890 true drug-indication pairs. The disease signatures were generated using Gene Logic BioExpress system and the compound profiles were derived from the Connectivity Map database (CMAP, build 02, http://www.broadinstitute.org/CMAP/).
Results: The similarity scoring algorithm called eXtreme Sum (XSum) better than the standard Kolmogorov-Smirnov (KS) statistic in terms of the area under curve and can achieve a four-fold enrichment at 0.01, false positive rate level, with AUC = 2.2E-4, P value = 0.0035.
Conclusion: Connectivity map can significantly enrich true positive drug-indication pairs given an effective matching algorithm.

Pharmacogenetics of Statin-Induced Myopathy: A Focused Review of the Clinical Translation of Pharmacokinetic Genetic Variants

Jasmine A Talameh and Joseph P Kitzmiller
J Pharmacogenomics Pharmacoproteomics 2014, 5:2 http://dx.doi.org/10.4172/2153-0645.1000128

Statins are the most commonly prescribed drugs in the United States and are extremely effective in reducing major cardiovascular events in the millions of Americans with hyperlipidemia. However, many patients (up to 25%) cannot tolerate or discontinue statin therapy due to statin-induced myopathy (SIM). Patients will continue to experience SIM at unacceptably high rates or experience unnecessary cardiovascular events (as a result of discontinuing or decreasing their statin therapy) until strategies for predicting or mitigating SIM are identified. A promising strategy for predicting or mitigating SIM is pharmacogenetic testing particularly of pharmacokinetic genetic variants as SIM is  related to statin exposure. Data is emerging on the association between pharmacokinetic genetic variants and SIM.
A current, critical evaluation of the literature on pharmacokinetic genetic variants and SIM for potential translation to clinical practice is lacking. This review focuses specifically on pharmacokinetic genetic variants and their association with SIM clinical outcomes. We also discuss future directions, specific to the research on pharmacokinetic genetic variants, which could speed the translation into clinical practice. For simvastatin, we did not find sufficient evidence to support the clinical translation of pharmacokinetic genetic variants other than SLCO1B1. However, SLCO1B1 may also be clinically relevant for pravastatin- and pitavastatin-induced myopathy, but additional studies assessing SIM clinical outcome are needed. CYP2D6*4 may be clinically relevant for atorvastatin-induced myopathy, but mechanistic studies are needed. Future research efforts need to incorporate statin-specific analyses, multi-variant analyses, and a standard definition of SIM. As the use of statins is extremely common and SIM continues to occur in a significant number of patients, future research investments in pharmacokinetic genetic variants have the potential to make a profound impact on public health.

Benefits of Pharmacogenetics in the Management of Hypertension

Clara Torrellas, Juan Carlos Carril and Ramón Cacabelos
J Pharmacogenomics Pharmacoproteomics 2014, 5:2 http://dx.doi.org/10.4172/2153-0645.1000126

Introduction: Hypertension, suffered by 35% of the population, stands out as the main risk factor for cardiovascular disorders with the highest death rate worldwide. Only a small number of patients with hypertension gets efficient control over blood pressure (BP) with appropriate drug therapy.  harmacogenetics, as a tool to identify antihypertensive therapeutic response-associated polymorphisms, could help to reduce this problem.
Objectives: We present here an epidemiological study of the prevalence of hypertension and its pharmacological treatment to demonstrate the error rate that physicians can commit when the patient´s pharmacogenetic profile is unknown.
Method: The sample consisted of 1115 individuals of which 332 met criteria for hypertension. We recorded each patient´s drug prescription prior to their visit to EuroEspes Biomedical Research Center, and analyzed their pharmacogenetic profile.
Results: About 30% of patients were hypertensive, of whom only 40.4% were receiving an active ingredient for hypertension control. Among them, CYP3A4/5 and CYP2C9 were the major metabolizing enzymes. Antagonists of angiotensin II receptors, followed by calcium-blocking agents and beta-adrenergic antagonists were the most commonly-prescribed drug categories. However, 61% of hypertensive patients were not taking suitable antihypertensive agents for their metabolism according to their genetic idiosyncrasy. Furthermore, the highest error rate was determined for CYP2C9.
Conclusion: The introduction of changes in the management of hypertension in the Spanish population could be useful to promote the prevention and treatment of high blood pressure in a more efficient way. The integration of pharmacogenetic testing into routine clinical procedures could optimize the therapeutic response, guiding the physician in the choice of the correct antihypertensive drug and the correct dose. The control of BP arises as an area of particular interest in assessing the validity and utility of pharmacogenetic testing/intervention.

Pharmacogenomics Study of Clopidogrel by RFLP based Genotyping of CYP2C19 in Cardiovascular Disease Patients in North-East Population of India

Prasanthi SV, Vinayak S Jamdade, Nityanand B Bolshette, Ranadeep Gogoi and Mangala Lahkar
J Pharmacogenomics Pharmacoproteomics 2014, 5:3 http://dx.doi.org/10.4172/2153-0645.1000132

Introduction and Objective: Pharmacogenetics is a genetically determined variability in drug responses. The genes and their allelic variants which affect our response to drugs are the main routes in development of pharmacogenetics. Clopidogrel is an antiplatelet drug, used against athero-thrombotic events in cardiovascular patients. The objective of our study was to identify the CYP2C19 Single Nucleotide Polymorphisms, responsible for altering the metabolism of clopidogrel, at gene level. And to document the prevalence of CYP2C19 gene mutations in clopidogrel treated cardiovascular disease patients in Assam population, Guwahati Medical College & Hospital, in North- East India.
Patients and Methods: We have studied 60 patients who received clopidogrel from Gauhati medical college and hospital Assam. Genomic DNA was extracted by using Hipura blood genomic DNA extracting mini preparation kit by following the manufacturer’s instructions.RFLP analysis was done by DNA amplification which was carried out by using set of primers and resulting ampicons of CYP2C19*2;CYP2C19*3 and CYP2C19*17 were subjected for Restriction digestion with SmaI, BamHI and Lwe0I respectively.
Results: We found that CYP2C19*2 had allelic frequency of ~40% in Gauhati Medical College and Hospital, Assam, North East India. None of the samples were mutated with CYP2C19*3 andCYP2C19*17 allele. Other CYP2C19 variant alleles with reduced or absent enzymatic activity have been identified. Conclusion: We found that loss of functional allele CYP2C19*2 had higher carriage frequency; whereas, CYP2C19*3 and *17 alleles were not found in cardiovascular patients who were taking clopidogrel. Personalized therapy targeting patients who carry these genetic variants might help to improve the clinical outcome.

Role of cytochrome P450 genotype in the steps toward personalized drug therapy

Larisa H Cavallari, Hyunyoung Jeong, Adam Bress
Pharmacogenomics and Personalized Medicine 2011:4 123–136
http://dx.doi.org/10.2147/PGPM.S15497

Genetic polymorphism for cytochrome 450 (P450) enzymes leads to interindividual variability in the plasma concentrations of many drugs. In some cases, P450 genotype results in decreased enzyme activity and an increased risk for adverse drug effects. For example, individuals with the CYP2D6 loss-of-function genotype are at increased risk for ventricular arrhythmia if treated with usual does of thioridazine. In other cases, P450 genotype may influence the dose of a drug required to achieve a desired effect. This is the case with warfarin, with lower doses often necessary in carriers of a variant CYP2C9*2 or *3 allele to avoid supratherapeutic anticoagulation. When a prodrug, such as clopidogrel or codeine, must undergo hepatic biotransformation to its active form, a loss-of-function P450 genotype leads to reduced concentrations of the active drug and decreased drug efficacy. In contrast, patients with multiple CYP2D6 gene copies are at risk for opioid-related toxicity if treated with usual doses of codeine-containing analgesics. At least 25 drugs contain information in their US Food and Drug Administration-approved labeling regarding P450 genotype. The CYP2C9, CYP2C19, and CYP2D6 genes are the P450 genes most often cited. To date, integration of P450 genetic information into clinical decision making is limited. However, some institutions are beginning to embrace routine P450 genotyping to assist in the treatment of their patients. Genotyping for P450 variants may carry less risk for discrimination compared with genotyping for disease-associated variants. As such, P450 genotyping is likely to lead the way in the clinical implementation of pharmacogenomics. This review discusses variability in the CYP2C9, CYP2C19, and CYP2D6 genes and the implications of this for drug efficacy and safety.

Asthma pharmacogenetics and the development of genetic profiles for personalized medicine

Victor E Ortega, Deborah A Meyers, Eugene R Bleecker
Pharmacogenomics and Personalized Medicine 2015:8 9–22
http://dx.doi.org/10.2147/PGPM.S52846

Human genetics research will be critical to the development of genetic profiles for personalized or precision medicine in asthma. Genetic profiles will consist of gene variants that predict individual disease susceptibility and risk for progression, predict which pharmacologic therapies will result in a maximal therapeutic benefit, and predict whether a therapy will result in an adverse response and should be avoided in a given individual. Pharmacogenetic studies of the glucocorticoid, leukotriene, and β2-adrenergic receptor pathways have focused on candidate genes within these pathways and, in addition to a small number of genome-wide association studies, have identified genetic loci associated with therapeutic responsiveness. This review summarizes these pharmacogenetic discoveries and the future of genetic profiles for personalized medicine in asthma. The benefit of a personalized, tailored approach to health care delivery is needed in the development of expensive biologic drugs directed at a specific biologic pathway. Prior pharmacogenetic discoveries, in combination with additional variants identified in future studies, will form the basis for future genetic profiles for personalized tailored approaches to maximize therapeutic benefit for an individual asthmatic while minimizing the risk for adverse events.

Clinical application of high throughput molecular screening techniques for pharmacogenomics

Arun P Wiita, Iris Schrijver
Pharmacogenomics and Personalized Medicine 2011:4 109–121
http://dx.doi.org/10.2147/PGPM.S15302

Genetic analysis is one of the fastest-growing areas of clinical diagnostics. Fortunately, as our knowledge of clinically relevant genetic variants rapidly expands, so does our ability to detect these variants in patient samples. Increasing demand for genetic information may necessitate the use of high throughput diagnostic methods as part of clinically validated testing. Here we provide a general overview of our current and near-future abilities to perform large-scale genetic testing in the clinical laboratory. First we review in detail molecular methods used for high throughput mutation detection, including techniques able to monitor thousands of genetic variants for a single patient or to genotype a single genetic variant for thousands of patients simultaneously. These methods are analyzed in the context of pharmacogenomic testing in the clinical laboratories, with a focus on tests that are currently validated as well as those that hold strong promise for widespread clinical application in the near future. We further discuss the unique economic and clinical challenges posed by pharmacogenomic markers. Our ability to detect genetic variants frequently outstrips our ability to accurately interpret them in a clinical context, carrying implications both for test development and introduction into patient management algorithms. These complexities must be taken into account prior to the introduction of any pharmacogenomic biomarker into routine clinical testing.

Clinical implementation of RNA signatures for pharmacogenomic decision-making

Weihua Tang, Zhiyuan Hu, Hind Muallem, Margaret L Gulley
Pharmacogenomics and Personalized Medicine 2011:4 95–107
http://dx.doi.org/10.2147/PGPM.S14888

RNA profiling is increasingly used to predict drug response, dose, or toxicity based on analysis of drug pharmacokinetic or pharmacodynamic pathways. Before implementing multiplexed RNA arrays in clinical practice, validation studies are carried out to demonstrate sufficient evidence of analytic and clinical performance, and to establish an assay protocol with quality assurance measures. Pathologists assure quality by selecting input tissue and by interpreting results in the context of the input tissue as well as the technologies that were used and the clinical setting in which the test was ordered. A strength of RNA profiling is the array-based measurement of tens to thousands of RNAs at once, including redundant tests for critical analytes or pathways to promote confidence in test results. Instrument and reagent manufacturers are crucial for supplying reliable components of the test system. Strategies for quality assurance include careful attention to RNA preservation and quality checks at pertinent steps in the assay protocol, beginning with specimen collection and proceeding through the variousphases of transport, processing, storage, analysis, interpretation, and reporting. Specimen quality is checked by probing housekeeping transcripts, while spiked and exogenous controls serve as a check on analytic performance of the test system. Software is required to manipulate abundant array data and present it for interpretation by a laboratory physician who reports results in a manner facilitating therapeutic decision-making. Maintenance of the assay requires periodic documentation of personnel competency and laboratory proficiency. These strategies are shepherding genomic arrays into clinical settings to provide added value to patients and to the larger health care system.

Dysregulation of the homeobox transcription factor gene HOXB13: role in prostate cancer

Brennan Decker, Elaine A Ostrander
Pharmacogenomics and Personalized Medicine 2014:7 193–201
http://dx.doi.org/10.2147/PGPM.S38117

Prostate cancer (PC) is the most common noncutaneous cancer in men, and epidemiological studies suggest that about 40% of PC risk is heritable. Linkage analyses in hereditary PC families have identified multiple putative loci. However, until recently, identification of specific risk alleles has proven elusive. Cooney et al used linkage mapping and segregation analysis to identify a putative risk locus on chromosome 17q21-22. In search of causative variant(s) in genes from the candidate region, a novel, potentially deleterious G84E substitution in homeobox transcription factor gene HOXB13 was observed in multiple hereditary PC families. In follow-up testing, the G84E allele was enriched in cases, especially those with an early diagnosis or positive family history of disease. This finding was replicated by others, confirming HOXB13 as a PC risk gene. The HOXB13 protein plays diverse biological roles in embryonic development and terminally differentiated tissue. In tumor cell lines, HOXB13 participates in a number of biological functions, including coactivation and localization of the androgen receptor and FOXA1. However, no consensus role has emerged and many questions remain. All HOXB13 variants with a proposed role in PC risk are predicted to damage the protein and lie in domains that are highly conserved across species. The G84E variant has the strongest epidemiological support and lies in a highly conserved MEIS protein-binding domain, which binds cofactors required for activation. On the basis of epidemiological and biological data, the G84E variant likely modulates the interaction between the HOXB13 protein and the androgen receptor, as well as affecting FOXA1-mediated transcriptional programming. However, further studies of the mutated protein are required to clarify the mechanisms by which this translates into PC risk.

Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer

Christopher P Leamon, Chandra D Lovejoy, Binh Nguyen
Pharmacogenomics and Personalized Medicine 2013:6 113–125
http://dx.doi.org/10.2147/PGPM.S24943

Ovarian cancer (OC) has the highest mortality rate of any gynecologic cancer, and patients generally have a poor prognosis due to high chemotherapy resistance and late stage disease diagnosis. Platinum-resistant OC can be treated with cytotoxic chemotherapy such as paclitaxel, topotecan, pegylated liposomal doxorubicin, and gemcitabine, but many patients eventually relapse upon treatment. Fortunately, there are currently a number of targeted therapies in development for these patients who have shown promising results in recent clinical trials. These treatments often target the vascular endothelial growth factor pathway (eg, bevacizumab and aflibercept), DNA repair mechanisms (eg, iniparib and olaparib), or they are directed against folate related pathways (eg, pemetrexed, farletuzumab, and vintafolide). As many targeted therapies are only effective in a subset of patients, there is an increasing need for the identification of response predictive biomarkers. Selecting the right patients through biomarker screening will help tailor therapy to patients and decrease superfluous treatment to those who are biomarker negative; this approach should lead to improved clinical results and decreased toxicities. In this review the current targeted therapies used for treating platinum-resistant OC are discussed. Furthermore, use of prognostic and response predictive biomarkers to define OC patient populations that may benefit from specific targeted therapies is also highlighted.

Pharmacogenetics in breast cancer: steps toward personalized medicine in breast cancer management

Sarah Rofaiel, Esther N Muo1, Shaker A Mousa
Pharmacogenomics and Personalized Medicine 2010:3 129–143
http://dx.dpi.org:/10.2147/PGPM.S10789

There is wide individual variability in the pharmacokinetics, pharmacodynamics, and tolerance to anticancer drugs within the same ethnic group and even greater variability among different ethnicities. Pharmacogenomics (PG) has the potential to provide personalized therapy based on individual genetic variability in an effort to maximize efficacy and reduce adverse effects. The benefits of PG include improved therapeutic index, improved dose regimen, and selection of optimal types of drug for an individual or set of individuals. Advanced or metastatic breast cancer is typically treated with single or multiple combinations of chemotherapy regimens including anthracyclines, taxanes, antimetabolites, alkylating agents, platinum drugs, vinca alkaloids, and others. In this review, the PG of breast cancer therapeutics, including tamoxifen, which is the most widely used therapeutic for the treatment of hormone-dependent breast cancer, is reviewed. The pharmacological activity of tamoxifen depends on its conversion by cytochrome P450 2D6 (CYP2D6) to its abundant active metabolite, endoxifen. Patients with reduced CYP2D6 activity, as a result of either their genotype or induction by the coadministration of other drugs that inhibit CYP2D6 function, produce little endoxifen and hence derive limited therapeutic benefit from tamoxifen; the same can be said about the different classes of therapeutics in breast cancer. PG studies of breast cancer therapeutics should provide patients with breast cancer with optimal and personalized therapy

Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition

M William Audeh
Pharmacogenomics and Personalized Medicine 2014:7 307–316
http://dx.doi.org/10.2147/PGPM.S39765

Inhibitors of the poly(adenosine triphosphate-ribose) polymerase (PARP)-1 enzyme induce synthetic lethality in cancers with ineffective DNA (DNA) repair or homologous repair deficiency, and have shown promising clinical activity in cancers deficient in DNA repair due to germ-line mutation in BRCA1 and BRCA2. The majority of breast cancers arising in carriers of BRCA1 germ-line mutations, as well as half of those in BRCA2 carriers, are classified as triple-negative breast cancer (TNBC). TNBC is a biologically heterogeneous group of breast cancers characterized by the lack of immunohistochemical expression of the ER, PR, or HER2 proteins, and for which the current standard of care in systemic therapy is cytotoxic chemotherapy. Many “sporadic” cases of TNBC appear to have indicators of DNA repair dysfunction similar to those in BRCA-mutation carriers, suggesting the possible utility of PARP inhibitors in a subset of TNBC. Significant genetic heterogeneity has been observed within the TNBC cohort, creating challenges for interpretation of prior clinical trial data, and for the design of future clinical trials. Several PARP inhibitors are currently in clinical development in BRCA-mutated breast cancer. The use of PARP inhibitors in TNBC without BRCA mutation will require biomarkers that identify cancers with homologous repair deficiency in order to select patients likely to respond. Beyond mutations in the BRCA genes, dysfunction in other genes that interact with the homologous repair pathway may offer opportunities to induce synthetic lethality when combined with PARP inhibition.

Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways

Sarah R Hosford, Todd W Miller
Pharmacogenomics and Personalized Medicine 2014:7 203–215
http://dx.doi.org/10.2147/PGPM.S52762

Breast cancers expressing estrogen receptor α, progesterone receptor, or the human epidermal growth factor receptor 2 (HER2) proto-oncogene account for approximately 90% of cases, and treatment with antiestrogens and HER2-targeted agents has resulted in drastically improved survival in many of these patients. However, de novo or acquired resistance to antiestrogen and HER2-targeted therapies is common, and many tumors will recur or progress despite these treatments. Additionally, the remaining 10% of breast tumors are negative for estrogen receptor α, progesterone receptor, and HER2 (“triple-negative”), and a clinically proven tumor-specific drug target for this group has not yet been identified. Therefore, the identification of new therapeutic targets in breast cancer is of vital clinical importance. Preclinical studies elucidating the mechanisms driving resistance to standard therapies have identified promising targets including cyclin-dependent kinase 4/6, phosphoinositide 3-kinase, poly adenosine diphosphate–ribose polymerase, Src, and histone deacetylase. Herein, we discuss the clinical potential and status of new therapeutic targets in breast cancer.

Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients

Anna Tessari, Dario Palmieri, Serena Di Cosimo
Pharmacogenomics and Personalized Medicine 2014:7 1–19
http://dx.doi.org/10.2147/PGPM.S53304

Breast cancer includes a body of molecularly distinct subgroups, characterized by different presentation, prognosis, and sensitivity to treatments. Significant advances in our understanding of the complex architecture of this pathology have been achieved in the last few decades, thanks to new biotechnologies that have recently come into the research field and the clinical practice, giving oncologists new instruments that are based on biomarkers and allowing them to set up a personalized approach for each individual patient. Here we review the main treatments available or in preclinical development, the biomolecular diagnostic and prognostic approaches that changed our perspective about breast cancer, giving an overview of targeted therapies that represent the current standard of care for these patients. Finally, we report some examples of how new technologies in clinical practice can set in motion the development of new drugs.

Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics

Kohji Noguchi, Kazuhiro Katayama, Yoshikazu Sugimoto
Pharmacogenomics and Personalized Medicine 2014:7 53–64
http://dx.doi.org/10.2147/PGPM.S38295

Adenosine triphosphate (ATP)-binding cassette (ABC) transporter proteins, such as ABCB1/P-glycoprotein (P-gp) and ABCG2/breast cancer resistance protein (BCRP), transport various structurally unrelated compounds out of cells. ABCG2/BCRP is referred to as a “half-type” ABC transporter, functioning as a homodimer, and transports anticancer agents such as irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38), gefitinib, imatinib, methotrexate, and mitoxantrone from cells. The expression of ABCG2/BCRP can confer a multidrug-resistant phenotype on cancer cells and affect drug absorption, distribution, metabolism, and excretion in normal tissues, thus modulating the in vivo efficacy of chemotherapeutic agents. Clarification of the substrate preferences and structural relationships of ABCG2/BCRP is essential for our understanding of the molecular mechanisms underlying its effects in vivo during chemotherapy. Its single-nucleotide polymorphisms are also involved in determining the efficacy of chemotherapeutics, and those that reduce the functional activity of ABCG2/BCRP might be associated with unexpected adverse effects from normal doses of anticancer drugs that are ABCG2/BCRP substrates. Importantly, many recently developed molecular-targeted cancer drugs, such as the tyrosine kinase inhisbitors, imatinib mesylate, gefitinib, and others, can also interact with ABCG2/BCRP. Both functional single-nucleotide polymorphisms and inhibitory agents of ABCG2/BCRP modulate the in vivo pharmacokinetics and pharmacodynamics of these molecular cancer treatments, so the pharmacogenetics of ABCG2/BCRP is an important consideration in the application of molecular-targeted chemotherapies.

Bosutinib: a SRC–ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia

Fuad El Rassi, Hanna Jean Khoury
Pharmacogenomics and Personalized Medicine 2013:6 57–62
http://dx.doi.org/10.2147/PGPM.S32145

Bosutinib is one of five tyrosine kinase inhibitors commercially available in the United States for the treatment of chronic myeloid leukemia. This review of bosutinib summarizes the mode of action, pharmacokinetics, efficacy and safety data, as well as the patient-focused perspective through quality-of-life data. Bosutinib has shown considerable and sustained efficacy in chronic myeloid leukemia, especially in the chronic phase, with resistance or intolerance to prior tyrosine kinase inhibitors. Bosutinib has distinct but manageable adverse events. In the absence of T315I and V299L mutations, there are no absolute contraindications for the use of bosutinib in this patient population.

Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer
Timothy A Yap, Sanjay Popat
Pharmacogenomics and Personalized Medicine 2014:7 285–295
http://dx.doi.org/10.2147/PGPM.S55339

The use of genomics to discover novel targets and biomarkers has placed the field of oncology at the forefront of precision medicine. First-generation epidermal growth factor receptor (EGFR) inhibitors have transformed the therapeutic landscape of EGFR mutant non-small-cell lung carcinoma through the genetic stratification of tumors from patients with this disease. Somatic EGFR mutations in lung adenocarcinoma are now well established as predictive biomarkers of response and resistance to small-molecule EGFR inhibitors. Despite early patient benefit, primary resistance and subsequent tumor progression to first-generation EGFR inhibitors are seen in 10%–30% of patients with EGFR mutant non-small-cell lung carcinoma. Acquired drug resistance is also inevitable, with patients developing disease progression after only 10–13 months of antitumor therapy. This review details strategies pursued in circumventing T790M-mediated drug resistance to EGFR inhibitors, which is the most common mechanism of acquired resistance, and focuses on the clinical development of second-generation EGFR inhibitors, exemplified by afatinib (BIBW2992). We discuss the rationale, mechanism of action, clinical efficacy, and toxicity profile of afatinib, including the LUX-Lung studies. We also discuss the emergence of third-generation irreversible mutant-selective inhibitors of EGFR and envision the future management of EGFR mutant lung adenocarcinoma.

ALK-driven tumors and targeted therapy: focus on crizotinib

Carlos Murga-Zamalloa, Megan S Lim
Pharmacogenomics and Personalized Medicine 2014:7 87–94
http://dx.doi.org/10.2147/PGPM.S37504

Receptor tyrosine kinases have emerged as promising therapeutic targets for a diverse set of tumors. Overactivation of the tyrosine kinase anaplastic lymphoma kinase (ALK) has been reported in several types of malignancies such as anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, neuroblastoma, and non-small-cell lung carcinoma. Further characterization of the molecular role of ALK has revealed an oncogenic signaling signature that results in tumor dependence on ALK. ALK-positive tumors display a different behavior than their ALK-negative counterparts; however, the specific role of ALK in some of these tumors remains to be elucidated. Although more studies are required to establish selective targeting of ALK as a definitive therapeutic option, initial trials have shown extraordinary results in the majority of cases.

Non-small-cell lung cancer: molecular targeted therapy and personalized medicine – drug resistance, mechanisms, and strategies

Marybeth Sechler, AD Cizmic, S Avasarala, M Van Scoyk, C Brzezinski, et al.
Pharmacogenomics and Personalized Medicine 2013:6 25–36
http://dx.doi.org/10.2147/PGPM.S26058

Targeted therapies for cancer bring the hope of specific treatment, providing high efficacy and in some cases lower toxicity than conventional treatment. Although targeted therapeutics have helped immensely in the treatment of several cancers, like chronic myelogenous leukemia, colon cancer, and breast cancer, the benefit of these agents in the treatment of lung cancer remains limited, in part due to the development of drug resistance. In this review, we discuss the mechanisms of drug resistance and the current strategies used to treat lung cancer. A better understanding of these drug-resistance mechanisms could potentially benefit from the development of a more robust personalized medicine approach for the treatment of lung cancer.

ERCC1 and XRCC1 as biomarkers for lung and head and neck cancer

Alec Vaezi, Chelsea H Feldman, Laura J Niedernhofer
Pharmacogenomics and Personalized Medicine 2011:4 47–63
http://dx.doi.org/10.2147/PGPM.S20317

Advanced stage non-small cell lung cancer and head and neck squamous cell carcinoma are both treated with DNA damaging agents including platinum-based compounds and radiation therapy. However, at least one quarter of all tumors are resistant or refractory to these genotoxic agents. Yet the agents are extremely toxic, leading to undesirable side effects with potentially no benefit. Alternative therapies exist, but currently there are no tools to predict whether the first-line genotoxic agents will work in any given patient. To maximize therapeutic success and limit unnecessary toxicity, emerging clinical trials aim to inform personalized treatments tailored to the biology of individual tumors. Worldwide, significant resources have been invested in identifying biomarkers for guiding the treatment of lung and head and neck cancer. DNA repair proteins of the nucleotide excision repair pathway (ERCC1) and of the base excision repair pathway (XRCC1), which are instrumental in clearing DNA damage caused by platinum drugs and radiation, have been extensively studied as potential biomarkers of clinical outcomes in lung and head and neck cancers. The results are complex and contradictory. Here we summarize the current status of single nucleotide polymorphisms, mRNA, and protein expression of ERCC1 and XRCC1 in relation
to cancer risk and patient outcomes.

Optimizing response to gefitinib in the treatment of non-small-cell lung cancer

Pietro Carotenuto, Cristin Roma, Anna Maria Rachiglio, Raffaella Pasquale, et al.
Pharmacogenomics and Personalized Medicine 2011:4 1–9
http://dx.doi.org:/10.2147/PGPM.S6626

The epidermal growth factor receptor (EGFR) is expressed in the majority of non-small-cell lung cancer (NSCLC). However, only a restricted subgroup of NSCLC patients respond to treatment with the EGFR tyrosine kinase inhibitor (EGFR TKI) gefitinib. Clinical trials have demonstrated that patients carrying activating mutations of the EGFR significantly benefit from treatment with gefitinib. In particular, mutations of the EGFR TK domain have been shown to increase the sensitivity of the EGFR to exogenous growth factors and, at the same time, to EGFR TKIs such as gefitinib. EGFR mutations are more frequent in patients with particular clinical and pathological features such as female sex, nonsmoker status, adenocarcinoma histology, and East Asian ethnicity. A close correlation was found between EGFR mutations and response to gefitinib in NSCLC patients. More importantly, randomized Phase III studies have shown the superiority of gefitinib compared with chemotherapy in EGFR mutant patients in the first-line setting. In addition, gefitinib showed a good toxicity profile with an incidence of adverse events that was significantly lower compared with chemotherapy. Therefore, gefitinib is a major breakthrough for the management of EGFR mutant NSCLC patients and represents the first step toward personalized treatment of NSCLC.

Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy

Jing Li, Martin H Bluth
Pharmacogenomics and Personalized Medicine 2011:4 11–33
http://dx.doi.org:/10.2147/PGPM.S18861

The new era of personalized medicine, which integrates the uniqueness of an Individual with respect to the pharmacokinetics and pharmacodynamics of a drug, holds promise as a means to provide greater safety and efficacy in drug design and development. Personalized medicine is particularly important in oncology, whereby most clinically used anticancer drugs have a narrow therapeutic window and exhibit a large interindividual pharmacokinetic and pharmacodynamics variability. This variability can be explained, at least in part, by genetic variations in the genes encoding drug metabolizing enzymes, transporters, or drug targets. Understanding of how genetic variations influence drug disposition and action could help in tailoring cancer therapy based on individual’s genetic makeup. This review focuses on the pharmacogenomics of drug metabolizing enzymes and drug transporters, with a particular highlight of examples whereby genetic variations in the metabolizing enzymes and transporters influence the pharmacokinetics and/or response of chemotherapeutic agents.

Transcriptome-wide signatures of tumor stage in kidney renal clear cell carcinoma: connecting copy number variation, methylation and transcription factor activity
Qi Liu, Pei-Fang Su, Shilin Zhao and Yu Shyr
Genome Medicine 2014, 6:117 http://genomemedicine.com/content/6/12/117

Background: Comparative analysis of expression profiles between early and late stage cancers can help to understand cancer progression and metastasis mechanisms and to predict the clinical aggressiveness of cancer. The observed stage-dependent expression changes can be explained by genetic and epigenetic alterations as well as transcription dysregulation. Unlike genetic and epigenetic alterations, however, activity changes of transcription factors, generally occurring at the post-transcriptional or post-translational level, are hard to detect and quantify.
Methods: Here we developed a statistical framework to infer the activity changes of transcription factors by simultaneously taking into account the contributions of genetic and epigenetic alterations to mRNA expression variations.
Results: Applied to kidney renal clear cell carcinoma (KIRC), the model underscored the role of methylation as a significant contributor to stage-dependent expression alterations and identified key transcription factors as potential drivers of cancer progression.
Conclusions: Integrating copy number, methylation, and transcription factor activity signatures to explain stage-dependent expression alterations presented a precise and comprehensive view on the underlying mechanisms during KIRC progression.

Developments in renal pharmacogenomics and applications in chronic kidney disease

Ariadna Padullés, Inés Rama, Inés Llaudó, Núria Lloberas
Pharmacogenomics and Personalized Medicine 2014:7 251–266
http://dx.doi.org/10.2147/PGPM.S52763

Chronic kidney disease (CKD) has shown an increasing prevalence in the last century. CKD encompasses a poor prognosis related to a remarkable number of comorbidities, and many patients suffer from this disease progression. Once the factors linked with CKD evolution are distinguished, it will be possible to provide and enhance a more intensive treatment to high-risk patients. In this review, we focus on the emerging markers that might be predictive or related to CKD progression physiopathology as well as those related to a different pattern of response to treatment, such as inhibitors of the renin–angiotensin system (including angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers; the vitamin D receptor agonist; salt sensitivity hypertension; and progressive kidney-disease markers with identified genetic polymorphisms). Candidate-gene association studies and genome-wide association studies have analyzed the genetic basis for common renal diseases, including CKD and related factors such as diabetes and hypertension. This review will, in brief, consider genotype-based pharmacotherapy, risk prediction, drug target recognition, and personalized treatments, and will mainly focus on findings in CKD patients. An improved understanding will smooth the progress of switching from classical clinical medicine to gene-based medicine.

 

 

 

 

 

 

.

Read Full Post »

« Newer Posts - Older Posts »